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ABBREVIATIONS 
2MeSATP  2-methylthio-ATP 
5’-GMP  guanosine 5'-monophosphate 
AA   arachidonic acid  
AC   adenylyl cyclase  
Ado   adenosine  
ADP   adenosine-5'-diphosphate  
ADPβS  adenosine 5'-O-(2-thiodiphosphate)  
AP   alkaline phosphatases  
AP-1   activating protein 1  
ATP   adenosine-5'-triphosphate  
BBB   blood brain barrier  
BDNF   brain-derived neurotophic factor  
bFGF   basic fibroblast growth factor  
BMPs   bone morphogenetic proteins  
BrdU   5-bromo-2’-deoxyuridine  
CC   corpus callosum  
CCK   cholecystokinin  
CGRP   calcitonin-gene related peptide  
CNS   central nervous system  
CNTF   ciliary neurotrophic factor  
COX-2  cycloxygenase-2  
CRMP-4  collapsin response mediator protein 4  
Ctr   control  
CTX   cortex  
cysLTs  cysteinyl-leukotrienes  
DA   dopaminergic  
DCX   doublecortin  
DG   dentate gyrus  
DH   dorsal horn  
Dlx-2   distal-less homeobox-2  
DNase   deoxyribonuclease  
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EAE   experimental autoimmune encephalomyelitis  
ECs   ependymal cells  
EdU   5-ethynyl-2’-deoxyuridine  
EGF   epidermal growth factor  
EL   extracellular loops  
E-NPP  ecto-nucleotide pyrophosphatase/phosphodiesterase  
E-NTPDase  ectonucleoside triphosphate diphosphohydrolase  
eNTs   extracellular nucleotides  
Epo   erythropoietin  
ERK1/2  extracellular-regulated kinases 1/2  
ESCs   embryonic stem cells  
ET   endothelin 
FAK   focal adhesion kinase 
FCS   fetal calf serum  
GDNF   glial cell line-derived neurotrophic factors 
GFAP   glial fibrillary acidic protein  
GL   granule cell layer  
GLAST  L-glutamate/L-aspartate transporter   
GLT1   Na+-dependent glutamate transporter 1  
GPCR   G protein-coupled receptors 
Gr   granule neurons 
GSDB   goat serum dilution buffer 
HBSS    Hanks' balanced salt solution  
HDAC   histone deacetylases  
ICM   inner cell mass   
IFNβ   interferon beta  
IFNγ   interferon gamma  
IL10   interleukin 10  
IP3   inositol trisphosphate  
LIF   leukemia inhibitory factor  
LW   lateral wall  
MAG   myelin associated glycoprotein  
MAP   mitogen-activated protein kinase 
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MBP   myelin basic protein  
MBS   meta-binding sites 
MCAo  middle cerebral artery occlusion 
MCP   monocyte chemotactic protein-1  
ML   molecular layer  
MRS2179  N
6
-methyl-2-deoxyadenosine 3',5'-bisphosphate  
MS    multiple sclerosis  
NA   noradrenaline  
NeuN   neuronal nuclei  
NeuroD  neurogenic differentiation  
NF-kB  nuclear factor kappa B  
NPY   neuropeptides  
NS   neurospheres  
NSCs   neural stem cells  
OB   olfactory bulb  
OPCs   oligodendrocyte progenitor cells  
OSN   olfactory sensory neurons  
P2YRs  P2Y receptors  
PBS   phosphate buffered saline 
PC   piriform cortex  
PC-PLC  phosphatidylcholine-phospholipase C  
PDGFαR  platelet-derived growth factor alpha receptor  
PG   periglomerular neurons  
PI3K   phosphoinositide 3-kinase  
PLA2   phospholipase A2 
PLC-β   phospholipase C-β  
PLD   phospholipase D  
PNS   peripheral nervous system 
PPADS  pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid  
Prox1   prospero homeobox protein 1 
PSA-NCAM  polysialylated neural cell adhesion molecule   
PTI   post traumatic survival time  
PVL   periventricular leucomalacia  
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RMS   rostral migratory stream  
SC    spinal cord  
SCI   spinal cord injury  
SGZ   subgranular zone  
SP   substance P  
STAT3  signal transducer and activator of transcription 3  
STR   striatum   
SV2   anti-synaptic vesicle2  
SVZ    subventricular zone  
Syt    synaptotagmin  
TBI   traumatic brain injury  
TEA   tetraethyl-ammonium  
TGFβ    transforming growth factor-beta  
TNAP   tissue non-specific form of alkaline phosphatase 
TNFα   tumor necrosis factor-alfa  
TSA   trichostatin A  
UDP   uridine-5'-diphosphate  
UTP   uridine-5'-triphosphate  
UTP-γS  uridine-5'-(γ-thio)-triphosphate  
VEGF   vascular endothelial growth factor  
VPA   valproic acid  
α,β-meATP  α,β-methylene-ATP  
βIII-tubulin  βIII-tub  
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1. INTRODUCTION 
 
1.1 THE PURINERGIC SYSTEM 
Adenosine-5'-triphosphate (ATP) has long been recognized only as an 
intracellular energy molecule, and its acceptance as an extracellular signaling molecule 
has taken a considerably long period of time. The potent effects of ATP on the heart and 
blood vessels were first described in 1929 (Drury and Szent Gyorgyi, 1929), while in 
1972 Burnstock proposed new roles for ATP as neurotransmitter in non-adrenergic, 
non-cholinergic nerves in the gut and bladder (Burnstock, 1972). In the following years 
ATP metabolites deriving from its enzymatic hydrolysis, like the nucleotide adenosine-
5'-diphosphate (ADP) and the nucleoside adenosine (Ado), as well as other extracellular 
nucleotides (eNTs) like the uridine-5'-triphosphate (UTP), uridine-5'-diphosphate 
(UDP), and sugar nucleotides, were progressively proposed as transmitters not only in 
sensory nerves, but also in motor nerves and central nervous system (CNS) neurons 
(Fields and Burnstock, 2006; Inoue et al., 2007). The actions of these molecules in the 
extracellular environment implicated the existence of post-junctional receptors. 
Accordingly, numerous subtypes of these receptors were progressively cloned, and 
scientists gradually coined and accepted the term “purinergic system” to describe the 
system composed by extracellular nucleotides/nucleosides and their receptors. The first 
classification of purinergic receptors family dates back to 1978, when Burnstock 
proposed some criteria for differentiating these receptors in two families: the P1 
receptors activated by Ado and antagonized by methylxantines, and the P2 receptors, 
responding to ATP and ADP (Burnstock et al., 1978).  
Nowadays, P2 receptors are divided into two families: the ionotropic P2X 
receptors and the metabotropic P2Y receptors (Burnstock and Knight, 2004). P2X 
receptors are ligand-activated cationic channels, specifically activated by ATP 
(Burnstock and Knight, 2004), while P2Y receptors are activated by purine or 
pyrimidine nucleotides, or by sugar-nucleotides, and couple to intracellular second-
messenger systems through heteromeric G proteins (Abbracchio et al., 2006). In 1994, 
the IUPHAR Subcommittee for Purinoceptor Nomenclature and Classification has 
approved the new classification and has proposed to substitute the term “P2 
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purinoceptors” with “P2 receptors”, in order to take into account the observation that 
some P2 receptors are preferentially activated by uridine nucleotides (Fredholm et al., 
1997). To date, at least seven P2X subtypes (P2X1-7) and eight P2Y members 
(P2Y1,2,4,6,11,12,13,14) have been cloned from different animal species (Abbracchio et al., 
2006). The missing numbers in the P2Y series correspond to receptors cloned from 
vertebrates different from mammals and for which no mammalian orthologs have been 
identified so far, or to receptors that have not been functionally characterized yet or that 
were incorrectly classified in the family. 
The concept that ATP is an extracellular signaling molecule has been established 
not only in the rapid signaling involved in neurotransmission, but also in a wide range 
of other biological processes, including release of cytokines, neurotransmitters and 
hormones, cell proliferation, differentiation and apoptosis in tissues as diverse as the 
skin, skeletal muscle, bone, nervous and immune system (Fields and Burnstock, 2006; 
Inoue et al., 2007). Thus, alterations in purinergic signaling may contribute to the 
development of disorders of the immune system, inflammation, neurodegeneration, 
osteoporosis and cancer. On this basis, a better understanding of the roles of purinergic 
signaling may help identifying novel therapeutic targets for several human diseases. 
1.1.1 SOURCES AND METABOLISM OF NUCLEOTIDES 
The first clues on the role of eNTs in signal transduction came from the 
observation that neurons and neuroendocrine cells released ATP packaged with other 
neurotransmitters (Burnstock, 1972). Moreover, it has been demonstrated that, 
following mechanical stress, also non secretory tissues can release nucleotides 
(Lazarowski et al., 2000) which may signal to the same secretory cell (autocrine 
stimulation) as well as to adjacent cells (paracrine stimulation). Following injury or 
inflammation, nucleotides can also be pathologically released as a consequence of cell 
lysis. There is ongoing debate, however, about the transport mechanisms involved in 
nucleotide release. There are hints for exocytotic release from endothelial and urothelial 
cells, osteoblasts, astrocytes, and mast and chromaffin cells, but other transport 
mechanisms have been proposed as well, including ATP-binding cassette transporters, 
connexin hemichannels and plasmalemmal voltage-dependent anion channels (Fields 
and Burnstock, 2006). More recently, pyrimidine nucleotides release has been described 
(Lazarowski et al., 2003). 
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Once released in the extracellular environment, nucleotides are rapidly degraded 
by ubiquitous ecto-nucleotidases (Zimmermann, 2000), a family of phosphatases 
expressed on the cell surface that are able to dephosphorylate different nucleotides. ATP 
hydrolysis sequentially produces ADP, AMP and adenosine, whereas UTP is degraded 
to UDP, UMP and uridine; many of these metabolites can act as extracellular signaling 
molecules. The local response to a specific nucleotide is thus the result of the effects of 
the nucleotide itself and of its degradation products. Distinct classes of ecto-
nucleotidases with different properties and different substrate specificities have been 
identified so far (Yegutkin, 2008). Some are membrane proteins with an extracellular 
catalytic domain, but soluble forms released in the extracellular space have also been 
described. Ecto-nucleotidases can be also released with ATP from sympathetic nerve 
terminals, representing one of the mechanisms to turn off neurotransmitter signaling 
(Todorov et al., 1997). A general scheme of nucleotide-hydrolyzing enzymes include: 
(i) the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family, (ii) the 
ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family, (iii) ecto-5'-
nucleotidase, and (iv) alkaline phosphatases (AP; Yegutkin, 2008). This complex 
enzymatic family demonstrates that ATP and other nucleotides can be considered as 
“classical neurotransmitters” whose signal can be regulated by enzymatic degradation. 
Nucleotides released or leaked from both glial cells and neurons play a role in 
cell-to-cell communication under both physiological and pathological conditions 
(Burnstock and Knight, 2004). Accordingly, in CNS both neuronal cells and the major 
classes of glia (i.e. astrocytes, microglia and oligodendrocytes) express a vast variety of 
purinergic receptors (Fields and Burnstock, 2006). For instance, astrocytes release ATP 
in response to various stimuli or even spontaneously, and communicate with neurons, 
microglial cells, and even vascular cells at capillaries (Inoue et al., 2007). Also 
microglial cells respond to a wide range of ATP receptor agonists, through increases in 
intracellular calcium, secretion of cytokines, and rapid changes in their morphology and 
migration capacity (Inoue, 2008). Therefore, eNTs represent a class of signaling 
molecules that functionally “unite” glia and neurons together. Not by chance neuron-
glia or glia-glia communication participates in the control of several pathophysiological 
mechanisms, including regulation of synaptic transmission (Wieraszko and Ehrlich, 
1994), neuroimmune interactions (Inoue et al., 2007), processing of information through 
the retina (Newman, 2008), Schwann cell proliferation and myelination (Fields, 2006; 
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Stevens, 2006), cell proliferation (Neary and Zimmermann, 2009), inflammation (Di 
Virgilio et al., 2009), pain (Burnsock, 2009a) and regulation of neural stem cells (Ulrich 
et al., 2012; see also 1.4.3). 
1.1.2 P2X RECEPTORS 
P2X receptors are membrane ion channels that open in response to the binding of 
extracellular ATP. ATP elicits rapid responses (<10ms) via these ion channels, resulting 
in selective permeability to Na
+
, K
+
, and Ca
2+
 cations (North, 2002). In vertebrates, 
seven genes encode P2X receptor subunits, which are 40-50% identical in their 
aminoacidic sequence. Each of three putative subunits, proposed to form a homo- or 
heterotrimeric complex, comprises two hydrophobic transmembrane spanning regions 
(TM1 and TM2), a large extracellular loop of about 270 amino acids and two 
intracellularly located terminal tails (amino NH2- and carboxy COOH-tail). The TM1 
and TM2 segments of the trimer are thought to line an integral pore with a diameter of 
about 8-20 Å, with the selective ion filter (activation gate) consisting of a small polar 
stretch in the TM2 region. Concerning one subunit, the amino acid residues range from 
388 (P2X4) to 595 (P2X7) in human P2X-Rs. The extracellular loop contains the ATP 
binding site as well as sites for antagonists and modulators (Khakh et al., 2001). The 
aminoacidic identity between P2X receptor subunits is distributed throughout the 
extracellular domain, a striking feature of which is the conservation among all known 
receptors of 10 cysteine residues, which form disulfide bonds to give the correct 
conformation to the receptor (Vial et al., 2004). All the P2X receptor subunits have 
consensus sequences for N-linked glycosylation (Asn-X-Ser/Thr), and some 
glycosylations are essential for trafficking to the cell surface. The extracellular domain 
carries few conserved glycine (G) and proline (P) residues which are involved in 
conformational changes subsequent to ligand-receptor binding. Extracellular protons, 
bivalent cations and some metals are P2X receptors allosteric modulators. In addition, 
P2X receptors can be modulated via phosphorylation of serine (S) and threonine (T) 
residues (Figure 1.1).  
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As of today, seven homomeric channels (P2X1-7) have been identified, but 
functional expression studies have also highlighted the existence of heteromeric 
P2X1/5, P2X2/3, P2X2/6, P2X4/6, P2X4/7 and P2X5 receptors which can assemble 
with any other subunit, except P2X7 (North, 2002).  
Figure 1.1: schematic representation of the general features of P2X receptors. 
Numbers indicate the position of important residues for agonists binding (i.e., Lys(K)63, 
K65, K299 may interact with the phosphate tail of ATP; K176 and Arg(R)281 may 
coordinate adenine binding). In addition, the extracellular loop of all P2X-Rs contains 
ten conserved cysteine residues forming disulphide bridges (green circles), Zn
2+
 binding 
sites (pink circles), glycosylated asparagine residues (blue symbols). The intracellular 
amino- and carboxy-tails are associated with conserved protein kinase C (orange) and 
trafficking (yellow) motifs, respectively. For the P2X3-R, six putative nucleotide binding 
sites (highlighted in red) have been postulated by molecular modelling (modified from 
Fischer and Krugel, 2007).  
1.1.3 P2Y RECEPTORS 
P2Y receptors (P2YRs) belong to the superfamily of G protein-coupled receptors 
(GPCR). GPCR are a family of membrane receptors responding to a wide variety of 
ligands such as nucleotides, biogenic amines, peptides and other small molecules 
(Marchese et al., 1999). The binding of the GPCR to its specific ligand results in the 
activation of the associated heterotrimeric G protein (α, β and γ subunits) that mediates 
a number of intracellular responses. In particular, ligand binding to its receptor results in 
13 
 
a decreased affinity of the α subunit for GDP, that is thus exchanged for GTP. This 
binding causes a conformational modification in the G protein and the dissociation of 
the α subunit from the βγ complex. Both α and βγ subunits can then activate signal 
transduction pathways (Rebois et al., 1997). 
From a phylogenetical point of view, the eight human P2YRs can be subdivided 
into two distinct subgroups characterized by a relatively high level of sequence 
divergence. The first subgroup encompasses P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 
receptors, whereas the second subgroup encompasses P2Y12, P2Y13 and P2Y14 receptors 
(Abbracchio et al., 2006).  
 
Figure 1.2: schematic representation of the general features of P2Y receptors. P2Y-Rs 
consist of seven transmembrane spanning segments (TM1-TM7) connected by three 
extracellular and three intracellular loops. The NH2-tail is located outside the cell, 
while the COOH-tail is located in the cytoplasm, the latter possessing consensus 
binding motifs for protein kinases. Among the extracellular loop and the outermost 
parts of the transmembrane segments, the hypothetical binding sites for receptor 
agonists at the human P2Y1-R are shown. In particular, three different parts responsible 
for the binding of agonists like ADP were assumed (blue circles: meta-binding site I, 
white letters: meta-binding site II, red circles: principal binding site). Several potential 
PKC and G protein-coupled receptor kinase phosphorylation sites are indicated on the 
third intracellular loop and the COOH-terminus (orange circles). The two arginine 
residues (R333/R334; dark blue circles) in the COOH-terminus of the human P2Y1-R 
are thought to be essential for Gq coupling (Modified from Fischer and Krugel, 2007). 
 
Jacobson and co-workers (Costanzi et al., 2004) presented a detailed model for the 
binding of nucleotides to the human P2Y1R (later extended to all P2YRs) by site-
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directed mutagenesis combined with molecular modelling analysis. According to their 
hypothesis, a multistep mechanism for the binding of small ligands like ATP may exist. 
Initially, the ligand is positioned at the P2Y1R in an energetically favorable 
conformation, which is defined by the extracellular loops (EL) and the outermost TM 
segments by two “meta-binding sites” (MBS). From MBS-I the ligand could progress to 
MBS-II, located on Arg(R)128, Asp(D)204, Ser(S)213, Thr(T)222, Lys(K)280 and 
Gln(Q)307. Finally, the ligand reaches the principal binding site located inside the TM 
bundle consisting of Gln(Q)307, Ser(S)314 for the binding of adenine, and Arg(R)128, 
Thr(T)222, Lys(K)280, Arg(R)310 for binding of the phosphate groups. Some of the 
amino acids (R128, T222, K280, Q307) are implicated in both MBS-II and the principal 
binding site (Figure 1.2). 
The two P2Y receptor subgroups also differ in their primary coupling to G 
proteins. In particular, all receptors in the first subgroup (i.e., P2Y1,2,4,6,11) couple to 
Gq/G11 and activate phospholipase C-β (PLC-β) with the generation of diacylglycerol 
and inositol trisphosphate (IP3) and the subsequent mobilization of Ca
2+
 from 
intracellular stores. The receptors in the second subgroup (i.e., P2Y12,13,14) almost 
exclusively use the Gi/o class of G proteins with subsequent inhibition of adenylyl 
cyclase (AC) and cAMP formation. The P2Y11 receptor subtype also couples to the Gs 
protein subunit to activate AC followed by an increase in cAMP when stimulated by 
ATP (Figure 1.3; Fischer and Krugel, 2007). Secondary couplings have been also 
reported, especially for receptors of the first subgroup in heterologous expression 
systems (Abbracchio et al., 2006). Among receptors of the second group, P2Y13 has 
been also reported to couple to Gα16 and to stimulate PLC in recombinant systems 
overexpressing this G protein (Fumagalli et al., 2004). Such “promiscuity” of G protein 
coupling may depend on the indirect activation of additional G protein subtypes within 
protein complexes containing the P2Y receptor.  
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Figure 1.3: second messenger coupling and intracellular signaling pathways of P2Y 
receptors. Nucleotides acting at P2YRs cause activation of specific G proteins: 
P2Y1,2,4,6,11-Rs are coupled to Gq/G11, which stimulate phospholipase C (PLC) and the 
mobilization of Ca
2+
 from intracellular pools; P2Y12,13,14-Rs are coupled to Gi/o 
inhibiting adenylyl cyclase (AC). Finally, the P2Y11 receptor is coupled also to 
stimulation of AC.  
 
From a pharmacological point of view, P2YRs can be broadly subdivided in four 
groups based on their responsivity to nucleotides: i) adenine nucleotide-preferring 
receptors, mainly responding to ADP and ATP. This group includes human and rodent 
P2Y1, P2Y12, and P2Y13, and human P2Y11; ii) uracil nucleotide-preferring receptors, 
including the human P2Y4 and P2Y6 responding to UTP or UDP, respectively; iii) 
receptors of mixed selectivity, the human and rodent P2Y2, the rodent P2Y4 and, 
possibly, P2Y11; and iv) the P2Y14 receptor, responding to both UDP and sugar 
nucleotides (mainly UDP-glucose and UDP-galactose; Abbracchio et al., 2006; Carter 
et al., 2009). In this latter group it could be possibly included a receptor, named GPR17, 
phylogenetically and structurally related to already known P2Y receptors, which has 
been recently reported to respond to both cysteinyl-leukotrienes and uracil nucleotides 
(Ciana et al., 2006, see also 1.5.2.2). Unfortunately, although important progress in 
exploring structure-activity relationships has been achieved, most of the P2Y receptor 
subtypes are still lacking potent and selective synthetic agonists and antagonists 
(Abbracchio et al., 2006).  
It is widely recognized that purinergic signaling is a primitive system involved in 
both neuronal and non-neuronal mechanisms, including exocrine and endocrine 
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secretion, immune responses, inflammation, pain, platelet aggregation, and endothelial-
mediated vasodilatation (for a detailed review see Burnstock and Knight, 2004); in this 
thesis we will focus our attention on the role of eNT in the CNS.  
1.1.4 PATHOPHYSIOLOGICAL ROLES OF EXTRACELLULAR NUCLEOTIDES IN THE NERVOUS 
SYSTEM 
The hypothesis that ATP plays a central role in modulating cerebral functions 
rises from the broad distribution of P2 receptors in the CNS (Abbracchio et al., 2006). 
ATP is released from nerve terminals and has rapid and direct actions, generally 
associated to activation, whether Ado has inhibitory effects with a negative feed-back 
action on the effects of ATP and of other neurotransmitters released at the synapse. The 
first evidence suggesting a role of ATP as a neurotransmitter in the brain was obtained 
in 1992, with the demonstration that its stable analogue, α,β-methylene-ATP (α,β-
meATP), provokes a current of excitation in rat neurons which is antagonized by P2 
antagonists (Edwards et al., 1992). 
The roles of eNTs as signaling molecules are now well established. ATP (and 
maybe other nucleotides) is co–localized with “classical” neurotransmitters at many 
central and peripheral synapses, from which it can be released upon presynaptic 
depolarizing stimuli via a regulated secretion pathway. In some brain areas, ATP 
regulates neurotransmission through the modulation of glutamate release from nerve 
endings. This effect is mediated by P2 receptors located on the presynaptic as well as on 
the post-synaptic element (Motin and Bennett, 1995). In particular, it has been 
suggested that ATP can amplify glutamate post-synaptic action following interaction 
with a P2Y receptor, or by activating an ecto-kinase responsible for the phosphorylation 
of membrane proteins associated to glutamate receptors (Chen et al., 1996). These 
observations have led to the hypothesis that ATP, and maybe also UTP, might 
participate in long-term synaptic potentiation, memory, and learning processes (Fujii, 
2004; Price et al., 2003). The experimental evidence indicating colocalization of ATP 
with neurotransmitters and neuropeptides in secretory vesicles of most synapses further 
confirms this hypothesis. Noradrenaline (NA) and ATP are released from sympathetic 
nervous system endings in variable ratios according to the tissue and to the animal 
species considered (Burnstock and Verkhratsky, 2010). Despite the demonstration that 
ATP is stored in the nerve endings together with NA, prejunctional neuromodulation 
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studies demonstrate that ATP and NA are released independently following different 
stimuli (Starke et al., 1996). It can thus be hypothesized that different nerve populations 
containing different ratios of NA and ATP exist in the sympathetic nervous system. 
Finally, indirect evidence demonstrates that ATP and acetylcholine co-localize in 
central and peripheral cholinergic terminals and that co-transmission with peptides such 
as substance P (SP), calcitonin-gene related peptide (CGRP), neuropeptide Y and 
somatostatin also exists (Burnstock, 1997; Zimmermann, 2008). In recent years, 
evidence has been accumulating to suggest that nucleotides are also released from non-
neuronal cells (e.g., circulating platelets and erythrocytes, inflammatory cells, 
exercising muscle cells, hypoxic cardiomyocytes) and, within the CNS, from glial cells. 
It was initially believed that release of nucleotides from glia could only occur under 
pathological conditions (e.g., brain ischemia and trauma) as a consequence of leakage 
from the cytosolic nucleotide pool due to loss of membrane permeability under milder 
stress or hypoxic conditions, or as a result of nucleic acid degradation upon cell death 
due to persistent or stronger insults. It is now known that significant nucleotide release 
from glia (astroglia, in particular) can also occur under physiological conditions, 
suggesting that these molecules not only participate in brain repair and recovery after 
damage, but may also play key roles in normal brain function. Among the other roles 
exerted by purinergic system, recent studies also highlighted a direct involvement of 
eNTs in neurogenesis, that will be discuss in details in the Paragraph 1.4.3. 
Following pathological/traumatic events a massive release of purines and 
pyrimidines at the site of injury is observed and they seem to have a dualistic effect: on 
one hand, they contribute to lesion worsening, but on the other side they are involved in 
tissue regeneration and repair. In the next sections the main roles of these molecules 
during pathological events will be briefly discussed, whereas a detailed dissertation of 
their role in reactive astrogliosis will be provided in the following paragraphs. 
 
Brain ischemia 
During ischemia or hypoxia in the CNS a massive release of nucleotides is 
observed (Melani et al., 2005; Neary et al., 1996). ATP participates to cell death 
induction immediately (minutes to hours) following tissue injury, probably as a 
consequence of a diffuse dysregulation of the release mechanisms and of a pathological 
activation of P2 receptors. For instance, it has been demonstrated that ATP has a 
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cytotoxic effect on cerebellar neurons (Amadio et al., 2002), and potentiates 
hypoglycemia-induced tissue injury (Cavaliere et al., 2002). In the weeks following 
ischemic injury, when homeostatic control is re-established in the injured area, ATP 
seems to contribute to differentiation and to promote the long-term functional repair of 
the damaged area (Abbracchio and Ceruti, 2006; Abbracchio and Verderio, 2006). 
During ischemic and hypoxic events, high extracellular concentrations of adenosine are 
also reached, in part as a consequence of ATP degradation. It has been demonstrated 
that adenosine has a protective role in cerebral ischemia in several experimental models. 
Accordingly, both adenosine administration as well as inhibition of its degradation 
reduce injury associated to cerebral or cardiac ischemia and protect from organ loss of 
function (Fredholm, 2010; Mentzer et al., 1996; Phillis and Regan, 1996). eNTs can 
also induce cell death, through the formation of P2X7 receptor-associated pore (Di 
Virgilio et al., 1996; Ferrari et al., 1997). This mechanism could influence neuronal 
remodeling through the elimination of critically injured cells, in particular during acute 
brain ischemic events, thus limiting the area of damaged tissue (Neary et al., 1996). 
Brain damage caused by a transient occlusion of the middle cerebral artery (MCAo) 
results in a sustained pathologically high ATP outflow; while in the infarct region the 
release of ATP is low because of disturbed cellular metabolism, in the peri-infarct area 
its concentration is increased, due both to the deregulation of its enzymatic degradation, 
and to the concomitantly enhanced outflow of the nucleotide from damaged cells 
(Melani et al., 2005). 
 
Spinal cord injury  
An abnormal purinergic signaling has been also observed following spinal cord 
injury (SCI). In the peritraumatic spinal cord regions, ATP is released at high levels and 
causes neuronal cell death through P2X7 receptors. In this respect, P2X7 receptor 
blockade is associated to improved functional recovery and diminished cell death in the 
peritraumatic zone (Wang et al., 2011). Analysis of P2X4 receptor expression following 
SCI also demonstrated a significant accumulation of P2X4-positive 
microglia/macrophages as early as 24 h after SCI, peaking on day 7 (Schwab et al., 
2005). Taken together, these observations confirm the role of the purinergic system in 
the traumatic degeneration, and possibly in tissue remodeling. 
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Chronic neurodegenerative diseases 
P2 receptor ligands have been proposed as potential neuroprotective agents 
following neuronal death associated with neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral 
sclerosis and multiple sclerosis (Burnstock, 2008). For instance, different P2 receptor 
subtypes are involved in the development and growth of dopaminergic neurons in CNS 
(Heine et al., 2007), and P2X7 receptors are involved in ATP-mediated necrotic volume 
increase in substantia nigra, which has been implicated in the pathogenesis of 
Parkinson’s disease (Jun et al., 2007). P2X7 receptors have been also found upregulated 
in the brain of patients with Alzheimer’s disease (McLarnon et al., 2006), and ATP 
released during neuronal excitation or injury enhances the inflammatory effects of 
cytokines and prostaglandin E2 in astrocytes, thus contributing to the chronic 
inflammation observed in Alzheimer’s disease (Xu et al., 2003). P2X7 receptor 
antagonism therefore represents a therapeutic strategy for blocking inflammatory 
responses associated to neurodegenerative disorders. In the brain, stress or damage 
cause the release of nucleotides and activation of P2Y2 receptors, leading to pro-
inflammatory responses including the stimulation and recruitment of glial cells, which 
can protect neurons from injury (Peterson et al., 2010). Indeed, P2Y2 receptor 
expression is increased in glial cells by stimulation with IL1β, a pro-inflammatory 
cytokine whose levels are elevated in Alzheimer’s disease, and this effect has been 
proposed to be neuroprotective, since it increases the non-amyloidogenic cleavage of 
the amyloid precursor protein (Camden et al., 2013). Thus, activation of P2Y2 receptors 
in glial cells can promote neuroprotective responses, therefore indicating this receptor 
subtype as a novel pharmacological target for the treatment of neurodegenerative 
diseases.  
 
1.2 STEM CELLS 
Strictly defined, stem cells possess the cardinal features of multipotency and self-
renewal. Multipotency is the ability to differentiate into multiple functional cell types, 
whereas self-renewal describes the ability of stem cells to make identical copies of 
themselves via cell division. Stem cells exhibit extensive proliferation and are often 
presumed to be able to divide indefinitely, yielding a virtually unlimited supply of cells 
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(Burns et al., 2009). A stem cells can divide by symmetric cell division, which generate 
two daughter cells with the same fate, or asymmetric cell division, which generate one 
daughter cell identical to the mother cell and a second one that is lineage-restricted. A 
variety of stem cells can be identified that differ in their potency, or in the diversity of 
cell types they can generate. 
Figure 1.4: stem cell differentiation. The mass of cells formed four to five days after 
fertilization is known as a blastocyst. The blastocyst contains a mass of outer cells 
known as the trophoblast that becomes the placenta and surrounds an inner cell mass 
(ICM). Pluripotent embryonic stem (ES) cells are derived from the ICM. In adult 
organs, multipotent stem cells can be found that can only give rise to cells of a single 
organ or tissue (modified from Stem cells basics for life researchers, www.bio-
rad.com). 
 
Following fertilization, a single totipotent zygote will be formed that is capable of 
developing into all embryonic and extra-embryonic tissues. However, given that the 
zygote is transient and does not self-renew, it is not generally regarded as a stem cell. 
The zygote will subsequently divide many times toward the generation of a sphere-
shaped conglomerate of cells, known as the “blastocyst”. This early embryonic structure 
has an outer layer called trophoblast, which will form the placenta, and an insider side 
called Inner Cell Mass (ICM), where embryonic stem cells (ESCs) can be isolated. 
Embryo
Blastocyst Inner Cell Mass
Trophoblast
Pluripotent stem cells
Multipotent
stem cells
Differentiated cells
Hematopoietic 
stem cells
Neuronal
stem cells
Mesenchymal
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ICM-derived ESCs are pluripotent with the potential of indefinite self-renewal and 
ability to differentiate into any cell type and tissue within the body (Olynik and 
Rastegar, 2012). Stem cells can also be found in adult organ. These cells, known as 
somatic stem cells, are multipotent since, unlike ESCs, they have a restricted 
differentiation potential and they can only give rise to cells of a single organ or tissue 
(Figure 1.4).  
The best studied tissue-specific stem cell population is the hematopoietic stem 
cell, which is capable of generating all blood cell types. Other tissue-specific stem cells 
have been identified in numerous organs including muscle, skin, gut, liver, pancreas, 
and brain. The most commonly discussed role for stem cells involves replacement of 
cell types lost due to disease or injury, i.e., “cell replacement therapy”. Such 
replacement may be achieved either by in vitro differentiation of stem cells into the 
desired cell type followed by transplantation of the pre-differentiated cells into the 
affected region, or by direct transplantation of stem cells followed by spontaneous in 
vivo differentiation of the stem cells into the needed cell types. An alternate cell 
replacement strategy involves the mobilization of resident tissue-specific stem cells to 
provide the substrate for cell replacement (Burns et al., 2009).  
 
1.3 THE TWO NEUROGENIC REGIONS IN THE ADULT BRAIN 
Since the early 1900s, it has been generally believed that the adult CNS of 
mammals has very limited regenerative capacity (Ramon y Cajal, 1928). The 
predominant repair mechanisms in the CNS were thought to be postmitotic, such as 
sprouting of axon terminals, changes in neurotransmitter-receptor expression, and 
synaptic reorganization. Joseph Altman and Gopal Das proposed the concept of 
persistent neurogenesis in the adult brain in the ‘60 where they used tritiated [3H] 
thymidine, which is incorporated into the DNA of dividing cells during S-phase of 
mitosis and can be detected autoradiographically, to suggest the production of new 
neurons in the cortex (Altman, 1963), hippocampus (Altman and Das, 1965, 1966), 
olfactory bulb (OB), and subventricular zone (SVZ) of the lateral ventricle (Altman, 
1969). However, little attention was given to these studies, perhaps because they were 
considered to lack any functional relevance. The field was revolutionized by the 
introduction of 5-bromo-2’-deoxyuridine (BrdU), a synthetic thymidine analogue, as 
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another S-phase marker of the cell cycle (Gratzner, 1982). Since BrdU can be detected 
by immunocytochemistry for phenotypic analysis and stereological quantification, this 
approach remains the most commonly used technique in the field. Before the end of the 
twentieth century, adult neurogenesis was observed with BrdU incorporation in all 
mammal samples examined, including those from human patients (Eriksson et al., 
1998). Combined retroviral-based lineage tracing (Price et al., 1987; Sanes et al., 1986) 
and electrophysiological studies provided the most convincing evidence so far that 
newborn neurons in the adult mammalian CNS are indeed functional and synaptically 
integrated (Belluzzi et al., 2003). In the early Nineties, Altman’s findings were further 
confirmed by two reports that demonstrated the presence of cells in the striatum of adult 
murine brain that were able to proliferate in vitro in the presence of epidermal growth 
factor (EGF) or basic fibroblast growth factor (bFGF), giving rise to free-floating 
clusters of cells called neurospheres (Reynolds et al., 1992). 
Neurospheres can be formed from single cells from the lateral wall of the lateral 
ventricle and passaged several times in vitro. Indeed, the undifferentiated cells within 
neurospheres can either self-renew, giving rise to secondary, tertiary neurospheres and 
so on, or differentiate to astrocytes, neurons and oligodendrocytes. The neurosphere-
forming assay has been used to detect the presence of neural stem cells (NSCs) in 
embryonic and adult neural tissues (Johansson et al., 1999). 
It is now well established that adult neural stem cells actively undergoing 
neurogenesis and gliogenesis are retained only in two regions of the murine CNS: the 
SVZ, and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) (Doetsch 
et al. 1999a; Kriegstein and Alvarez-Buylla 2009; Seri and Garcia-Verdugo 2001). 
Outside these “typical” germinal niches no constitutive neurogenesis takes place under 
normal conditions in the mature parenchyma with few exceptions amongst mammals. 
However, it is now known that the mature nervous parenchyma retains some active 
proliferation and glial turnover, sustained by persisting glial progenitors (Figure 1.5). 
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Figure 1.5: schematic representation of adult neurogenesis. Constitutive 
neurogenesis, granting continuous renewal of specific neuronal populations, is 
restricted to germinal layer-derived neurogenic sites (subventricular zone, SVZ; 
subgranular zone, SGZ). Although retaining some multipotency, progenitors 
widespread within the parenchyma mainly contribute to the slow renewal of glial cells 
(Modified from Martino et al., 2011).  
 
On these bases, the idea emerged that the non-germinal CNS may be endowed 
with a latent stem cell potential, normally repressed in vivo, that, if properly evoked, 
might be exploited in situ for reparative purposes (Boda and Buffo 2010; see Paragraph 
1.5).  
1.3.1 THE SUBVENTRICULAR ZONE 
The largest germinal region in the adult mammalian brain is the SVZ, which 
extends along the length of the lateral wall of the lateral ventricle. Here, over 30,000 
neuroblasts are estimated to be produced every day in rodents (Alvarez-Buylla et al., 
2001). The cellular composition and three-dimensional organization of the SVZ in adult 
mice was described in great detail by means of electron microscopy, [
3
H] thymidine 
autoradiography, and immunocytochemistry (Doetsch et al., 1997). Within the SVZ, 
three main cell types are morphologically and functionally distinguished: astrocyte-like 
stem cells (type B cells) give rise to clusters of transit-amplifying cells (type C cells), 
which in turn generate neuroblasts (type A cells, Figure 1.6). In rodents, newborn 
neurons proliferate and migrate along the rostral migratory stream (RMS) to the 
olfactory bulbs (OBs). Along the entire wall of the ventricle are also present ependymal 
cells (type E cells) which separate the SVZ from the ventricular cavity and are 
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characterized by long and numerous cilia (Doetsch et al., 1997). Type B cells are 
considered the primary precursors and act as bona fide CNS stem cells, both in vitro and 
in vivo. Doetsch and colleagues (Doetsch et al., 1999b) demonstrated that subventricular 
treatment with the antimitotic substance cytosine-beta-D-arabinofuranoside resulted in 
elimination of type A and C cells, while part of the B cells remained and started 
dividing soon after the treatment. Two days later, C cells re-emerged, followed by type 
A cells, showing that type B cells are the primary precursor cells in the SVZ. 
 
Figure 1.6: subventricular zone (SVZ) cell lineage and antigenic properties. (A) 
Diagram illustrating the lineage and antigenic properties of the different SVZ 
progenitor cells. (B) Photograph of GFAP immunostaining in a coronal section 
containing the SVZ. The arrows point to the SVZ. (C) Confocal image of GFAP (green) 
and DCX (red) co-immunostaining in the dorso-lateral SVZ (modified from Lacar et al., 
2010).  
 
Type B cells can be characterized by the expression of L-glutamate/L-aspartate 
transporter (GLAST), glial fibrillary acidic protein (GFAP) and the intermediate 
filament nestin. Type B cells give rise to actively proliferating (transit-amplifying) type 
C cells which are scattered along the network of migrating neuroblasts. They show the 
strongest proliferative activity among the three types of precursor cells and are the 
fastest proliferating cells in the SVZ. They are immunopositive for nestin, the 
homeobox transcription factor distal-less homeobox-2 (Dlx-2) and Mash1. Type C cells 
are considered to be the precursor cells to type A cells and are not found in the RMS. 
Type A cells are migrating neuroblasts and correspond to proliferating, migrating neural 
precursor cells, which show positive immunolabeling for polysialylated neural cell 
adhesion molecule (PSA-NCAM), doublecortin (DCX) and neuronal class III β-Tubulin 
(Doetsch et al., 1997, 1999a, 1999b; Garcia-Verdugno et al., 1998; Kim et al., 2011). 
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As early as 14 days after birth, some of the new neurons have reached the OB and 
migrate radially to their final positions. It has been shown that type B cells ensheat the 
chains of type A cells, and provide a trophic support and isolation from electrical and 
chemical influence from the surrounding parenchyma. Although migrating type A cells 
still undergo cell division, proliferation rates are reduced compared to the SVZ and their 
cell cycle time is lengthened. Once the migrating type A cells reach the OB, they 
disperse and migrate toward the granule cell and the periglomerular layers. Only upon 
entry in the OB do these cells achieve neuronal maturity, detectable by altered 
electrophysiological properties, release of neurotransmitters and expression of mature 
neuronal markers (Lie et al., 2004). Periglomerular and granule cells are the two major 
types of interneurons in the OBs and are responsible for the modulation of incoming 
sensory signals. These unusual interneurons lack an axon and instead have reciprocal 
dendro-dendritic synapses with mitral or tufted cells (Shepherd et al., 2007; Figure 1.7). 
 
Figure 1.7: subventricular zone (SVZ)/olfactory bulb (OB) system. 1. Proliferation 
and fate determination: stem cells in the SVZ of the lateral ventricle (blue) give rise to 
transit amplifying cells (green) that differentiate into immature neurons (red). 2. 
Migration: Immature neurons (red) migrate in chains through the rostral migratory 
stream (RMS). The migrating neurons are ensheathed by astrocytes (blue). 3. 
Integration: Immature neurons differentiate into interneurons (red) in the granule cell 
and the periglomerular layer. Olfactory sensory neurons (OSN); tufted neurons (T); 
mitral neurons (M); granule neurons (Gr); periglomerular neurons (PG; from Lie et 
al., 2004). 
RMS 
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The unilateral movement of neuroblasts from their birthplace in the SVZ to their 
integration sites in the granular and periglomerular zones in the OB requires multiple 
intrinsic and extrinsic cues working coherently. The OB has been postulated to generate 
a persistent attractive cue for the directed migration of the neuroblasts (Liu and Rao, 
2003). However, complete removal of the OB did not affect the continuous proliferation 
and migration of newborn precursors towards the absent OB (Kirschenbaum et al., 
1999). Similarly, surgical disconnection of the RMS pathway from the OB did not block 
neuronal differentiation of the NSCs, but promoted ectopic positioning of the 
differentiated neurons in the anterior olfactory nucleus and frontal cortex, as they could 
no longer migrate into the OB (Jankovski et al., 1998). A number of cell intrinsic and 
extrinsic factors have been shown to regulate NSC migration. For example, directional 
migration cues, which are probably more relevant following neural injury, include 
members of the chemokine family, such as CXCL12/CXCR4 (Dziembowska et al., 
2005). There may be also chemoattractive agents secreted from the OB such as sonic 
hedgehog (Shh) (Angot et al., 2008) or secreted or membrane-bound factors on the 
astrocytic glial tube that surrounds the NSCs in the RMS (Peretto et al., 2005), which 
may include molecules such as vascular endothelial growth factor (VEGF) (Wittko et 
al., 2009), the neuropeptides NPY and cholecystokinin (CCK; Stanic et al., 2008). 
1.3.2 THE DENTATE GYRUS OF THE HIPPOCAMPUS 
The second region in the mammalian brain with substantial adult neurogenesis is 
the DG of the hippocampus. Here, precursor cells reside in the SGZ, at the boundary 
between the granule cell layer and the hilus. 
Neurogenesis in this region has been extensively studied, partially due to its major 
role in the processing and storage of new information. Progenitor cells migrate a short 
distance from the SGZ into the granule cell layer (GL) and send their dendrites into the 
molecular layer (ML) and their axons into the CA3 region of the hippocampus 
(Markakis and Gage, 1999). Adult-born hippocampal granule neurons are 
morphologically indistinguishable from surrounding granule neurons (Kempermann, 
2003), and they develop mature electrophysiological properties (van Praag et al., 2002).  
In the SGZ, three types of neural progenitors have been identified based on their 
morphology and the expression of specific molecular markers. Type 1 hippocampal 
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progenitors (or B cells) have a radial process spanning the entire granule cell layer and 
ramifying in the inner molecular layer. These cells express nestin, GFAP and Sox2, but 
do not express S100β, a marker of mature astrocytes (Fukuda et al., 2003). Type B cells 
do not give rise to neurons directly but generate intermediate progenitors, which 
correspond to the small basophilic cells that are darkly stained by hematoxylin, referred 
to as type D cells or type 2 progenitors. Type 2 hippocampal progenitors have only 
short processes and do not express GFAP. Immature type 2 cells (type 2a) appear to 
divide and function as intermediate progenitors while more mature darkly stained type 2 
cells have a prominent process and have properties of neurons at different stages of 
maturation, characterized by the expression of DCX, PSA-NCAM, collapsin response 
mediator protein 4 (CRMP-4, also known as TUC-4 or Ulip-1), neurogenic 
differentiation (NeuroD), prospero homeobox protein 1 (Prox1), and neuronal nuclei 
(NeuN; Seri et al., 2004, Figure 1.8). 
 
Figure 1.8: generation of new granular neurons in the dentate gyrus of the 
hippocampus from neural stem cells in the subgranular zone (SGZ). Adult 
neurogenesis in the dentate gyrus of the hippocampus undergoes different 
developmental stages. Stage 1. Proliferation: stem cells (blue) give rise to transient 
amplifying cells (light blue). Stage 2. Differentiation: transient amplifying cells 
differentiate into immature neurons (green). Stage 3. Migration: immature neurons 
(light green) migrate a short distance into the granule cell layer. Stage 4. Axon/dendrite 
targeting: immature neurons (orange) extend their axonal projections along mossy fiber 
pathways to the CA3 pyramidal cell layer. They send their dendrites in the opposite 
direction toward the molecular layer. Stage 5. Synaptic integration: new granule 
neurons (red) receive inputs from the entorhinal cortex and send outputs to the CA3 and 
hilus regions. DG, dentate gyrus region; ML, molecular cell layer; GL, granular cell 
layer (from Ming and Song, 2005). 
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1.4 FACTORS INFLUENCING ADULT NEUROGENESIS 
1.4.1 PHYSIOLOGICAL FACTORS INFLUENCING ADULT NEUROGENESIS 
In the adult brain neurogenesis is dynamically regulated by a number of intrinsic 
as well as extrinsic factors. Endogenous extrinsic factors in the local microenvironment, 
often referred to as the “neurogenic niche” or “stem cell niche”, include neural 
precursor cells, surrounding mature cells, cell-to-cell interactions, cilia, secreted factors, 
and neurotransmitters. Microenvironments of the SVZ and SGZ, but not of other brain 
regions, are thought to possess specific factors that are permissive for the differentiation 
and integration of new neurons (Faigle and Song, 2013). The importance of the stem 
cell niche in determining the fate of adult NSCs is highlighted by several different 
transplantation experiments. SVZ-derived committed neural precursor cells differentiate 
into glial cells when grafted into ectopic non-neurogenic regions of the brain 
(Seidenfaden et al., 2006). Furthermore, SVZ precursor cells generate hippocampal 
neurons when transplanted into the DG of the hippocampus, whereas SGZ precursors 
generate olfactory interneurons after transplantation into the RMS (Suhonen et al., 
1996). Similarly, neural precursor cells derived from the adult spinal cord differentiate 
into granule cell neurons after implantation into the hippocampus, but fail to generate 
neuronal phenotypes, and differentiate into glial cells only after transplantation back to 
their original site in the spinal cord (Shihabuddin et al., 2000). In contrast, Merkle et al. 
showed that SVZ-derived NSCs maintained their region-specific potential in vivo, and 
that environmental factors at the host graft site were not sufficient to re-specify the 
grafted cells after heterotopic transplantation (Merkle et al., 2007).  
Several growth factors have been shown to be involved in regulating 
neurogenesis in the adult brain, most importantly EGF, FGF and VEGF. Members of 
the FGF and EGF growth factor families are primary mitogens used to propagate adult 
neural progenitors in vitro and are likely to perform similar functions in vivo (Lie et al., 
2004). In fact, infusion of EGF or FGF-2 increases cell proliferation in the SVZ and 
transient amplifying cells of the SVZ appear to express the EGF receptor (Doetsch et 
al., 2002; Morshead et al. 1994). VEGF receptors are expressed on endothelial cells and 
neural progenitors in the adult hippocampus and SVZ (Maurer et al., 2003) and the 
intracerebroventricular (i.c.v.) administration of VEGF increases neurogenesis in the 
SVZ and the SGZ of adult rat (Jin et al., 2002).  
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Bone morphogenetic proteins (BMPs) comprise a group of multifunctional 
extracellular signaling molecules of which over 20 members have been identified to 
date, and constitute the largest subgroup of the transforming growth factor-beta (TGFβ) 
superfamily (Kingsley, 1994). In the adult neurogenic niche, BMPs promote glial 
differentiation and inhibit neuronal fate specification. In the adult SVZ, BMP ligands 
and their receptors are expressed by the neural stem cell and progenitor cell population, 
and act as potent inhibitors of neuronal differentiation of Type B and C cells. 
Furthermore, BMPs were found to be important for promoting survival of neuroblasts 
migrating along the RMS (Lim et al., 2000). Interestingly, the BMP inhibitor Noggin is 
produced by ependymal cells of the SVZ and antagonizes endogenous BMP signaling 
and BMP-mediated premature glial differentiation at the expense of neurogenesis, thus 
promoting the formation of new neurons from SVZ precursors. In the adult SGZ, 
endogenously produced Noggin had previously been shown to be important for self-
renewal and proliferation of adult hippocampal NSCs in vitro and in vivo (Bonaguidi et 
al., 2008). 
Also chemokines have been reported to have a role in the regulation of neural cell 
proliferation, migration and survival, and can act in a paracrine or autocrine manner 
(Bajetto et al., 2002; Cartier et al., 2005). Adult NSCs express many chemokine 
receptors; in particular, neurospheres derived from adult mouse SVZ have been shown 
to express a range of chemokine receptors, including CCR1-8,10 and CXCR1-6 (Tran et 
al., 2004). Chemokines are expressed in different brain regions, with the highest levels 
in the OB, suggesting a role for these molecules in regulating basal adult NSC migration 
(Turbic et al., 2011). Functionally, specific chemokines can promote NSC proliferation, 
survival or migration (Dziembowska et al., 2005; Imitola et al., 2004; Krathwohl and 
Kaiser, 2004) in vitro. Following neural damage, NSC migration to the site of injury is 
promoted by CXCL12 (Imitola et al., 2004; Itoh et al., 2009), and is mediated, at least 
in part, by induction of metalloprotease expression in the NSCs (Barkho et al., 2008). 
CCL2, CCL3, and CXCL1 also promote NSC migration to the striatum following 
quinolinic acid lesion (Gordon et al., 2012).  
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Signal Effect on neurogenesis Neurogenic area 
EXTRINSIC 
Morphogens 
Wnt 
 
 
Notch 
 
Shh 
 
 
BMP 
 
Growth Factors 
FGF2 
VEGF 
Neurotransmitters 
GABA 
 
 
Glutamate 
 
Dopamine 
 
INTRINSIC 
Transcription Factors 
CREB 
 
Pax6 
Sox2 
 
NeuroD 
Epigenetic modulators 
miR-124 
miR-137 
 
 
Increases neurogenesis  
Required for neuronal differentiation 
Stimulates NSC proliferation/self-renewal 
Required for NSC proliferation, maintenance 
Required for dendritic arborization 
Required for progenitor proliferation 
Required for NSC maintenance 
Required for neuroblast migration 
Decreases neurogenesis 
Promotes neuroblast survival 
 
Increases neurogenesis 
Increases neurogenesis 
 
Decreases NSC proliferation 
Required for dendritic arborization 
Required for NSC quiescence 
Required for survival of migrating neuroblasts 
Required for neuronal survival 
Required for progenitor proliferation 
 
 
 
Required for neuronal survival 
Required for dendritic arborization 
Promotes neuronal differentiation 
Required for NSC proliferation 
Required for neural progenitor cell proliferation 
Necessary for survival, maturation of neuroblasts 
 
Promotes neuronal differentiation 
Required for NSC proliferation, maintenance 
 
 
SGZ 
SGZ 
SGZ/SVZ 
SGZ/SVZ 
SGZ 
SVZ 
SVZ 
SVZ 
SVZ 
SVZ 
 
SGZ 
SGZ/SVZ 
 
SVZ 
SGZ 
SGZ 
SVZ 
SGZ/SVZ 
SGZ/SVZ 
 
 
 
SGZ/SVZ 
SGZ/SVZ 
SVZ 
SGZ/SVZ 
SGZ/SVZ 
SGZ 
 
SVZ 
SGZ/SVZ 
Table 1.1: overview of signaling in adult neural stem cells. (Modified form 
Faigle and Song, 2013) 
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Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) 
activated signal transducer and activator of transcription 3 (STAT3), mitogen activated 
protein (MAP) kinase and PI-3K/Akt pathways upon ligand binding to their receptors, 
and have been shown to regulate NSC proliferation and differentiation (Ernst and 
Jenkins, 2004; Heinrich et al., 2003; Turnley and Bartlett, 2000). Specifically, in the 
dentate gyrus the activation of STAT3 by CNTF appears to be essential for the 
formation and maintenance of NSCs (Müller et al., 2009). 
Moreover, several soluble and membrane-bound extracellular factors and their 
intracellular signaling cascades including Wnt, sonic hedgehog (shh) and Notch have 
been recently identified as determinants of the local microenvironment of the SVZ and 
SGZ (Balordi and Fishell, 2007; Imayoshi et al., 2010; Kuwabara et al., 2009). Finally, 
cell-intrinsic mechanisms including transcription factors and epigenetic regulators of 
neurogenesis have recently been shown to be crucially involved in modulating 
neurogenesis in the adult brain (for review see Faigle and Song, 2013; Table 1.1).  
Moreover, although the precise mechanisms that generate new neurons in the 
adult brain remain elusive, also a range of environmental, behavioral, genetic factors 
have been shown to be involved in the regulation of adult neurogenesis.  
Environmental stimuli can greatly affect the proliferation and survival of newborn 
neurons in the adult CNS. Exposure of rodents to an enriched environment increases the 
survival of newborn neurons in the SGZ without affecting SVZ neurogenesis (Brown et 
al., 2003). Physical exercise, such as running, promotes SGZ neurogenesis by 
increasing cell proliferation and survival of the new granule neurons (Van Praag et al., 
1999a, 1999b). VEGF signaling may be responsible for the increased neurogenesis by 
both enriched environment and running (Cao et al., 2004). Hippocampus-dependent 
learning, such as blink reflex or water maze learning, appears to increase the survival of 
new granule neurons that have been generated only at a particular time window before 
the training (Leuner et al., 2004). Similarly, enriched odors exposure increases SVZ cell 
proliferation, but not SGZ neurogenesis (Rochefort et al., 2002). Both physical and 
psychosocial stress paradigms, as well as some animal models of depression, lead to a 
decrease in cell proliferation in the SGZ (Duman et al., 2001). Adult neurogenesis in 
both the SGZ and SVZ is also reduced during aging (Enwere et al., 2004; Kuhn et al., 
1996). Adrenal steroids may contribute to the aging-associated decline of neurogenesis 
in the SGZ (Cameron and Gould 1994). Reducing corticosteroid levels in aged rats can 
32 
 
restore the rate of cell proliferation, which suggests that aged neural progenitors retain 
their proliferation capacity as in younger adult animals (Cameron and McKay, 1999). 
Other hormones, including estrogen and prolactin, also regulate adult neurogenesis 
(Perez-Martin et al., 2003; Shingo et al., 2003). 
1.4.2 PATHOLOGICAL FACTORS INFLUENCING ADULT NEUROGENESIS 
Injury and pathological stimulations not only feature different aspects of adult 
neurogenesis in neurogenic regions, but also have an impact in otherwise non-
neurogenic regions (Arlotta et al. 2003, Parent, 2003). Most brain injuries lead to 
increased proliferation of progenitors in the SGZ and the SVZ and sometimes cause 
migration of newborn neurons to injury sites.  
Ischemic brain insults potently stimulate progenitor proliferation in both the SGZ 
and SVZ of adult rodents as shown by BrdU incorporation (Kokaia and Lindvall, 2003; 
Parent, 2003). In an experimental stroke model immature neurons also migrate from the 
SVZ to the damaged striatum and follow blood vessels. Most of these new neurons die 
between two and five weeks after injury (Arvidsson et al. 2002). These studies suggest 
that the local environment, although providing cues for attracting immature neurons and 
inducing neuronal subtype differentiation, is not adequate for long-term survival of the 
newborn cells. Several factors have been shown to promote neurogenesis following 
ischemia, including bFGF, EGF, BMP7, GDNF (glial cell line-derived neurotrophic 
factors) and cerebrolysin (Baldauf and Reymann, 2005; Chou et al., 2006; Ninomiya et 
al., 2006; Jin-qiao et al., 2009; Shen et al., 2010) and the inflammatory mediator tumor 
necrosis factor alfa (TNFα, Iosif et al., 2008). These factors appear to regulate NSC 
proliferation or survival and it is not clear whether they also play a role in the migration 
of the NSCs per se. Importantly, induction of endogenous neurogenesis following 
ischemia results in neuronal replacement (Parent, 2003) and functional 
electrophysiological integration (Lai et al., 2008), and is associated with improved 
functional recovery in rodent models (Bao et al., 2011).  
The migration of neurons from the SVZ towards the damaged areas of the brain is 
not observed only in cases of ischemia, but also in other CNS diseases. For example, 
studies of adult rodent models of limbic epileptogenesis or acute seizures show that 
seizure or seizure-induced injury stimulate neurogenesis in both the SGZ and SVZ 
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(Parent, 2003). These neuroblasts also show more rapid migration to the OB, and some 
appear to exit the RMS prematurely and migrate into injured forebrain regions.  
Moreover adult neurogenesis is significantly altered in chronic degenerative 
neurological diseases. Increased SVZ proliferation and neuronal production in response 
to degeneration are observed in patients with Huntington’s disease (Curtis et al., 2005). 
Data from simulated animal models of Huntington’s disease agreed with the post-
mortem findings in the human Huntington’s disease brains, with the SVZ showing 
lesion-induced upregulation of NSC proliferation, recruitment to the injured striatum, 
and differentiation into mature neurons (Collin et al., 2005; Gordon et al., 2007; 
Tattersfield et al., 2004). However, induced neurogenesis is transient and late derived 
precursors mostly display a glial phenotype (Gordon et al., 2007). Exogenous factors, 
such as BDNF, enhanced SVZ neurogenesis, promote precursor recruitment, neuronal 
differentiation and survival at the lesion site (Henry et al., 2007). Similarly, bFGF 
promotes neurogenesis and increases striatal spiny neuron differentiation, as well as 
their survival (Jin et al., 2005).  
Brains of Alzheimer’s disease patients also show increased expression of 
immature neuronal markers, such as DCX and PSA-NCAM, in the SGZ and the CA1 
region of Ammon’s horn (Jin et al., 2004a). In a transgenic mouse model of 
Alzheimer’s disease, an approximately twofold increase in BrdU incorporation and 
expression of immature neuronal markers in the SGZ and SVZ has been observed even 
before the neuronal loss and deposition of amyloid (Jin et al., 2004b). In the case of 
Parkinson’s disease patients, the proliferation of progenitors in the SGZ and SVZ is 
impaired probably by a mechanism that also involves a reduced secretion of EGF and 
CNTF by NSCs caused by the decreased dopaminergic (DA) transmission (O’Keeffe et 
al., 2009; Yang et al., 2008). Proliferation of transit-amplifying C cells in the SVZ is 
completely restored by DA agonists (ropinirole and pramipexole) and selective agonists 
at D2 or D3 receptors (Winner et al., 2009). 
Multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) 
are demyelinating diseases characterized by multifocal inflammatory lesions, with 
progressive oligodendrocyte and axonal loss. Although SVZ type B cells generally give 
rise to OB interneurons, they can also generate NG2-positive oligodendrocyte 
progenitor cells (OPCs) and give rise to mature myelinating oligodendrocytes (Menn et 
al., 2006), while PSA-NCAM-positive NSCs can be differentiated into myelin basic 
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protein-expressing myelinating oligodendrocytes (Cayre et al., 2006; Lachapelle et al., 
2002). Focal demyelination in the corpus callosum has been shown to induce SVZ 
expansion, resulting in mobilization of the newborn progenitors to the lesion sites 
(Menn et al., 2006), while in EAE, SVZ-derived progenitors migrate into periventricular 
white matter and exclusively differentiated into astrocytes and oligodendrocytes 
(Picard-Riera et al., 2002). Consistent with the rodent studies, human active MS plaques 
frequently show PSA-NCAM-positive progenitor accumulation, accompanied by 
increased cell proliferation and NSC numbers in the SVZ (Nait-Oumesmar et al., 2007). 
SVZ stem/precursor cells introduced via intravenous or intracerebral injection have 
been shown to enter and populate demyelinating lesions in rodent and primate CNS 
(Oka et al., 2004; Pluchino et al., 2003), and this migration appears to rely on the 
inflammatory environment (Giannakopoulou et al., 2011). The chemokine CXCL12, 
which is expressed by astrocytes in active MS lesions (Calderon et al., 2006), plays a 
role in NSC and oligodendrocyte precursor recruitment (Carbajal et al., 2010; Maysami 
et al., 2006). Mitogenic factors, such as EGF and bFGF, also assist progenitor cell 
mobilization, as well as their subsequent differentiation into oligodendrocytes at lesion 
sites. These findings indicate that an inflamed brain environment can trigger NSC 
proliferation and migration, with the specific cell types generated depending on the 
brain region. However, persistent inflammation in the brain can also result in 
accumulation of non-migratory NSCs in the SVZ, and pro-inflammatory factors such as 
interferon gamma (IFNγ) have a role in down-regulating their self-renewal capacity 
(Pluchino et al., 2008). This is consistent with the anti-proliferative effects of IFNγ on 
NSCs in vitro (Wong et al., 2004; Lum et al., 2009). Therefore the timing and balance 
of pro- and anti-inflammatory agent expression is important in dictating the NSC 
response to inflammatory CNS damage.  
1.4.3 EXTRACELLULAR NUCLEOTIDES AND NEUROGENESIS 
Recent evidence suggests an important role of the purinergic system in controlling 
adult neurogenesis. Mishra and co-workers (2006) were the first to show that the cells 
constituting secondary neurospheres expressed the mRNA for the P2Y1,2,6, but not for 
the P2Y4 receptor subtype. By measuring intracellular Ca
2+
 concentration they also 
showed that ATP (P2Y2 agonist), ADP (P2Y1 agonist) and, to a lesser extent, UTP 
(P2Y2,4 agonist) evoked rapid Ca
2+
 transients in secondary neurospheres, while UDP 
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had no effect. This latter finding suggested that, although expressed by neurospheres, 
the P2Y6 receptor is not functionally active. The P2Y1 specific antagonist N
6
-methyl-2-
deoxyadenosine 3',5'-bisphosphate (MRS2179) and the P2 non-selective antagonists, 
suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), 
significantly reduced the response evoked by the agonists; on the contrary, the 
application of antagonists alone had no effect on the cytosolic concentrations of Ca
2+
 
(Mishra et al., 2006). Adenosine 5'-O-(2-thiodiphosphate) (ADPβS, non-selective 
agonist for P2Y1,12,13) and UTP were also able to increase the proliferation of secondary 
neurospheres kept in culture in the presence of low growth factor (EGF and bFGF) 
concentrations. Also in this case, the antagonists MRS2179, suramin and PPADS 
drastically reduced the effect induced by purinergic agonists, while the application of 
the antagonist alone had no effect. These data led to the conclusion that the nucleotides 
acted mainly through the action of the P2Y1 and P2Y2 receptors and exerted a 
synergistic effect on the proliferation induced by growth factors such as EGF or bFGF 
(Mishra et al., 2006). Later, Stafford and colleagues (2007) demonstrated that also 
primary neurospheres derived from the SVZ of the adult mouse express mRNA for all 
the P2YRs (with the exception of the P2Y4), and for the P2X4 and P2X7 receptors 
subtypes. ATPγS, ADPβS and UTP evoked transient increases in cytoplasmic Ca2+ 
concentration in primary neurospheres while the application of UDP produced no effect, 
again suggesting that the P2Y6 receptor was not functional. Furthermore, increases in 
cytoplasmatic Ca
2+
 concentrations induced by ADPβS and ATP were completely 
inhibited by the P2Y1 selective antagonist MRS2179, further confirming a primary 
involvement of this receptor in the observed effects (Stafford et al., 2007). Stafford and 
colleagues also demonstrated that a single administration of ATPγS, ADPβS and 
adenosine (P1 agonist) was able to reduce the number and size of the resulting primary 
neurospheres. The administration of specific antagonists (MRS2179 selective for P2Y1, 
MRS2395 selective for P2Y12 and SCH58261 selective for A2A) before the addition of 
the above-mentioned agonists reduced their effects, whereas the administration of 
antagonists per se had no effects. The same studies were then conducted on secondary 
neurospheres, and the authors observed that ATPγS and adenosine retained their 
inhibitory effect while ADPβS enhanced cell proliferation, thus supporting the results 
obtained earlier by Mishra and collaborators (Stafford et al., 2007). Grimm and 
colleagues (2009) further investigated the combined effect of growth factors and 
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nucleotides and demonstrated that treatment of adherent and undifferentiated (nestin 
positive) cells with ADPβS or UTP induced the phosphorylation of ERK and CREB 
(Grimm et al., 2009). Grimm and colleagues used a pharmacological approach to 
understand which receptor subtypes were involved in the effect exerted by the 
nucleotides on ERK and CREB phosphorylation. Using a selective agonist for the P2Y1 
receptor subtype (MRS2365) they observed a slight decrease of ERK and CREB 
phosphorylation compared to what observed with ADPβS. The use of a P2Y12 selective 
antagonist (MRS2395) showed no effects on the activity of ADPβS, whereas Cangrelor, 
a selective competitive antagonist at both P2Y12 and P2Y13 receptors (Fumagalli et al., 
2004), and MRS2179 treatment resulted in a significant reduction in the 
phosphorylation of ERK and CREB. These data suggest that the P2Y1 and P2Y13 
receptors were the main mediators of the effect of ADPβS on ERK and CREB (Grimm 
et al., 2009). Upon differentiation of the neural precursors into astrocytes, 
oligodendrocytes and neurons (induced by removal of growth factors and by the 
addition of serum), only astrocytes were still able to respond to the application of 
ADPβS and UTP with an increase in the phosphorylation of ERK and CREB, while 
oligodendrocytes and neurons lost their ability to respond to agonists, suggesting the 
absence in these two populations of still functionally active P2YRs (Grimm et al., 
2009). Besides the effect on proliferation and differentiation, nucleotides and EGF can 
also influence cell motility and act as chemotactic signals. In fact, in NSC cultured in a 
medium lacking growth factors, a short exposure to agonists (ATP, ADPβS and UTP) 
resulted in significant changes in cell structure. Moreover it has been demonstrated that 
the addition of agonists to a culture medium with reduced growth factors concentrations 
stimulates cell migration (Grimm et al., 2009). These effects were due to the ability of 
ATP, ADPβS and UTP to induce changes in the phosphorylation of AKT and FAK 
(focal adhesion kinase) mediated by ERK and CREB. FAK is a tyrosine kinase located 
between the intercellular connections and exerts its action by changing actin 
polymerization and altering contacts between cells (Mitra et al., 2005). AKT is a kinase 
implicated in many cellular processes, and its activity is associated with cell motility as 
it influences the organization of the actin cytoskeleton and the interactions of the cell 
with the extracellular matrix (Qian et al., 2004). This study demonstrated that EGF and 
nucleotides are able to act as autocrine or paracrine signals in order to maintain the 
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cellular structure of the SVZ and to regulate the migration of neuroblasts towards the 
OB (Grimm et al., 2010). 
In the SVZ and in the OB specific ectonucleotidase were found (Hassenklöver et 
al., 2010). The tissue non-specific form of alkaline phosphatase (TNAP) is expressed by 
all the neural progenitors of the adult SVZ cells (type B, C and A cells). TNAP is 
responsible for hydrolysing extracellular nucleoside triphosphates to the respective 
nucleoside. By contrast, NTPDase2 (which preferentially hydrolyses nucleoside 
triphosphates to nucleoside diphosphates) is specifically expressed by type B cells 
(either residing in the SVZ or ensheating type A cells along the RMS, by neural 
progenitors of the dentate gyrus and by postnatal radial glial cells of the cerebral cortex 
(Figure 1.9).  
 
Figure 1.9: purinergic signaling in adult neural development. The tissue non-specific 
form of alkaline phosphatase (TNAP) is expressed by all the neural progenitors of the 
adult SVZ cells (type B, C and A cells). By contrast, NTPDase2 is specifically expressed 
by type B cells. The NTPDase2- and TNAP-expressing neurospheres derived from the 
SVZ release ATP and express several P2Y receptors (modified from Neary and 
Zimmermann, 2009). 
 
Although the presence of P1, P2X2,4,5,6,7 and P2Y1,2 receptors in the murine OB 
(Hassenklöver et al., 2010) and of P2X1,2,6,7 and P2Y1,2,4 in the SVZ of adult mice has 
been proved, in vivo pharmacological studies are almost completely missing, and the 
physiological relevance of the purinergic system in these brain regions is still elusive. 
Hassenklöver and collaborators investigated the effects 2-methylthio-ATP (2MeSATP, 
TNAP
(P2Y1,2,6,12,13,14, NTPDase2, TNAP)
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P2Y1 agonist) and ATP (P2X and P2Y2 agonist) administration to ex-vivo sections of 
OB and SVZ of Xenopus laevis larvae, and observed a significant increase in [Ca
2+
]i in 
both regions. Furthermore, they showed that the non-selective antagonists suramin and 
PPADS attenuated these responses, confirming that the observed effect were due to the 
presence of purinergic receptors in both areas (Hassenklöver et al., 2010). To 
understand which receptor subtypes were involved, Hassenklöver and collaborators 
evaluated the effect of the removal of calcium in the culture medium of cells derived 
from the SVZ of X. laevis. In these conditions, the increase in [Ca
2+
]i induced by the 
two agonists were significantly reduced in OB, while in the cells of the SVZ agonists 
still retained a significant effect. This difference between the two areas has suggested 
that in the OB the increase in [Ca
2+
]i induced by nucleotides was almost completely due 
to the activation of ionotropic P2X receptors, whereas in the SVZ was the result of the 
combined effect of ionotropic and metabotropic receptor (P1 and/or P2Y), which are 
known to be coupled to intracellular cascades linked to calcium release from internal 
stores (Hassenklöver et al., 2010). 
Suyama and colleagues (2012) have conducted further in vivo studies to 
investigate the role of purines on SVZ cells proliferation. ATP, suramin or MRS2179 
were chronically infused in the lateral ventricle of adult mice for 3 days. Mice were also 
treated with BrdU following two different protocols to highlight either the proliferation 
of rapidly proliferating cells (transit amplifying cells) or of stem cells. ATP, suramin 
and MRS2179 treatment did not induce changes in stem cell proliferation, but when 
short BrdU administration was used to mainly label cells in rapid proliferation, ATP 
increased the number of BrdU
+
 cells. Furthermore, 38% of BrdU
+ 
cells were also 
positive for the typical type C cell marker Mash1, suggesting that exposure to ATP 
promoted the proliferation of this cells type. Authors suggested the P2Y1 receptor 
subtype as the possible mediator of this effect. In fact, the administration per se of both 
suramin and MRS2179 lowered the percentage of proliferating type C cells. In addition, 
a similar decrease was also observed in P2Y1 knock-out mice. Finally, Suyama and 
collaborators demonstrated that the P2Y1 receptor was expressed in 73.2% of DCX
+ 
cells and 31.1% of Mash1
+
 cells, but not in BrdU/GFAP double-positive cells (Suyama 
et al., 2012).  
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In conclusion, the currently available data on the role of the purinergic system in 
the OB and SVZ are still limited and further studies are needed to define in detail the 
role of purines in these brain areas and in the control of adult neurogenesis. 
1.5 NEUROGENESIS IN NON-NEUROGENIC REGIONS 
As previously mentioned, neurogenesis outside the two classical neurogenic 
regions appears to be extremely limited in the intact adult mammalian CNS. However 
after pathological stimulation, such as brain insults, adult neurogenesis occurs in regions 
otherwise considered to be non-neurogenic, such as the brain parenchyma and the spinal 
cord. In particular, in the brain parenchyma two glial cell types are considered to retain 
stem cell properties: astrocytes and polydendrocyets, also known as oligodendrocyte 
precursor cells (OPCs).  
Parenchymal astrocytes react to insults by proliferation and GFAP up-regulation. 
Reactive astroglia reacquire self-renewal capability and generate astrocytes, neurons 
and oligodendroglia in a favorable environment in vitro (Buffo et al., 2008). 
Accordingly, in vitro transduction of astrocytes with retroviruses containing neurogenic 
transcription factors (e.g., Pax6, Dlx2 or Ngn2) promoted neuronal fates (Berninger et 
al., 2007; Heinrich et al., 2011; Heins et al., 2002). Moreover, also in vivo transduction 
of adult reactive glia evoked neurogenic attempts, that, however, remained abortive, as 
cells did not progress to fully mature neurons (Buffo et al., 2005; Kronenberg et al., 
2010). 
In basal conditions, OPCs represent the vast majority of actively cycling 
progenitors outside the germinal niches in the adult CNS (Buffo et al., 2005; Dawson et 
al., 2003; Horner et al., 2000) and develop into mature oligodendrocytes. However, it 
has been suggested that, under some conditions, NG2 cells can give raise to astrocytes 
and neurons, as described in more details below (1.5.2.1). A first sensational 
demonstration that these cells can be reprogrammed to generate neurons (Kondo and 
Raff, 2000a) has been followed by only a few in vitro confirmations (Liu et al., 2007) 
and conflicting in vivo results (Dimou et al., 2008; Richardson et al., 2011).  
In the spinal cord (SC) the cells lining the central canal, namely ependymal cells 
(ECs), are considered the stem-like cells in this part of the CNS. In the intact tissue, 
these cells are virtually quiescent, self-renew very slowly and give raise to a very small 
number of neurospheres in vitro. However, after SC injury (SCI) or hypoxia, ECs 
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proliferate and express GFAP, a marker of multipotency (Ceruti et al., 2009). Activated 
ECs generate a significantly higher number of neurospheres (Barnabé-Heider et al., 
2010), and give raise to astrocytes, oligodendrocytes and, under some conditions, 
motoneurons when exposed to differentiating agents in vitro (Moreno-Manzano et al., 
2009). However, fate-mapping analysis of ECs revealed generation of astrocytes and 
oligodendrocytes only following SCI in vivo (Meletis et al., 2008).  
1.5.1 ASTROCYTES AND REACTIVE ASTROGLIOSIS 
Astrocytes, one of the most abundant cell type in the CNS (Markiewicz and 
Lukomska, 2006), were for long time believed to mainly provide architectural structure, 
nutrition and homeostasis in the healthy brain. Nowadays this view has changed and 
they are also known to control neuronal activity (Araque et al., 1999), to regulate 
neurogenesis from neural stem cells in the adult brain (Song et al., 2002), or to act as a 
source of neural stem cells themselves (Buffo et al., 2008).  
Since the late nineteenth century, astrocytes have been divided in two main 
subtypes, protoplasmic or fibrous, based on their anatomical location and cellular 
morphology. These two main categories retain their validity and usefulness today. 
Protoplasmic astrocytes are located in the grey matter and possess numerous highly 
branched fine processes whereas the fibrous astrocytes can be found in the white matter 
and have less branched and thicker processes (Sofroniew and Vinters, 2010). Electron 
microscopic analyses revealed that the processes of protoplasmic astrocytes in the grey 
matter envelop synapses, while the processes of fibrous astrocytes in the white matter 
contact nodes of Ranvier. Both types of astrocytes form gap junctions between distal 
processes of neighboring astrocytes (Peters, et al., 1991). Astrocytic processes 
associated with synapses tightly regulate synapse formation, maintenance and plasticity 
through the regulation of extracellular K
+
 and the uptake and release of many 
molecules, including neurotransmitters, constituting the so-called tripartite synapse 
(Halassa et al., 2009). Finally, they also provide to neurovascular coupling and to the 
formation of blood brain barrier (BBB), integrating glia, neurons and brain vasculature 
into functional networks (Franke et al., 2012; Figure 1.10). 
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Figure 1.10: schematic representations that summarize astrocyte functions in the 
healthy CNS. In the grey matter, astroglial perisynaptic processes ensheath synapses, 
whereas in the white matter astroglial processes terminate at nodes of Ranvier, the sites 
of action potential generation. Astrocytes assume also numerous and well-defined 
supportive functions, including structural support, providing for neurovascular 
coupling, regulation of extracellular K
+
, uptake of neurotransmitters, metabolic support 
of neurons. Finally they are connected via gap junctions into syncytia and communicate 
through propagated waves of Ca
2+
 and other active substances (modified from 
Sofroniew and Vinters, 2010). 
 
In addition to play an essential homeostatic role and to contribute to information 
processing in physiological conditions, astrocytes are capable to respond to any kind of 
insult to the CNS. In their reaction to injury, named reactive astrogliosis, astrocytes 
leave their quiescent state and become activated. During this process, they undergo 
hypertrophy, upregulate intermediate filaments composed of nestin, vimentin, and 
GFAP, and activate cell proliferation (Pekny and Nilsson, 2005; Buffo et al., 2008). 
Moreover, in their reactive state astrocytes can continue to divide, migrate to form the 
glial scar, and release a plethora of factors mediating the tissue inflammatory response 
and remodeling after lesion (Elmquist et al., 1997; Silver and Miller, 2004; Figure 
1.11).  
42 
 
 
Figure 1.11: hallmarks of astrocyte reactivity. Upon CNS injury, activated astrocytes 
increase their homeostatic and trophic functions (a), the production of growth factors 
and cytokines, as well as the release of nucleotides and toxic compounds (b). Their 
secretion is regulated via complex autocrine and paracrine loops (b). Astrogliosis 
includes cell proliferation (c) and migration towards the lesion site (d). Reactive 
astrocytes participate in glial scar formation, and contribute to the resealing of the 
damaged blood–brain barrier, thus excluding infiltrating leukocytes and meningeal 
fibroblasts from the injured tissue (e). Nt/Nu, nucleotides/nucleosides; BBB, blood–
brain barrier (From Buffo et al., 2010)  
 
It is now increasingly clear that the modalities and dynamics of astrocyte response 
to damage are crucial to the outcome of several brain pathologies and to the degree of 
neurological damage.  
Upon injury, the astroglia response is evoked by several changes occurring in the 
CNS parenchyma. These changes include the production of a variety of molecular 
signals, partly derived from plasma extravasation, able to trigger the transition from the 
quiescent to the activated state or to modulate astrocyte reactivity over time. The 
distinction between activating and modulating signals remains largely undefined. 
However, very early triggers such as purines/pyrimidines and pro-inflammatory 
cytokines (Abbracchio and Ceruti, 2006) are predominantly considered to evoke the 
initial astrocyte activation (although their release can be also maintained over time thus 
contributing to later responses). The major role of the later secondary mediators (e.g., 
endothelin, GFs, inflammatory molecules) may instead be to sustain the long-term 
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features of astrogliosis until inhibitory molecules, such as interferon beta (IFNβ), 
interleukin 10 (IL10), and erythropoietin (Epo), predominate over inductive triggers (de 
Bilbao et al., 2009; Ito et al., 2009; Vitellaro-Zuccarello et al., 2008). At this final stage, 
resolution of gliosis leads to the reacquisition of quiescent morphological and functional 
features in astrocytes far from the source of injury (isomorphic gliosis), or to the 
stabilization of astroglia reactive traits in the form of a permanent glial scar close to the 
lesion site (anisomorphic gliosis) (see below; Elmquist et al., 1997).  
Astrocyte responses to injury are aimed at both protecting the nervous system, and 
at sealing off the damaged area, leaving the heavily injured zone to its natural 
degenerative fate, while preserving the less affected tissue. Once activated, these 
responses seem to proceed in a quite stereotyped way, independently of the initial 
source of injury. Hence, they may lead to predominant reparative or destructive 
outcomes depending on the context in which they occur, for example the extent and 
type of injury (i.e., chronic vs. acute), and the time point after damage. The healing 
response to injuries of the mature CNS culminates in the formation of a tight barrier, the 
glial scar, which consists predominantly of reactive astrocytes. Scarring astrocytes have 
long been considered as a major impediment to regeneration of damaged axons (Davies 
et al., 1997; Liuzzi and Lasek 1987; Ramon y Cajal 1928) and reactive gliosis regarded 
as detrimental to nervous tissue repair and functional restoration. Although astrocytes 
continue and even intensify their trophic activities upon injury, in the condition of 
extremely severe or prolonged damage, such as in the core of ischemic insults, their 
energetic metabolism may succumb, and essential functions, such as the activity of 
Na
+
/K
+
 ATPase regulating membrane potential, may be lost. The consequent 
depolarization of astrocyte membrane, together with an increased extracellular Na
+
 
concentration, can reverse glutamate transport, produce glutamate efflux and transform 
astrocytes into a source of substances toxic to neurons. Nevertheless, these events are 
thought to normally occur at a time when neuronal damage is already beyond repair, 
implicating that they have a limited impact on secondary death (Rossi et al., 2007). 
Glutamate, however, may also be released by reactive and fully functional astrocytes 
through their hemichannels, which can be opened by lowering extracellular Ca
2+
 
concentration, acidosis, or even through P2X7 receptors activated by excessively high 
extracellular ATP. All these events occur during lesions such as ischemia, and may 
account for the spreading of death signals (Rossi et al., 2007). Damage diffusion may 
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also occur via astrocytic gap junctions, although this form of cell-to-cell communication 
is globally reduced upon damage (Contreras et al., 2004). A series of studies further 
revealed that the secretory activity of reactive astrocytes can exacerbate tissue lesion. 
For instance, released pro-inflammatory cytokines such as TNFα can inhibit neurite 
growth and kill oligodendrocytes (Neumann et al., 2002; D’Souza et al., 1996). 
Similarly, reactive astrocytes can produce and release arachidonic acid metabolites, 
nitric oxide and reactive oxygen species. 
The concept of a protective role for astroglial reactivity has only recently been 
established, emerging from the ability of reactive astrocytes to isolate the damaged core 
of vascular and traumatic lesions from the surrounding healthy tissue, thus reducing the 
spreading of toxic substances and metabolites released from dead cells and limiting the 
development of secondary damage (Rolls et al., 2009). These beneficial effects are 
related to the capability of astrocytes to produce signals supportive for neuronal and 
oligodendroglial survival, to preserve and restore altered homeostatic conditions, and, 
when lost, to re-establish the anatomical barriers (e.g., the BBB) necessary for the 
correct CNS functioning. Astrocyte protective actions are exerted by scavenging 
extracellular glutamate, storing energy, supplying neighboring cells with energetic 
compounds, and neutralizing toxic substances. For instance, one of the major causes of 
secondary damage in case of ischemia or trauma is the massive release of glutamate 
(due to direct cell injury or neuronal dysfunction) that triggers secondary excitotoxic 
events in neurons. Astrocytes are crucial regulators of glutamatergic signaling in normal 
nervous tissue function by active removal of extracellular glutamate operated by the 
Na
+
-dependent glutamate transporter 1 (GLT1) and GLAST (Danbolt, 2001). When the 
energy substrates glucose and oxygen are lost (i.e., in ischemia), the persistence of this 
function in astrocytes is to some extent granted due to the capacity of astroglia to 
maintain high energy levels upon lesion and to utilize diverse energy sources. For 
example, astrocytes convert stored glycogen to glucose or lactate to obtain energetic 
substrates, thereby sustaining their own metabolisms or possibly passing these 
substrates to neighboring neurons for energy production (Brown, 2004). Moreover, 
CNTF-activated astrocytes also increase fatty acid beta-oxidation and ketolysis to 
produce energy, while decreasing glycolytic pathways. This metabolic plasticity confers 
a remarkable ability to resist to metabolic insults and to support the survival of 
surrounding neurons (Escartin et al., 2007). Furthermore, the enhanced capability to 
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metabolize fatty acids has also a detoxificant function when potentially toxic free fatty 
acids are released from phospholipids in the plasma membrane in several lesion 
conditions (Phillis and Regan, 2004). Other beneficial aspects of astrocyte reactivity are 
related to their participation in tissue remodeling after injury. VEGF is produced by 
reactive astrocytes after traumatic injury, inflammatory lesions, and hypoxic conditions. 
In addition of being directly neuroprotective, this growth factor strongly promotes 
angiogenesis, consistent with a role for reactive astrocytes in neovascularization after 
lesion (Argaw et al., 2009; Carmeliet, 2005; Rosenstein and Krum, 2004). Finally, the 
wide set of GFs upregulated by astrocytes after lesion conditions provides direct trophic 
support to neurons and oligodendrocytes to limit secondary damage. Moreover, some of 
these factors to some extent create a permissive environment for remyelination by their 
action on oligodendrocyte precursor migration, oligodendrocyte proliferation, and 
differentiation together with other signals (i.e., IL6) (Williams et al., 2007). In 
summary, the long-standing concept of astrogliosis as an obstacle to brain repair has 
now greatly evolved with the discoveries of the many and essential beneficial effects of 
astrocyte reactivity for damage limitation and tissue preservation. It is also increasingly 
clear that the inhibitory components of the scar undergo extensive remodeling over time 
so that the scar becomes progressively more permissive to axon growth. 
1.5.1.1 P2 receptors in reactive astrogliosis 
eNTs have been implicated as endogenous triggers of reactive astrogliosis. Upon 
trauma or ischemia, brain cells are exposed to elevated concentrations of nucleotides 
and nucleosides for prolonged periods as a result of leakage from the nucleotide 
cytosolic pool (due to loss of membrane permeability) or nucleic acid degradation upon 
cell death, due to persistent or stronger insults. Thus, during emergencies astrocytes and 
surrounding cells are exposed to high micromolar nucleotide concentrations. Since 
astrocytes express the whole panel of P2YRs at the mRNA level, as well as the 7 
ionotropic P2X subtypes (Fumagalli et al., 2003), the purinergic system appears as a 
key modulator of the astrocytic response to injury. Indeed, in vitro (Bolego et al., 1997; 
Brambilla et al., 1999; Neary et al., 1999) and in vivo (Franke et al., 2001) evidence 
indicates that ATP and its analogues promote astrocytic proliferation and emission of 
long and branched GFAP-positive processes through the activation of specific G 
protein-coupled P2Y receptors.  
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The first evidence in this respect dates back to the early 90s when Kim and 
Rathbone were purifying brain proteins that stimulated proliferation of cultured chick-
brain astrocytes (Kim et al., 1991; Rathbone et al., 1992). They isolated a potent 
mitogenic fraction that was not a protein, and was identified by chemical analysis as 
guanosine 5'-monophosphate (5’-GMP). Rathbone and his colleagues soon determined 
that guanosine, adenosine and their respective 5’-mono-, di- and triphosphate 
derivatives also stimulated proliferation and DNA synthesis of chick astrocytes in vitro 
(Neary et al., 1996). The ability of the hydrolysis-resistant ATP analogue α,βmeATP to 
influence both proliferation and differentiation of primary rat striatal astrocytes in 
culture has been also demonstrated (Abbracchio et al., 1994). ATP can act in 
combination with FGF, EGF, platelet-derived growth factor (PDGF) as well as nerve 
growth factor (NGF) to stimulate astrocytic proliferation, contributing to the process of 
reactive astrogliosis and to hypertrophic/hyperplastic responses (Neary et al., 2006). 
Moreover α,βmeATP, by inducing a concentration-dependent increase of GFAP-
positive processes, promoted maturation of astrocytes towards a more differentiated 
phenotype characterized by longer and thicker processes (Abbracchio et al., 1995). In 
subsequent studies, similar effects were obtained with other nucleotides, such as ATP, 
adenosine 5’-O-(2-thiodiphosphate) (ADPβS), 2meSATP, βγmeATP and UTP. 
Nucleotide-induced astrogliosis was inhibited by pertussis toxin (suggesting the 
involvement of a G protein-coupled P2Y receptor) and by several typical P2 receptor 
antagonists, such as suramin and PPADS, but not by P2 receptor antagonists that 
preferentially block P2X receptors, such as 2’,3’-O-(2,4,6-trinitrophenyl)-ATP (TNP-
ATP) (Bolego et al., 1997; Brambilla et al., 2002). Importantly, the relevance of these in 
vitro findings were also confirmed in vivo by Franke and co-workers (Franke et al., 
2001) while investigating the morphological effects induced by local application of P2X 
and P2Y ligands in the nucleus accumbens of rats. A strong mitogenic effect was 
induced on astrocytes by ADPβS, 2meSATP, α,βmeATP and, to a smaller extent, 
uridine-5'-(γ-thio)-triphosphate (UTP-γS). Finally, it has been demonstrated that the 
selective stimulation of astroglial P2Y1Rs is involved in the secretion of glutamate 
(Domercq et al., 2006) and in the regulation of several cytokines/chemokines already 
known to be involved in astrogliosis, such as IL-6 (Fujita et al., 2009), GDNF (Sun et 
al., 2008) TNF-α, monocyte chemotactic protein-1/chemokine (MCP-1/CCL2) and IP-
10/CXCL10 messenger RNA (mRNA) expression (Kuboyama et al., 2011). 
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P2YRs in astrocytes are linked to a variety of signal transduction mechanisms. 
This receptor family can activate: (1) the MAP kinase pathway, an obligatory step for 
the triggering and/or persistence of reactive astrogliosis, (2) the phosphoinositide 3-
kinase (PI3K)/Akt pathway, associated with cell growth, fiber regeneration, and 
inhibition of apoptosis, and (3) the PKC pathway (Brambilla et al., 2003; Burgos et al., 
2007; Franke et al., 2009; Jacques-Silva et al., 2004; Neary and Kang, 2005; Neary et 
al., 2003). In rat primary astrocytes culture, stimulation of P2YRs led to activation of 
extracellular-regulated kinases 1/2 (ERK1/2) via multiple parallel signaling pathways 
involving Gi/o protein-dependent and calcium-independent stimulation of 
phosphatidylcholine phospholipase C (PC-PLC) and/or phospholipase D (PLD), with 
consequent activation of the Ras/Raf system (Brambilla et al., 2003). Application of a 
rapid and reversible stretch-induced injury to cultured astrocytes resulted in immediate 
ERK1/2 activation, which was already maximal after 10 min (Neary et al., 2003). ERK 
activation was prevented by apyrase and P2 receptor antagonists, suggesting that injury 
caused the release of ATP, which may in turn autocrinally and heterocrinally signal to 
astrocytes and stimulate ERK1/2 activity. Studies with various P2 receptor antagonists 
indicated that, in this experimental model, activation of P2Y1 and P2X2 receptor 
subtypes might be particularly important for the detected effects (Neary et al., 2003).  
The PI3K/Akt pathway is associated with controlling the balance between 
survival and cell death. Akt activation after trauma, axotomy and ischemia is well 
established. Purinergic stimulation of Akt phosphorylation in astrogliosis was studied in 
vitro (Burgos et al., 2007; Jacques-Silva et al., 2004; Neary and Kang, 2005) and in vivo 
in the rat brain (Franke et al., 2009). In particular, the involvement of P2Y1Rs in Akt 
activation in vivo suggests that the PI3K/Akt cascade stimulates astroglial proliferation 
and prevents apoptosis, indicating contribution of specific P2R subtypes during 
neurodegenerative diseases associated with excessive gliosis (Franke et al., 2009). 
Both the ERK and the Akt pathways are known to influence gene expression 
through phosphorylation/activation of transcription factors, such as c-Fos, c-Jun, Elk1, 
ATF2 or STAT3. c-Fos is an early gene product that contains a binding site for the 
activating protein 1 (AP-1) in its promoter and heterodimerizes with c-jun to form an 
AP-1 complex (Masood et al., 1993; Hope et al., 1994; Perez-Cadahia et al., 2009). 
Triple-labeling studies demonstrated c-Fos expression in P2Y1R-positive GFAP-
labelled astrocytes. Previous in vitro experiments reported an extracellular ATP-induced 
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up-regulation of c-Fos protein and the formation of AP-1 transcription complexes 
(Bolego et al., 1997). eNTs also increased DNA binding of nuclear factor kappa B (NF-
kB), another transcription factor crucially involved in several inflammatory events 
including reactive astrogliosis. Pharmacological data indicated involvement of distinct 
P2 receptors in the activation of these two families of transcription factors. In particular, 
ATP and ADP were equipotent in inducing NF-kB activation (followed by BzATP, with 
no effect of UTP), whereas ADP was the most potent trigger for AP-1 activation 
(followed by ATP, with no effect by either BzATP or UTP) (John et al., 2001). Finally, 
ATP triggers reactive astrogliosis by activation of a P2YR linked to the induction of 
cycloxygenase-2 (COX-2), and P2YR antagonists might counteract excessive COX-2 
activation in both acute and chronic neurological diseases (Brambilla et al., 1999). 
Transduction signaling to COX-2 induction involves an early activation of 
phospholipase A2 (PLA2) and arachidonic acid (AA) release; this may, hence, act as an 
inducer of the COX-2 gene via the PKC/MAPK pathway (Brambilla and Abbracchio, 
2001). The different associated intracellular signaling pathways, e.g. STAT3, nuclear 
NF-κB, signaling molecules suppressor of cytokine signaling 3 (SOCS3), cAMP, 
JNK/c-Jun, FGF and MAPK (Figure 1.12), are implicated in mediating different 
aspects and/or different degrees of reactive astrogliosis, such as GFAP up-regulation, 
cell hypertrophy, proliferation and pro- or anti-inflammatory effects (Sofroniew, 2009).  
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Figure 1.12: schematic illustration of examples of signal transduction pathways in 
astroglial cells following P2Y1R activation. Stimulation of P2Y1Rs leads to the 
activation of phospholipases A2 and C (PLA2, C) and protein kinase C (PKC), as well 
as to an increase in intracellular calcium ([Ca
2+
]i). The activation of P2Y1Rs result in 
the induction of second messenger and enzyme cascades, e.g. activation of the mitogen 
activated protein kinase (MAPK) pathway proteins [ERK1/2, p38, c-Jun N-terminal 
kinase (JNK)], and of PI3K/Akt. P2Y1R-mediated signal transducer and activator of 
transcription 3 (STAT3) signaling may play a role in astrocyte proliferation and 
reactive astrogliosis. P2Y1R activation appeared to be involved in the activation of 
caspase (Casp) cascades, in the release of arachidonic acid, and in the increase in 
prostaglandin E2 (PGE2) levels. In addition, P2Y1R activation induces the activity of 
transcription factors such as nuclear factor κB (NF-κB), cyclic element-binding protein 
(CREB) and activator protein 1 (AP-1) which up-regulate the expression of 
proinflammatory genes, e.g. c-Fos, c-Jun, c-Myc (from Franke et al., 2012). 
1.5.2 OLIGODENDROCYTE PRECURSOR CELLS (OPCS) 
OPCs comprise approximately 8% of the glia population in the CNS and they 
undergo a complex temporally regulated program of proliferation, migration, and 
differentiation following their appearance at mid-gestation. It was shown that these cells 
first develop in the ventricular germinal zones of the embryonic spinal cord and brain 
and disseminate through the developing CNS by proliferation and migration, becoming 
more-or-less uniformly distributed throughout the CNS soon after birth in rodents 
(reviewed by Miller, 1996; Richardson et al., 2006). OPCs can be identified by cell-type 
specific markers including the transcription factor Olig2, the lipid antigen A2B5, the 
platelet derived growth factor alpha receptor (PDGFαR), and the chondroitin sulfate 
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proteoglycan NG2. Due to the expression of the latter, they are also known as NG2 
cells. During their differentiation into mature oligodendrocytes they lose the expression 
of these progenitor marker proteins and pass through an intermediate stage, called pre-
oligodendrocyte, in which they are O4-positive, towards a mature myelinating stage 
where they express myelin proteins, including the myelin associated glycoprotein 
(MAG) and myelin basic protein (MBP) (Nishiyama et al., 2009). 
OPCs are not only the primary source of oligodendrocytes during development; 
they can also generate oligodendrocytes in the mature CNS and represent the primary 
source of remyelinating cells in demyelinated multiple sclerosis lesions (Nishiyama et 
al., 2009). However, not all OPCs develop into mature oligodendrocytes and a large 
number remain as progenitors in the mature white and grey matter. Since these 
progenitors are more abundant than would be required for the replacement of lost 
oligodendrocytes, OPCs may have other important yet-to-be understood functions 
within the CNS. Moreover, OPCs constitute the major dividing population of cells 
within the adult brain and make up about 70% of the cells labelled following a pulse 
injection of BrdU (Dawson et al., 2003). Electrophysiologically, NG2 cells show a 
characteristic ‘‘complex’’ pattern, distinct from the passive glial patterns, but also 
different from neuronal features. In fact, both cultured and in situ OPCs express distinct 
voltage-gated ion channels depending on their maturation stage (Sontheimer et al., 
1989), including both inward and outward rectifying K
+
 channels (Sontheimer and 
Kettenmann 1988; Williamson et al., 1997), Na
+
 channels (Berger et al., 1992) and 
different subtypes of Ca
2+
 channels (Verkhratsky et al., 1990). OPCs express also 
neurotransmitter receptors, proteins usually associated with neuronal activities (Barres 
et al., 1990, Berger et al., 1992; Sontheimer et al., 1989). Furthermore, there is a 
synaptic association between OPCs and neurons in the developing and adult CNS 
(Bergles et al., 2000; Gallo et al., 2008; Jabs et al., 2005). These synaptic contacts 
between OPCs and axons have been described for neurons in the cerebellum, 
hippocampus, and corpus callosum (Bergles et al., 2000; Kukley et al., 2007; Ziskin et 
al., 2007). Excitation of NG2-positive cells can occur via neuronal release of GABA or 
glutamate which activate GABAA or AMPA receptors, respectively, on OPCs and 
trigger a calcium signal (Gallo et al., 2008; Hamilton et al., 2010; Paukert and Bergles, 
2006). Furthermore some NG2 cells were found to display spiking sodium currents in 
response to an initial depolarization stimulus (De Biase et al., 2010; Chittajallu et al., 
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2004; Clarke et al., 2012; Káradóttir et al., 2008). Thus, NG2 cells appear ambiguous, 
glial in form (since they do not possess axons), but with some electrical properties akin 
to neurons, and are now consider as a ‘‘fifth neural cell type’’ after neurons, 
oligodendrocytes, astrocytes and microglia (Richardson et al., 2011). 
1.5.2.1 OPCs as multipotent neural stem cells 
Their chimeric nature contributed to the idea that NG2 cells might be more plastic 
than previously imagined and perhaps capable of transforming into neurons as well as 
glia; the question of whether OPCs are multipotent progenitor cells, however, is 
currently a highly debated topic. The first study rising this hypothesis was published by 
Kondo and Raff (Kondo and Raff, 2000a). In this study they demonstrated that NG2-
glia purified from early postnatal (P6) rat optic nerves can be reprogrammed by first 
treating with fetal calf serum (FCS) or BMPs to generate type-2 astrocytes, followed by 
growth in bFGF to generate multipotent stem cells that could be grown as neurospheres 
and could differentiate to oligodendrocytes, astrocytes and even neurons (Kondo and 
Raff, 2000a). In a later study they also showed that the neuronal fate potential of OPCs 
was due to epigenetic modification and to the reactivation of Sox2, a transcription factor 
that is expressed early in the developing neural tube and is essential for the maintenance 
of the multipotent state in NSCs (Kondo and Raff, 2004). The involvement of 
epigenetic mechanisms, and in particular the role of the histone deacetylases (HDAC) in 
the commitment of OPCs has been later further demonstrated. In this respect, it has 
been shown that HDAC inhibitors, such as valproic acid (VPA) and trichostatin A 
(TSA), induce neuronal differentiation at the expense of glial differentiation in in vitro 
conditions that favor glia-specific differentiation. Further, HDAC inhibition upregulated 
the neuron-specific gene NeuroD, a neurogenic basic helix–loop–helix transcription 
factor (Hsieh et al., 2004), and activated the Ras–ERK pathway (Jung et al., 2008), 
resulting in the induction and suppression of neuronal and glial differentiation, 
respectively. All this evidence led to the widespread hope that NG2-glia can be a 
regenerative resource for neurodegenerative diseases that involve neuronal as well as 
glial loss. A number of studies have encouraged this hope by describing neuronogenic 
properties of NG2-glia in the rodent CNS. Supporting this hypothesis, Tamura and 
colleagues have shown that in the neocortex and piriform cortex NG2-glia express DCX 
(Tamura et al., 2007). Since antibody-labeling experiments are notoriously difficult and 
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artifact-prone and genetic labeling should be more predictable, thanks to the advances in 
this field, transgenic mouse model became a useful tool to investigate the multipotence 
of this cells. In particular a lot of studies took advantages of the Cre-loxP technologies. 
This method utilized transgenic mouse lines that express the site-specific recombinase 
Cre driven by various promoters that are active in OPCs. When these mouse lines are 
crossed to Cre reporter mouse lines, the expression of a reporter gene (usually a 
fluorescent protein, i.e. GFP, EGFP or YFP) is activated permanently in cells that 
express Cre, thereby allowing identification of their progeny by persistent reporter 
expression. Using NG2creBAC transgenic mice, Zhu et al. demonstrated that NG2 cells 
generate oligodendrocytes throughout the grey and white matter of the brain and spinal 
cord (Zhu et al., 2008a, 2008b). In addition, a subpopulation of protoplasmic astrocytes 
in the grey matter of ventral forebrain and spinal cord appeared to be derived from NG2 
cells. Surprisingly, none of the GFAP
+
 astrocytes in the white matter was generated 
from NG2 cells under normal conditions, suggesting heterogeneity of the source of 
astrocytes. Using the same transgenic mouse model, Honsa and colleagues followed the 
progeny of NG2 cells in mice that were subjected to focal brain cerebral ischemia. The 
number of EGFP
+
 cells after ischemia was significantly increased; cells displayed 
heterogeneous morphology and expressed markers of astrocytes and neuronal precursor 
cells. Moreover, OPCs multipotency was confirmed by detailed electrophysiological 
analysis, which also proved the generation of astrocytic and neuronal precursor 
phenotypes from EGFP
+
 cells after ischemia (Honsa et al., 2012). Other studies have 
used inducible Cre lines in which Cre-mediated excision is activated by tamoxifen in 
transgenic lines that express a fusion protein consisting of Cre and various forms of the 
mutated ligand-binding domain of estrogen receptor (CreER) engineered to bind 
tamoxifen with a higher affinity than endogenous estradiol (Metzger and Chambon, 
2001). Using PDGFRα–CreERT2: Rosa26-YFP mice, Rivers and co-workers (Rivers et 
al., 2008) found that, although NG2-glia generate predominantly Sox10-positive 
oligodendrocyte lineage cells during normal adulthood some Sox10-negative, YFP
+
 
cells appeared in the anterior piriform cortex (PC), acquired NeuN and MAP2 reactivity 
and morphologically resembled piriform projection neurons. However, using their own 
independently generated line of PDGFRα–CreERT2 mice, Kang et al. (2010) failed to 
detect production of long-term surviving GFP
+
 neurons in the PC or elsewhere in the 
forebrain (Kang et al., 2010). One other study has reported PC neurons from NG2-glia 
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(Guo et al., 2010). This study used Plp-CreER
T2
: Rosa26-YFP mice to follow the fate of 
NG2-glia in the healthy adult CNS. Plp is expressed in differentiated oligodendrocytes 
as well as NG2-glia, so Guo and co-workers (2010) could not address questions about 
new oligodendrocyte production; however, similar to the group of River (Rivers et al., 
2008), they did observe YFP-labeling of PC projection neurons. Labelled neurons first 
became apparent 17 days post tamoxifen and increased in number for at least 180 days. 
In addition, reporter expression was detected in some protoplasmic astrocytes in the 
ventral forebrain. In one study YFP
+
-NeuN
+
 neurons were observed for only a few days 
following tamoxifen injection into NG2-CreER
T2
: Rosa26-YFP mice (Zhu et al., 2011), 
suggesting that these neurons were eliminated from the CNS after a short time or else 
became NeuN negative (or YFP negative). Finally, by using a Olig2-creER™ 
transgenic mice, Dimou and collaborators (2008) observed that when Cre was induced 
in adult mice, the reporter gene was expressed almost exclusively in either NG2 cells or 
mature oligodendrocytes, and in a few protoplasmic astrocytes in grey matter but not in 
neurons (Dimou et al., 2008). In conclusion, also Cre-lox fate mapping studies have still 
not completely eliminated the controversy around the multipotency and fate of OPCs. 
This is likely because, in most studies, the final fate of NG2 cells has been followed 
under physiological conditions and not after CNS insults that profoundly change cells 
reactivity and the local extracellular milieu. 
1.5.2.2 The G protein-coupled receptor GPR17 
GPR17 was originally classified as an orphan G protein-coupled receptor (GPCR) 
before the discovery of its endogenous ligands. It displays the classical 7 
transmembrane domains structure and consists of 399 amino acids (Ciana et al., 2006; 
Lecca et al., 2008). GPCRs constitute the largest superfamily of membrane receptor and 
have been involved in a multitude of biological responses in all organs and systems 
including the central and peripheral nervous system (PNS). Pathological changes in 
their expression and functions play established role in neurological and 
neurodegenerative diseases, thus highlighting these receptors as interesting targets for 
drug development. GPR17 was first identified thanks to a screening of a human cDNA 
library for P2Y-receptor homologous sequences (Bläsius et al., 1998). Subsequently 
also the rat and mouse GPR17 orthologous were identified and cloned, showing a 80% 
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homology in the amino acid sequence to the human GPR17 (hGPR17) (Ciana et al., 
2006; Lecca et al., 2008). 
 
GPR17 receptor: structure and pharmacological characteristics 
Alignment of rat, mouse and human GPR17 amino acid sequences showed almost 
complete overlapping of TM3, TM6, and TM7 and conservation of a typical amino acid 
motif in TM6 (H-X-X-R) that is present in several GPCRs, and is believed to be 
essential for ligand binding (Ciana et al., 2006). Although GPR17 amino acid sequence 
is conserved among species, the gene structure is quite different. The human GPR17 
gene (hGpr17) is located on chromosome 2 and it is composed of four exons, only two 
of which contain coding sequences. Two distinct transcripts of the hGPR17 receptor 
were identified to be generated by alternative polyadenylation, lately named short 
(hGPR17-S) and long isoform (hGPR17-L) (Benned-Jensen and Rosenkilde, 2010). The 
rat and mouse GPRl7 gene ortholog (rGpr17 and mGpr17, respectively) are both 
located on chromosome 18. rGpr17 is composed by only one exon, whereas mGpr17 
has two different exons and only a small portion of the second exon encodes for the 
protein.  
It has been shown that this receptor is a close relative of both already known P2Y 
receptors (see 1.1.3) and G protein-coupled CysLT1 and CysLT2 receptors responding to 
cysteinyl-leukotrienes (cysLTs), inflammatory lipid mediators generated by 5-
lipoxygenase metabolism of arachidonic acid. Indeed, GPR17 is located at intermediate 
phylogenetic position between P2Y and CysLT receptors and represents the closest 
receptor to a common ancestor which also originated P2Y12,13,14 receptors and CysLT1 
and CysLT2. In line with this, its deorphanisation led to its identification as a new dual 
uracil nucleotides/cysteinyl-leukotrienes receptor (Ciana et al., 2006) responding to both 
uracil nucleotides (UDP, UDP-glucose and UDP-galactose) and cysLTs (LTD4 and 
LTC4) (Ciana et al., 2006). Consistent with this hybrid pharmacology, activation of 
GPR17 by uracil nucleotides was counteracted by the P2Y receptor antagonists 
Cangrelor and MRS2179, whereas its activation by cysLTs was antagonized by 
Montelukast and Pranlukast, two already marketed CysLT receptor blockers. Agonist 
response profile of GPR17, was different from those of already known CysLT and P2Y 
receptors as determined in vitro by [
35S]GTPγS binding, with EC50 values in the 
nanomolar and micromolar range, for cysteinyl-leukotrienes and uracil nucleotides, 
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respectively (Ciana et al., 2006). Moreover it has also been suggested that cellular 
response to receptor activation can be modulated by the independent or simultaneous 
exposure to uracil nucleotides or cystenil leukotrienes. Bioinformatic analysis indeed 
showed the presence of two distinct binding sites for the two different classes of 
ligands. Uracil nucleotides and cystenil leukotrienes can therefore simultaneously bind 
to GPR17 and, for instance, UDP-glucose can potentiate GPR17 response towards 
LTD4, through an allosteric mechanism (Parravicini et al., 2010). Exposure of GPR17 
to both UDP-glucose and LTD4 leads to receptor desensitization, followed by 
internalization and re-sensitization upon agonists removal (Daniele et al., 2011). This 
study also highlighted the effect of UDP-glucose on LTD4-induced GPR17 
desensitization, suggesting a fine regulation of receptor pharmacology and function in 
the presence of one or both endogenous ligands.  
In contrast with the above-mentioned results, Benned-Jensen and Rosenkilde 
(2010) reported that UDP and UDP-glucose, but not cysteinyl leukotrienes, promoted 
GPR17-dependent GTPγS-binding. In line with these study a very recent publication by 
Qi and colleagues (Qi et al., 2013) demonstrated that neither nucleotides, nucleotide 
sugar nor cysteinyl leukotrienes promote activation of GPR17 when assessed by 
standard and well established signaling assay. The reasons for these discrepancies 
between different laboratories are still unclear. 
Finally, it has also been suggested that GPR17 is a ligand-independent, 
constitutive negative regulator of the CysLT1 receptor. It is therefore difficult to 
distinguish between direct or indirect responses to cystenil leukotrienes in those systems 
where both GPR17 and CysLTl receptor are expressed, such as peripheral blood cells 
(Maekawa et al., 2009). 
The majority of the pharmacological studies have been performed in transfected 
cells, cell lines or in primary cultures, where the coupling of receptor with the G protein 
Gi has been shown (Ciana et al., 2006; Fumagalli et al., 2011). Only in transfected cells 
a direct correlation between the agonist-induced activation of GPR17 and intracellular 
increases of Ca
2+
 was observed. This signaling cascade is probably generated by the βy 
subunits of Gi protein (Benned-Jensen and Rosenkilde, 2010; Ciana et al., 2006). 
Calcium increases however were not detected in cells endogenously expressing the 
receptor; this can be explained by tissue or cell specific expression of the βy subunits 
associated to GPR17 (Maekawa et al., 2009). 
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Furthermore, electrophysiological studies in 1321N1 astrocytoma cells stably 
expressing the human receptor GPR17 have shown that activation of the receptor with 
micromolar concentrations of UDP, UDP-glucose and UDP-galactose and nanomolar 
concentration of LTD4 leads to an increase of outward rectifying K
+
 currents by a Ca
2+-
dependent intracellular signaling pathway (Pugliese et al., 2009). The same group have 
recently demonstrated that receptor stimulation by its agonist UDP-glucose enhances 
delayed rectifier outward K
+
 currents without affecting transient K
+
 conductance also in 
an “in vitro” native system (purified primary OPCs culture compared to heterologously 
transfected cells). This effect was observed in a subpopulation of OPCs and immature 
pre-oligodendrocytes whereas it was absent in mature cells, in line with GPR17 
expression. The effect of UDP-glucose on K
+
 currents is concentration-dependent, 
blocked by the GPR17 antagonists MRS2179 and Cangrelor, and sensitive to the K+ 
channel blocker tetraethyl-ammonium (TEA), which also inhibits oligodendrocyte 
maturation. In this respect authors propose that stimulation of K
+
 currents is responsible 
for GPR17-induced oligodendrocyte differentiation (see below; Coppi et al., 2013). 
 
GPR17 expression profile 
hGPR17 is highly expressed in tissues that undergo ischemic damage, namely 
brain, heart and kidney. The same pattern of expression has been confirmed in rats and 
mice (Ciana et al., 2006; Lecca et al., 2008). Interestingly, a recent study has shown that 
the hGPR17 short isoform is mainly expressed in heart and kidney, whereas the long 
isoform is present only in the brain (Benned-Jensen and Rosenkilde, 2010). This distinct 
pattern of expression suggests a specification of GPR17 function related to its 
localization, at least in human.  
A detailed analysis of GPR17 expression profile has been first of all performed in 
rat and mice brain. GPR17 was detected on SMI-311
+
/NeuN
+
 neurons by 
immunohistochemistry techniques; conversely, no co-localization with cortical 
astrocytes was found as shown by labeling with the specific marker GFAP. The vast 
majority of GPR17
+
 cells co-express the OPC marker Olig2 and NG2; furthermore, no 
co-localization of GPR17 was found with more mature myelinating oligodendroglial 
markers, such as CNPase and the myelin-associated glycoprotein MAG. Finally, no 
GPR17 expression was found in resting microglia detected by anti-Iba1 staining in the 
intact brain (Lecca et al., 2008; Figure 1.13).  
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Figure 1.13: cellular localization of GPR17 in the intact mouse brain. (A) In 
the intact cortex, GPR17 expression was observed in large rounded cells clustered at 
high density (asterisks) and in sparse ramified cells (arrows and A’ inset). Virtually all 
GPR17
+
 large cell bodies displayed co-expression of the neuronal proteins SMI311 (B) 
or NeuN (C), demonstrating their neuronal identity. (D, D’) panels show higher 
magnification images of two neurons immunopositive for both GPR17 (red channel, D), 
and NeuN (green channel, D’);(D’’) merging of the two fluorescence channels. In the 
cortex, no co-localization of GPR17 with the astroglial markers GFAP (E) and S100β 
(F; arrows indicate GPR17
+
 cells) was found. (G) partial co-localization of GPR17 and 
the oligodendrocyte marker NG2. Indeed, several ramified GPR17-labeled cells co-
stained for NG2 (blue arrows in G); however, also single staining for NG2 (arrowheads 
in G) or GPR17 (white arrows in G) was found. GPR17 co-stained also with Olig2, 
another oligodendrocyte marker (H, H’). In some cases, NG2+ or Olig2+ cells show 
immunoreactivity for GPR17 in discrete cell body compartments (inset in G and H’’, 
respectively). I and J depict no co-localization of GPR17 with myelin-related proteins 
(CNPase and MAG, respectively). Some ‘‘resting’’ microglial cells were also found in 
cortex, as suggested by staining with the specific marker Iba1 (K): in the intact brain, 
none of these cells expressed GPR17 (from Lecca et al., 2008).  
58 
 
In the spinal cord the same expression profile was observed, and additionally 
GPR17 co-localized with CC1-positive mature oligodendrocytes and with the 
ependymal cells lying the central canal which are considered to be the neuronal stem 
cells of the spinal cord (Ceruti et al., 2009). 
Extensive studies on primary OPCs culture have characterized GPR17 expression 
during cell differentiation. Receptor expression, almost absent in early OPCs, gradually 
increases in more mature precursors, reaches a plateau in immature/pre-
oligodendrocytes, and then gradually decreases during terminal differentiation. In line 
with these findings, GPR17 is co-expressed with the early oligodendrocyte marker NG2 
and with markers of pre/immature oligodendrocyte phenotype (such as O4), but it is 
down-regulated in cells expressing myelin proteins, such as myelin basic protein, which 
is highly synthesized in fully mature cells (Ceruti et al., 2011; Fumagalli et al., 2011). 
Other studies showed the expression of GPR17 on human and mouse mastocysts 
and bone marrow-derived monocytes, where the receptor seems to highly co-localize 
with CysLTl receptor (Maekawa et al., 2009, 2010).  
Finally, and most interesting, a trascriptome analysis performed on human and 
mouse adult neural stem cells and fetal embryonic tissue revealed expression of the 
receptor specifically in adult neuroprogenitors (Maisel et al., 2007). In line with these 
results strong GPR17 expression has been also detected by RT-PCR in adult rat 
hippocampus derived NPCs. Here, the antagonist Montelukast significantly and 
specifically increased the proliferation of NPCs and NSCs in vitro. However, it neither 
affected the cells’ fate nor their differentiation potential (Huber et al., 2011). 
 
GPR17 functions 
Upon brain injury, the extracellular concentration of nucleotides and cysteinyl-
leukotrienes are markedly increased at the site of damage, suggesting that they may act 
as “danger signals”. Moreover, as previously mentioned, GPR17 is highly express in 
tissues undergoing ischemic damage and in particular in the brain. Due to these two 
reasons most of the studies on GPR17 were aimed at understanding its function in the 
CNS and at unveiling its possible therapeutic potential in several pathological 
conditions. 
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Role of GPR17 in brain ischemia - The therapeutic potential of GPR17 was first 
assessed in a rat model, and subsequently in a mouse model, of ischemia (MCAo, 
middle cerebral artery occlusion). The application of a P2Y antagonist and, more 
specifically, the use of anti-sense oligonucleotide targeting GPR17 were both sufficient 
to reduce the penumbra area of the ischemic damage. It is not clear, however, if 
reduction of the ischemic damage was mainly due to the effect on a specific cell type 
expressing the receptor or if it was more general. Anyway, in this case GPR17 appeared 
to be pro-inflammatory and its blockage, by antagonist or anti-sense oligonucleotide 
application, improved functional recovery (Ciana et al., 2006; Lecca et al., 2008). 
Recently the role of GPR17 has been also assessed in human injured brain. After 
traumatic brain injury (TBI), GPR17 underwent profound changes in cells participating 
to tissue damage and repair according to a precise spatio-temporal pattern. GPR17 was 
selectively induced in patients deceased from intracranial, but not extracranial 
complications, and receptor expression negatively correlates with patients’ post 
traumatic survival time (PTI), being very high at short survival periods (2h) and 
markedly decreased at PTI longer than 16 days (Franke et al., 2013). Strong GPR17 
immunoreactivity was found in shrunk dying pyramidal neurons inside or in the 
immediate vicinity of the traumatic core. This is consistent with rodent data showing 
early and transient GPR17 upregulation in neurons inside and at the borders of ischemic 
lesions. Data from TBI patients also showed that GPR17 is specifically induced in IB4-
positive activated microglia/macrophages infiltrating the lesion, confirming GPR17 
participation to the lesion remodeling that precedes the reconstruction of neuronal 
circuitries. At variance from rodents, in the cortex of TBI patients GPR17 decorated a 
subset of reactive astrocytes, suggesting that, in humans, GPR17 may also regulate 
astrocytic post-traumatic activation. Thus, the role of GPR17 in the injured human brain 
may be broader than that observed in rodents. Moreover, in several human samples, 
GPR17 was found in bi-/tripolar or more ramified OPCs, suggesting a role in 
postinjury-induced OPC differentiation. Some GPR17-expressing OPCs were clearly 
resuming proliferation. Thus, in both humans and rodents, GPR17 participates to post-
injury attempts to generate new myelinating oligodendrocytes (Franke et al., 2013).  
Finally, two recent papers published by the same group (Mao et al., 2012, 2013) 
also highlighted a role for GPR17 in an experimental model of hypoxic ischemia-
induced periventricular leucomalacia (PVL) in neonatal rats. The number of white 
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matter NG2
+
/GPR17
+
/BrdU
+
 and O4
+
/GPR17
+
/BrdU
+
 cells was significantly increased 
within 72 hours and 7 days after induction of PVL, respectively. Moreover, treatment 
with UDP-glucose improved the limb motor function and coordination of PVL neonatal 
rats and significantly mitigated the histopathological white matter damage induced by 
hypoxic ischemia, thus suggesting a role for GPR17 activation in alleviating the 
deleterious effects of ischemia-induced PVL.  
 
Role of GPR17 in spinal cord injury (SCI) - Induction of spinal cord injury (SCI) by 
acute compression resulted in marked cell death of GPR17
+
 neurons and 
oligodendrocytes inside the lesion followed by the appearance of proliferating GPR17
+
 
microglia/macrophages migrating to and infiltrating into the lesioned area. Moreover, 
72 h after SCI, GPR17
+
 ependymal cells started to proliferate and to express GFAP, 
suggesting their activation and ‘de-differentiation’ to pluripotent progenitor cells. The 
administration of anti-sense oligonucleotides targeting GPR17, gave positive results in 
terms of damage reduction and functional recovery also in this model, again suggesting 
an active role of GPR17 in the early phases of tissue damage development (Ceruti et al., 
2009). In this scenario the function of GPR17 was described to be temporal and cellular 
specific; the first response to injury provoked the death of neurons and oligodendrocytes 
through GPR17 activity; at later times the recruitment of microglia and GPR17-positive 
macrophages seemed to shed the first steps of tissue remodeling and repair, that was 
followed by the upregulation of GFAP, as a marker of stem-cell like properties, on 
GPR17
+
 ependymal cells. Due to this dualistic pattern of activation, it can be 
hypothesized that GPR17 represents an interesting target to develop new approaches to 
the management of secondary damage in SCI aimed at both reducing cell death and 
fostering tissue repair. 
 
Role of GPR17 in oligodendrocyte differentiation - Several studies performed in our 
laboratory suggest that GPR17 contributes to OPC differentiation. In mouse cortical 
primary mixed astrocytes/precursor cell cultures, GPR17 expression was markedly 
influenced by the culturing conditions. In the presence of GFs, no significant GPR17 
expression was found. When cultures were shifted to a differentiating medium without 
GFs, a dramatic and time-dependent increase in the number of highly branched GPR17-
positive cells was observed. Under these conditions, GPR17 was induced in the totality 
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of O4-positive immature oligodendrocytes (Ceruti et al., 2011). Instead, in cultures 
originally grown in the absence of GFs, GPR17 was already expressed in 
morphologically more mature OPCs. Shifting of these cultures to differentiating 
conditions induced GPR17 only in a subpopulation of O4-positive cells. Under both 
culture protocols, appearance of more mature CNPase- and MBP-positive cells was 
associated to a progressive loss of GPR17. GPR17 expression also sensitized cells to 
adenine nucleotide-induced cytotoxicity (Ceruti et al., 2011). These data are in 
accordance with the in vivo model of ischemia where the knock-down of GPR17 was 
shown to be protective, suggesting that GPR17 may sensitize cells to cell death in 
presence of high levels of ATP and ADP also in vivo. Another study published by our 
group reported a detailed molecular characterization of GPR17 during the spontaneous 
in vitro differentiation and maturation of primary rodent NG2
+
 OPCs (Fumagalli et al., 
2011). In cultured OPCs, the GPR17 transcript was first detected in bipolar NG2
+
 
polydendrocytes. Receptor expression gradually increased along with morphological 
differentiation in cells with more processes emerging from the cell body, was maximal 
in immature pre-oligodendrocytes, and then gradually decreased along with terminal 
maturation (Fumagalli et al., 2011). In line with these findings, and as already 
demonstrated in vivo, the GPR17 receptor protein decorated two subsets of slowly 
proliferating cells. The first one corresponded to early, morphologically immature and 
slowly proliferating NG2+ precursor cells that also expressed Olig2, PDGFRα, and the 
immature PLP isoform DM-20; the second one corresponded to more ramified, still 
immature pre-oligodendrocytes that were losing NG2 and PDGFRα immunoreactivity 
and already expressed O4, O1, and the two splicing variants of the myelin protein PLP. 
After this differentiation stage, GPR17 expression was progressively turned down, and 
the GPR17 protein was never found in fully mature MAG
+
 or MBP
+
 oligodendrocytes 
(Figure 1.14).  
 
62 
 
  
Figure 1.14: scheme showing GPR17 expression as a function of OPC differentiation. 
The drawing illustrates the typical differentiation steps of OPCs, from immature 
precursors to mature oligodendrocytes. Tables summarize single-cells RT-PCR (mRNA) 
and immunocytochemical (protein) data for GPR17 and other known markers 
identifying specific OPC differentiation stages. At early stage (stage 1), bipolar OPCs 
already express GPR17 mRNA, but receptor protein expression is detectable only when 
NG2
+
 cells acquire a more complex morphology (stage 2, polydendrocyte stage). After 
this stage, GPR17 gradually increases in pre/immature oligodendrocytes, reaching a 
maximum when O4 is expressed (stage 3). GPR17 expression is then turned down, and 
mature MBP
+
 cells no longer express the receptor (stage 4). The graded changes of the 
GPR17 protein during differentiation are highlighted in a yellow-orange-red triangle, 
where orange represents the maximum expression level. N.D., not done (from Fumagalli 
et al., 2011).  
 
Moreover, administration of the agonist UDP-glucose triggered an increase in the 
differentiation of precursor cells to myelinating oligodendrocytes (Ceruti et al., 2011; 
Fumagalli et al., 2011); on the contrary the pharmacological inhibition of GPR17 or its 
knock-down by siRNAs impaired the normal differentiation program of OPCs. Thus, 
these data suggest that GPR17 acts as an intrinsic regulator of oligodendrogliogenesis. 
Indeed, at early differentiation stages the receptor has to be express to keep OPCs in an 
immature state which is necessary to prepare them for myelination; conversely, at a 
later stage of differentiation GPR17 has to be turned down to allow the terminal 
differentiation of immature oligodendrocytes. 
However, whether GPR17-mediated signaling positively or negatively regulates 
this critical process is now highly debated. Indeed, in contrast with the results obtained 
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by our group, a very recent paper by Hennen and co-workers identified a new small-
molecule (MDL29,952), which activated GPR17 and arrested oligodendrocyte in an 
immature, non myelininating stage (Hennen et al., 2013). We can speculate that these 
apparently conflicting results could be due to the exposure of OPC cultures to GPR17 
agonist at different stages of cell differentiation. 
Moreover, in another study by Chen and co-workers, the authors analyzed 
oligodendrocyte myelination in mouse models of ectopic over-expression and knock-
down of GPR17. Interestingly, GPR17 over-expression under the CNPase promoter, at 
a differentiation stage when it is no longer physiologically expressed, resulted in 
impaired postnatal myelination and premature death. On the contrary, in a GPR17 
knock-out model, myelination started at embryonic stage, much earlier than the 
physiological process in wild type littermates (Chen et al., 2009). It appears clear that in 
the transgenic mouse models utilized in this paper, forcing GPR17 transcription in 
oligodendrocytes at a maturation stage when they physiologically downregulate its 
expression (i.e., CNPase cells) might have created conflicting intracellular signals 
leading to cell suicide. Thus, although further confirming the key role played by GPR17 
in OPC maturation, the conclusions drawn based on this transgenic mouse model may 
lead to a misinterpretation of the native function of the receptor. 
Taken together these observations led to the conclusion that during development 
GPR17 is a "cell intrinsic timer" that precisely regulates the onset of myelination. The 
molecular mechanism that support this hypothesis could stem in the correlation between 
GPR17 over-expression in vitro and the upregulation of the transcription factor Id2 and 
the translocation of this same factor and Id4 to the nucleus, where they are known to 
inhibit the expression of genes involved in oligodendrocytes maturation (Chen et al., 
2009). In the same line, a trascriptome analysis showed negative regulation of GPR17 
by mTOR (mammalian target of rapamycin), another transcription factor that normally 
promotes OPCs differentiation in myelinating oligodendrocytes (Tyler et al., 2011).  
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2. AIM OF THE STUDY 
 
For almost a full century, a central dogma of developmental biology declared that 
the generation of new neurons in the brain concluded shortly after birth (Gross, 2000). 
This hypothesis was based on evidence from Santiago Ramon y Cajal, who in 1913 
sustained that neurons were generated only during the prenatal phase of development 
(Ming and Song, 2005). 
In fact, he stated that “Once development was ended, the founts of growth and 
regeneration of the axons and dendrites dried up irrevocably. In adult centres, the nerve 
paths are something fixed and immutable: everything may die, nothing may be 
regenerated” (Ramon y Cajal, 1928). Therefore, it has been long believed that no new 
neurons are generated in the adult brain and that the loss of neurons that accompanied 
most of central nervous system (CNS) pathologies cannot be restored. 
However, this doctrine ended in 1965 when newly generated neurons were found 
in two specific regions of the adult brain: the subgranular zone (SGZ) in the dentate 
gyrus (DG) and the subventricular zone (SVZ) of the lateral ventricle wall. As 
confirmed by subsequent studies, in the SVZ three main cell types can be 
morphologically and functionally distinguished: GFAP
+
 precursors (Type B cells) give 
raise to transit-amplifying Mash1
+
 Type C cells, which eventually further differentiate 
to doublecortin (DCX)
+
 neuroblasts (Type A cells) which migrate towards the olfactory 
bulb (OB) in rodents where they integrate in existing networks (Doetsch et al., 1997, 
1999a, 1999b; Garcia-Verdugno et al., 1998; Kim et al., 2011). Once isolated, cells 
from the SVZ can grow in vitro as clonal clusters of proliferating cells, called 
neurospheres (NS), which can either self-renew or differentiate to astrocytes, neurons 
and oligodendrocytes (Johansson et al., 1999; Reynolds et al., 1992). 
Studies carried out during the last two decades revealed that in mammalian CNS 
parenchyma, which is commonly considered as non-neurogenic, some processes of 
gliogenesis and, to a lesser extent, neurogenesis also occur. In particular, cells 
expressing the proteoglycan NG2 (also known as polydendrocytes or oligodendrocyte 
precursor cells OPCs), represent the vast majority of proliferating cells in the healthy 
adult CNS (Dawson et al., 2003). They give raise to mature oligodendrocytes during 
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development and adulthood and can re-establish myelination in the diseased CNS 
(Fancy et al., 2011). It has been also suggested that, under some conditions, NG2 cells 
can give raise to both astrocytes and neurons. In particular, NG2 cells lineage plasticity 
may be markedly widened by insults and epigenetic agents that profoundly change their 
reactivity and the surrounding local milieu (Honsa et al., 2012). However, more than 10 
years ago a first sensational demonstration that these cells can be reprogrammed to 
generate neurons (Kondo and Raff, 2000a) has been followed by only a few in vitro 
confirmations (Liu et al., 2007) and conflicting in vivo results (Dimou et al., 2008; 
Richardson et al, 2011). The possibility to promote and foster the endogenous 
neurogenic/gliogenic ability of the brain has emerged as a new, safe, and ethically 
acceptable opportunity for both acute and chronic brain diseases. An in-depth 
understanding of the molecular basis controlling brain progenitor cells in physiological 
and pathological conditions would highlight possible pharmacological/biotechnological 
approaches to help preventing excessive tissue degeneration while enhancing local 
reparative mechanisms. Nevertheless, despite increased information on lineage specific 
transcription factors, cell-cycle regulators and epigenetic factors involved in the fate and 
plasticity of NSCs (Christie and Turnley, 2013), the understanding of extracellular cues 
driving the behavior of embryonic and adult NSCs is still very limited. 
Extracellular adenine, uracil and sugar nucleotides (eNTs) are universal signaling 
molecules involved in many biological processes acting via specific membrane 
receptors: the ionotropic P2X receptors and the metabotropic P2Y receptors. P2X 
receptors are ligand-activated cationic channels, specifically activated by ATP, while 
P2Y receptors are activated by purine or pyrimidine nucleotides, or by sugar-
nucleotides, and couple to intracellular second-messenger systems through heteromeric 
G proteins (Abbracchio et al., 2006). eNTs play key roles in neurotransmission and 
neuromodulation and are involved in several cellular functions, including proliferation 
and migration, apoptosis and cytokine secretion. Moreover nucleotides released from 
both glial cells and neurons contribute to cell to-cell communication and represent a 
class of signaling molecules that functionally link glia and neurons together 
(Abbracchio and Burnstock, 2009; Fields and Burnstock, 2006).  
In the adults brain, neurogenesis is dynamically regulated by a number of intrinsic 
as well as extrinsic factors and also by a range of environmental-, behavioral-, genetic- 
factors (see Introduction, Paragraph 1.4). Among the other factors already known to be 
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involved in adult neurogenesis, recently, also a role for eNTs in controlling the 
functions of stem cells in the subventricular zone SVZ has emerged, although available 
data are conflicting. In vitro results by the neurosphere assay have shown that ADP or 
its stable analogue adenosine 5'-O-(2-thio)-diphosphate (ADPβS) promoted the 
proliferation of SVZ cells, probably acting on the P2Y1 receptor (P2Y1R), but only at 
low growth factor (GF) concentrations. Conversely, an anti-proliferative effect of 
various eNTs, including ADPβS, was observed at standard GFs concentrations (around 
20 ng/ml; Stafford et al., 2007). Activation of the P2Y1R also promoted SVZ cell 
differentiation (Grimm et al., 2009) and migration (Grimm et al., 2010) in vitro. In vivo, 
the contribution of eNTs in controlling SVZ cell proliferation is poorly understood. In a 
recent study, ATP (which non-selectively activates all the P2X and some P2Y receptor 
subtypes) has been infused in the adult SVZ (Suyama et al., 2012). Upon ATP 
administration, the proliferation of transit-amplifying cells (type C cells) increased, 
whereas no effect was observed on proliferation of either type B stem cells or type A 
neuroblasts. A possible involvement of the P2Y1R was hypothesized based on the 
inhibitory effect on Mash1
+
 type C cell proliferation exerted by the administration of the 
P2Y1R-selective antagonist 2'-deoxy-N6-methyladenosine-3',5'-bisphosphate 
(MRS2179) per se, and by the reduced number of type C cells in P2Y1R-KO mice 
(Suyama et al., 2012). In addition to their important physiological actions, eNTs 
modulate brain functions in pathological conditions, when their extracellular 
concentrations rise to micromolar levels (Abbracchio et al., 2006). Under these 
conditions, eNTs trigger and sustain reactive astrogliosis, the astrocytic reaction to brain 
trauma or ischemia (Abbracchio and Ceruti, 2006), whose protective/detrimental 
double-edged sword effect is still a matter of debate (Buffo et al., 2010). Activation of 
the ADP-responsive P2Y1R promotes astrogliosis, and modulates astrocytic secretion of 
a plethora of factors, including cytokines/chemokines and GFs (Franke et al., 2012). 
These molecules might act as autocrine/paracrine signals on surrounding cells, 
including SVZ, NSCs and progenitors.  
Previous studies from our laboratory have identified the purinergic receptor 
GPR17 as a new marker of early stages of NG2 cell differentiation, showing that 
GPR17 activation accelerates NG2 cells’ oligodendrocyte fate (Fumagalli et al., 2011; 
Ceruti et al., 2011; Boda et al., 2011). Interestingly, GPR17 is also one of the key genes 
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expressed by human adult neural stem cells (Maisel et al., 2007), suggesting a possible 
role in cell fate determination. 
Based on these premises, the aim of my PhD project was to investigate the role of 
purinergic signaling in regulating stem cell proprieties of adult brain subventricular 
zone and of NG2+ parenchymal progenitors. 
In particular, the work presented in the first section of the Results was aimed at 
investigating the role of ADPβS, acting as agonist at the P2Y1,12,13 receptor subtypes, in 
modulating adult neurogenesis in the mouse SVZ, with a focus on the possible effects 
exerted by reactive astrocytes. First of all we performed in vitro experiment by the 
neurospheres assay to test the ability of the ADP analogue to modulate the proliferation 
and self-renewal capability of neural stem cells and to control the differentiative 
potential of neurospheres (NS). Moreover, to test whether ADPβS was acting directly 
on NSCs only or whether reactive astrocytes were involved, we grew NS in the 
conditioned media derived from control astrocytic cultures or from astrocytes cultured 
in presence of ADPβS. We also performed in vivo experiments in which ADPβS was 
chronically infused in the lateral ventricle of adult mice for one week and we then 
analyzed the effect of the treatment on the three main cell types within the SVZ by 
immunohistochemistry of specific markers. Finally, to verify whether ADPβS can act 
directly on NSCs, we took advantage of GLAST::CreERT2;Rosa-YFP transgenic mice 
in which stem cells expressing the L-glutamate/L-aspartate GLAST and their progeny 
are permanently labelled by the fluorescent protein YFP upon tamoxifen administration.  
The aim of the second part of my PhD thesis was to unveil the stem cell properties 
of NG2
+
 precursor cells and to implemant their differentiation towards a neuronal 
lineage, also through the modulation of the GPR17 receptor. 
Indeed, at variance from other proteins expressed by NG2
+
 progenitors, GPR17 is 
a membrane receptor that can be easily activated/inhibited with specific ligands, thus 
allowing the modulation of the final fate of these cells. Thus, we hypothesized that, 
thanks to the multipotency of NG2
+
 precursors, it could be possible to generate cell 
types other than oligodendrocytes (e.g., neurons) if GPR17 is selectively activated or 
inhibited in cultures grown under different experimental conditions from those utilized 
in our previous works (see above). Primary OPCs from the cerebral cortex of P2 rat 
pups were kept in culture for 6-8 days as mixed astrocytes-OPCs cultures and purified 
by vigorous shaking of flasks, and immunopanning selection. OPCs have been then 
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cultured according to two protocols able to unveil their stem cell properties (Kondo & 
Raff, 2000a; Liu et al., 2007). In either protocol, we have verified if and how the 
exposure to various pharmacological agents (including GPR17 receptor ligands) can 
modulate OPCs plasticity and their differentiation to neurons. In particular, we have 
utilized the non-selective GPR17 agonist UDP-glucose (100 µM) and antagonist 
Cangrelor (10 µM), in parallel to the anticonvulsant agent valproic acid (VPA, 500 
µM). Besides being utilized in the therapy of epilepsy, bipolar disorders and migraine 
(Monti et al., 2009), VPA acts as histone deacetylase (HDAC) inhibitor, thus 
amplifying the differentiative potential of these cells. In vivo and in vitro experiments 
have demonstrated that HDAC inhibition indeed reduces OPCs differentiation towards 
the oligodendrocytic lineage and increases their maturation towards an astrocytic or 
neuronal phenotype (Yu et al., 2009). 
We believe that the new emerging field of the role of nucleotides in modulating 
embryonic and adult neural development will contribute to further understanding the 
interactive role of small signal molecules in the control of neurogenesis. New tools for 
enhancing neurogenesis by supporting progenitor cell proliferation, migration or 
differentiation or preventing cell death might eventually lead to therapeutic approaches 
in neuropsychiatric or neurodegenerative disease associated with impaired neurogenesis 
or with neuronal loss. 
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3. MATERIALS AND METHODS 
 
3.1 THE NEUROSPHERE ASSAY 
3.1.1 NEUROSPHERE CULTURES 
Neurosphere cultures were generated from adult wt CD1 mice. Briefly, 4-6 
animals for each experiment were anesthetized with diethyl ether, and then killed by 
decapitation. The brain was exposed, surgically removed, and placed in an ice-cold 
sterile Hanks' Balanced Salt Solution (HBSS, Euroclone, Milan, Italy). First of all, to 
dissect the subventricular zone (SVZ) a coronal section from the whole brain was 
obtained (about 2 mm in thickness) by cutting the tissue between the rhinal fissure and 
the hippocampus. The coronal section was then divided into the two hemispheres and, 
for each of them, a parasagittal cut just lateral to the lateral ventricles, and a horizontal 
cut above the corpus callosum were made (Figure 3.1). Finally, the thin layer of tissue 
surrounding the ventricles (excluding the striatal parenchyma) was dissected and placed 
in an ice-cold tube with HBSS.  
Figure 3.1: schematic representation of the dissection protocol. (A) Murine adult 
brain in which the areas of interest are highlighted: blue, the olfactory bulb (OB); red, 
lateral ventricle and rostral migratory stream; dotted lines show the level of the coronal 
section (modified from Bonfanti and Peretto, 2007). (B) Coronal section in which the 
subventricular zone (SVZ), the striatum (STR), the corpus callosum (CC) and the cortex 
(CTX) are visible. (C) Coronal section of half hemisphere. The dotted lines represent 
the two cuts that are made to isolate the SVZ (modified from Garcia-Verdugno et al., 
1998). 
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Upon harvesting the periventricular regions from all brains, HBSS was removed 
and tissues were incubated in trypsin-EDTA solution at 37°C for 10 min. An equal 
volume of DMEM/F12 + 10% fetal bovine serum (FBS, Euroclone) was added at the 
end of the enzymatic incubation to inactivate trypsin. Tissue were then gently triturated 
through a series of descending-diameter pipettes to make a single-cell suspension. The 
cells were centrifuged at 800 rpm for 7 min and the pellet was then resuspended in 2 ml 
of Neurosphere Medium (Table 3.1) and mechanically dissociated.  
 
Components Final Concentration 
DMEM/F-12 + glutamax
TM 
(Life Technologies, Milan, Italy) To volume 
Penicillin (Euroclone) 100 U/mL 
Streptomicin (Euroclone) 100 µg/mL 
HEPES (Sigma-Aldrich, Milan, Italy) 8 mM 
Heparin (Sigma) 2 ng/mL 
D-glucose (Euroclone) 6 mg/mL 
B27 supplement (Life Technologies) 1:50 
Table 3.1: composition of Neurosphere Medium 
The cell suspension was centrifuged again for 9 min at 900 rpm and the pellet was 
resuspended in 2 ml of Neurosphere Medium, mechanically dissociated and filtered 
with a 70 μm cell strainer (BD Pharmigen). Finally the cell suspension was centrifuged 
for a third time for 10 min at 1,000 rpm, and the cells plated at low density (20,000 
cells/ml) in a six-well plate. Cultures were supplemented with EGF and bFGF (20 
ng/mL) every other day (Figure 3.2). 
 
Figure 3.2: schematic representation of the experimental protocol. Cells obtained 
from the dissociation of SVZ were plated at low density and kept in culture for seven 
days till the formation of primary neurospheres. Growth factors (GFs) were added 
every other day.  
Primary
neurospheres
GFs (EGF + bFGF)
0 2 4 6 7DAYS 
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Primary neurospheres were generated: (i) in Neurosphere Medium, (ii) in 
Neurosphere Medium + ADPβS (50 µM), or in conditioned media derived from 
astrocytes cultured (iii) under control condition (astro CTR), or (iv) in the presence of 
ADPβS (astro ADPβS) (50 µM, Sigma-Aldrich; see below). This concentration of 
ADPβS was selected based on previous work showing that: (i) it activates astrocytes in 
vitro by reproducing features of their response to lesion in vivo (Franke et al., 2012; 
Quintas et al., 2011), and (ii) it modulates adult stem cell functions (Grimm et al., 2009; 
Mishra et al., 2006; Stafford et al., 2007). In selected experiments, the P2Y1 selective 
antagonist MRS2179 (50 µM, Sigma-Aldrich) was added at the time of SVZ cell plating 
to the neurosphere medium + ADPβS or to the conditioned medium derived from 
astrocytes cultured in the presence of ADPβS. 
After 7 days in culture, the number of generated neurospheres and their size were 
evaluated. For each condition, neurospheres included in 5 randomly chosen optical 
fields at 10X magnification were analyzed under a Zeiss Axiovert 8400 microscope 
(Carl Zeiss, Milan, Italy), equipped with a CCD camera module. Neurosphere diameters 
were measured using the ImageJ software (Research Service Branch, National Institutes 
of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/).  
3.1.2 PASSAGING OR DIFFERENTIATION OF NEUROSPHERES 
In selected experiments, primary neurospheres grown as indicated above were 
dissociated, and cells re-plated in control Neurosphere Medium irrespectively of their 
original culturing condition to generate secondary neurospheres.  
For passaging, neurospheres were spun down and dissociated mechanically using 
a P200 micropipet tip (30 times up and down). As for primary neurospheres, 20,000 
cells/ml were plated in a six-well plate. The number and size of secondary neurospheres 
were then analyzed after 2 days in vitro. 
Alternatively, to test cell proliferation and differentiation, 7-days-old control 
secondary neurospheres were allowed to adhere to the culturing substrate (Lab-Tek II 
Chamber Slide
TM
 System) previously coated with laminin (0.5 mg/mL stock solution 
diluted 1:50 in HBSS, Sigma-Aldrich) without being dissociated, and were grown for 7 
additional days in Neurosphere Medium without growth factors and in the absence or 
presence of ADPβS (50 µM). In this case, cells migrated from the core of the sphere and 
underwent differentiation (Figure 3.3). 
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Figure 3.3: schematic representation of the differentiation protocol. 7-days-old 
secondary neurospheres were plated as adherent cells without being dissociated and 
grown for 7 additional days w/o FBS and GFs in the absence or presence of ADPβS. 
 
Differentiation to astrocytes or neurons was evaluated by immunocytochemistry 
with the specific markers glial fibrillary acidic protein (GFAP) and βIII-tubulin (βIII-
tub), respectively. Cell number was evaluated by staining nuclei with the Hoechst33258 
dye (see below).  
 
3.2 MIXED GLIAL CELL CULTURES AND PREPARATION OF 
CONDITIONED MEDIA  
3.2.1 PRIMARY MIXED GLIAL CELL CULTURES FROM RAT CEREBRAL CORTEX 
Mixed glial cells were obtained from P2 Sprague-Dawley rat cortex and were 
used to isolate oligodendrocyte precursors cells (OPCs) and astrocytes.  
Animals were anesthetized with diethyl ether then killed by decapitation. The 
brain was exposed and surgically removed. The olfactory bulbs and the cerebellum were 
cut off and the brain was divided along the midline into two cerebral hemispheres to 
isolate the cortex. After removal of meninges, cortices were minced with a sterilized 
razor blade into ~ 1 mm
3
 chunks and placed in a 50 ml tube containing HBSS on ice. 
When all the cortices were isolated, three washes with HBSS without (w/o) Calcium 
and Magnesum were performed followed by a 30 min incubation at 30 C° in a trypsin-
EDTA solution (c.f. 0.5% e 0.2% in HBSS w/o Ca2
+
 and Mg
+
) +1% deoxyribonuclease 
(DNase; Sigma-Aldrich; c.f. 0.01 mg/mL). At the end of the enzymatic incubation an 
equal volume of HBSS + 10% FBS was added to stop trypsinization, and the cell pellet 
was triturated and dissociated until nearly homogenous. The tissue suspension was 
DIFFERENTIATION
DMEM/F12 w/o FBS and GFs
+/- ADPβS
Secondary
neurospheres
0 1 4 7
DAYS 
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passed through a 100 µm cell strainer placed on a 50 ml conical tube to collect the flow-
through that was then centrifuged for 10 min at 1,200 rpm. The pellet was then 
resuspended in DMEM Medium (1 ml for each brain) (Table 3.2). Finally, 1 ml of the 
cell suspension was plated on T75 cm
2
 tissue culture flask already containing 12 ml of 
DMEM Medium added with 20% FBS. To help cells adhesion, the day before 
preparation flasks were coated overnight at room temperature with poly-D-lysine 
coating solution (1 mg/ml stock solution diluted 1:100 in sterile ddH2O), and then 
washed three times with sterile ddH2O and dried completely in a tissue culture hood. 
The medium was changed every other day with fresh medium. Ten days after plating, 
mixed glial cultures reached confluence, and phase-dark, process-bearing OPCs 
appeared on top of a phase-gray bed layers of astrocytes. The culture was therefore 
ready to be shaken to isolate either OPCs or astrocytes. 
 
Components Final Concentrations 
DMEM high glucose (Euroclone) To volume 
Penicillin (Euroclone) 100 U/mL 
Streptomicin (Euroclone) 100 µg/mL 
Sodium Pyruvate (Euroclone) 1 mM 
Fungizone (Life Technologies) 2,5 µg/mL 
L-Glutamine (Euroclone) 2 mM 
Table 3.2: composition of DMEM Medium 
3.2.2 ASTROCYTE CONDITIONED MEDIA 
After removal of overlaying oligodendrocytes and microglia by vigorous shaking 
of flasks (see 3.4), astrocytes were kept in Neurosphere Medium (see above) in the 
absence or presence of ADPβS (50 µM) for 3 additional days. In parallel, two flasks 
containing only Neurosphere Medium with or without ADPβS (50µM) were kept in the 
incubator to test for the effect of a prolonged incubation at 37°C on the properties of our 
media. All the media were then collected, filtered and utilized for the neurosphere assay 
(see above), and for the cytokine assay. 
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3.2.3 CYTOKINE ARRAY 
The expression of cytokines, chemokines and acute-phase inflammatory proteins 
was determined in neurosphere media and in the conditioned media from astrocytic 
cultures by means of the Proteome Profiler
TM
 Rat Cytokine Array Panel A (R&D 
Systems Europe, Abingdon, UK). The array consists of nitrocellulose membranes 
spotted with antibodies directed against the following 29 proteins (alternative names are 
shown in parenthesis): CINC-1, CINC-2/, CINC-3, CNTF, Fractalkine, GM-CSF, 
sICAM-1 (CD54), IFN-γ, IL-1, IL-1, IL-1ra, IL-2, IL-3, IL-4, IL-6, IL-10, IL-13, IL-
17, IP-10 (CXCL10), LIX, L-Selectin, MIG (CXCL9), MIP-1 (CCL3), MIP-
3(CCL20), RANTES (CCL5), Thymus Chemokine (CXCL7), TIMP-1, TNF-, 
VEGF. The test was performed according to manufacturer’s instructions. Briefly, 
aliquots of the various culture media were mixed with a cocktail of biotinylated 
detection antibodies, and then incubated overnight at 4°C on separate nitrocellulose 
membranes included in the array. This allowed the binding of any cytokine/detection 
antibody complex to its cognate immobilized capture antibody on the membrane. 
Following a wash to remove unbound material, streptavidin-HRP solution was added to 
the membrane for 30 min at room temperature. Detection of bound complexes was then 
performed by ECL (GE Healthcare, Milan, Italy) and autoradiography. The integrated 
optical density of each spot on the array was quantified by the Image J software. 
 
3.3 ANIMALS, SURGICAL PROCEDURES, AND IN VIVO TREATMENTS 
In vivo experiments were performed on wild type (wt) C57BL/6 and on 
GLAST::CreErt2;Rosa-YFP (Mori et al., 2006; Rolando et al., 2012) adult mice (2-4 
months of age). The experimental plan was designed according to the guidelines of the 
NIH, the European Community Council (86/609/EEC), and the Italian laws for care and 
use of experimental animals (DL116/92). It was also approved by the Italian Ministry of 
Health and the Bioethical Committee of the University of Turin. Surgical procedures 
and perfusions were carried out under deep general anesthesia (ketamine, 100 mg/kg; 
Ketavet, Bayern, Leverkusen, Germany; xylazine, 5 mg/kg; Rompun; Bayer, Milan, 
Italy).  
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In the first set of experiments, ADPβS was chronically infused in the lateral 
ventricle of adult C57BL/6 mice for one week by osmotic minipumps. Osmotic 
minipumps (Alzet osmotic pumps 1007D) were implanted into the left cerebral ventricle 
(coordinates relative to bregma: anterior, 0; lateral, 1 mm; depth, 1.8 mm) to deliver 
ADPβS (100 µM in phosphate buffered saline, PBS; Sigma-Aldrich) or vehicle. The 
concentration of ADPβS was chosen based on literature data, to reproduce the massive 
release of eNTs that is observed following traumatic or ischemic brain injuries (Franke 
et al., 2012; Melani et al., 2005). To analyze cell proliferation, animals received two 
i.p./day injections of the thymidine analogue 5-bromo-2’-deoxyuridine (BrdU, Sigma 
Aldrich; 50 mg/kg in saline/day) on the last 3 days of ADPβS treatment (Figure 3.4).  
 
Figure 3.4: experimental design. ADPβS or PBS were administered i.c.v. by 
minipumps to 8 weeks-old mice for one week. To primarily monitor the proliferation of 
transit amplifying cells, animals also received two pulses of BrdU per day on the last 
three days of agonist administration. 
 
To test whether ADPβS was acting directly on stem cells we took advantages 
of the GLAST::CreErt2;Rosa-YFP transgenic mice model. In these mice all the cell 
expressing the stem cells marker GLAST (astrocyte specific glutamate/aspartate 
transporter) and their progeny become fluorescence upon tamoxifen administration. 
Animals received tamoxifen (Tam in Figure 3.5) dissolved in corn oil to induce Cre 
activity and YFP reporter expression (one administration of 5 mg each by oral gavage 
for two days) before starting the pharmacological treatment with the ADP analogue. 
ADPβS was again chronically infused in the lateral ventricle of adult mice for one week 
by osmotic minipumps. In this case, we restricted the analysis to a small pool of cycling 
cells by injecting animals with another marker of cells proliferation, 5-ethynyl-2’-
deoxyuridine (EdU, Life Technologies; 50 mg/kg in saline i.p; Ponti et al., 2013) 2 
hours before sacrifice (Figure 3.5). In these experiments, EdU was chosen instead of 
0
BrdU
PBS/ADPβS (100 μM) 
Sacrifice
i.c.v.
days 65 7
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BrdU since its visualization follows a one-step procedure without DNA denaturation, 
and was therefore more convenient for triple immunostaining (see below). 
 
Figure 3.5: experimental design. ADPβS or PBS were chronically infused in the 
lateral ventricles of GLAST::CreERT2;Rosa-YFP transgenic mice for one week via 
osmotic minipumps. Animals were also treated with EdU two hours before sacrifice to 
stain rapidly dividing cells. 
3.3.1 IMMUNOHISTOCHEMISTRY, IMAGE PROCESSING AND DATA ANALYSIS 
For histological analysis, animals were anaesthetized (see above) and 
transcardially perfused with 4% paraformaldehyde in PBS. Brains were collected, 
postfixed overnight, cryoprotected, cut coronally in 30 µm-thick slices, and stained 
according to standard protocols (Rolando et al., 2012). Incubation with primary 
antibodies (anti-GFAP, 1:1,000, dako, Milan, Italy; anti-doublecortin, DCX, 1:400, 
Santa Cruz Biotechnologies, Heidelberg, Germany; anti-GFP, 1:700, Life Technologies; 
anti-BrdU, 1:250, Abcam, Cambridge, UK; anti-Mash1, 1:200, BD Pharmingen Milan, 
Italy) was performed overnight at 4°C in PBS with 1.5% normal serum and 0.25% 
Triton-X 100. In the case of BrdU staining, slices were previously treated with 2N HCl 
for 20 min at 37°C, followed by 10 min in 0.1 M borate buffer (pH 8.5). Sections were 
then exposed (2 hours, RT) to secondary specie-specific antibodies (all at 1:500 
dilution) conjugated to Alexa Fluor® 488, 546, 649 (Life Technologies) or to Cy3 
(Jackson ImmunoResearch Laboratories, West Grove, PA). Click-It
TM
 EdU Cell 
Proliferation Assay Kit (Life Technologies) was utilized to detect EdU incorporation, 
according to the manifacturers’ instructions. Nuclei were counterstained with the 
Hoechst33258 dye (1:10,000 in PBS; 20’ at RT; Life Technologies, Milan, Italy). 
Stained sections were mounted on microscope slides with Tris-glycerol supplemented 
i.c.v.
GLAST::CreERT2; Rosa-YFP 
PBS/ADPβS (100 μM)
Tam Sacrifice
1 week EdU
2hrs
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with 10% Mowiol (Calbiochem, La Jolla, CA), and analyzed either by an E-800 Nikon 
microscope (Nikon, Melville, NY) equipped with a color CCD Camera or by a Leica 
TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). 
Quantifications were performed by the ImageJ (Research Service Branch, National 
Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/) or the Neurolucida 
softwares (MicroBrightfield, Colchester, VT). For the evaluation of the number of 
positive cells for the different markers, comparisons were made between hemispheres 
ipsilateral to the infusion site of control (Ctr) and treated animals (unless differently 
stated); data are derived from a minimum of 6 up to 23 sections from 3-4 
animals/experimental condition and/or time point. In the Results section and in the 
Legends to figures, “n” refers to the number of animals analyzed. Results are expressed 
as either the absolute number of positive cells/section or per lateral wall length (which 
was similar in the analyzed samples: Ctr mice, 283.62±3.84 µm vs. ADPβS-treated 
animals, 295.93±6.20 µm), as indicated in the figure legends and in the Results section.  
 
3.4 IN VITRO GENERATION OF PURE OLIGODENDROCYTE CULTURES 
OPCs were isolated from mixed glial cultures (see 3.2.1) by the shaking method 
followed by an immunopurification protocol (Mayer-Pröschel, 2001). This second part 
consists in a negative selection procedure to remove undesired cells (e.g., astrocytes, 
meningeal cells, type 1 astrocytes and microglia/macrophages) using the Ran-2 
antibody (Bartlett et al., 1980). 
Tissue culture-grade plastic was not directly coated with cell surface–specific 
antibodies used in immunopurification. Instead, a layer of anti-immunoglobulin 
antibodies was adsorbed to the dish the day before culture shaking, thereby improving 
the subsequent binding of cell-type specific antibody. In particular, 100µl of anti-IgG 
stock solution (1 mg/ml, MP Biomedicals, Santa Ana, CA) were diluted with 20 ml of 
50 mM Tris HCl, pH 9.5. Two 100 mm tissue culture dishes were then coated with 10 
ml of this antibody solution each and incubated overnight at 4°C, taking care to ensure 
sterility. 
The following day, mixed cultures were shaken on an orbital shaker for 3-4 hours 
at 200 rpm. In the meantime the two IgG coated dishes were rinsed 3 times with PBS 
and the solution of RAN2 antibody (kindly provided by Prof. Carla Taveggia, Axo-Glia 
78 
 
Unit, Institute of Experimental Neurology Division of Neuroscience, San Raffaele 
Scientific Institute, Milan) was added (0.5 mL Ab + 6 mL of MEM + 1mg/ml BSA + 
HEPES 1N for each plate) and incubated at least for 3h at RT. 
At the end of the shaking period, the medium containing the detached cells was 
collected from each flask in 50 ml sterile conical tubes and centrifuged for 10 min at 
1,200 rpm. Pellets were resuspended in NM15 Medium (Table 3.3) + insulin (5µg/ml) 
and the cell suspension was incubated at room temperature in the first RAN2 antibody-
precoated plate. After 20 min, the cells which did not attach to the plate were transferred 
to the second RAN-2-precoated plate and incubated for additional 20 min at RT. The 
supernatant was then collected and centrifuged at 1,200 rpm for 10 min. The obtained 
pellet was resuspended in the appropriate medium in accordance with the protocol 
applied subsequently (see 3.5). 
OPCs were plated onto poly-D,L-ornithine coated 13-mm coverslips (final 
concentration 5µg/ml; Sigma-Aldrich) for immunocytochemistry. 
 
Components Final concentrations 
MEM (Life technologies) To volume 
FBS (Euroclone) 15% 
Glucose (Sigma) 6 mg/ml 
Penicillin (Euroclone) 100 U/mL 
Streptomicin (Euroclone) 100 µg/mL 
Table 3.3: composition of NM15 Medium 
 
3.5 NEUROGENIC PROTOCOLS 
To test the ability of OPCs to generate neurons we tested two different protocols 
already published in literature and claimed to foster neurogenesis (Kondo and Raff, 
2000a; Liu et al., 2007). 
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First of all we reproduced the 3-phases protocol published by Kondo and Raff 
(Kondo and Raff, 2000a), renamed here neurogenic protocol #1. According to this 
protocol, cells were initially maintained for 5 days in DMEM Medium (see Table 3.2) 
+10 ng/ml PDGF + B27 supplement (1:50) to induce OPCs proliferation (phase A). 
Cells were then shifted to DMEM Medium + 10 ng/ml PDGF + B27 supplement (1:50) 
+ 15% FBS to promote their differentiation towards type 2 astrocytes and cultured for 3 
days (phase B). Finally, cells were maintained for 5 additional days in DMEM Medium 
+ B27 supplement (1:50) +10 ng/ml bFGF (phase C) to induce their differentiation to 
neurons (Figure 3.6).  
 
Figure 3.6: schematic representation of neurogenic protocol #1. Cells were grown 
according to a 3-phase protocol already published by Kondo and Raff (Kondo and Raff, 
2000a). See text for details. 
 
We then set up an additional successful neurogenic protocol, renamed here 
neurogenic protocol #2 (Figure 3.7; Liu et al., 2007).  
 
Figure 3.7: schematic representation of neurogenic protocol #2. Cells were grown 
according to a second already published neurogenic protocol (Liu et al., 2007). 
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In neurogenic protocol #2 cells were exposed for 2 days to Proliferation Medium 
(DMEM Medium + 10ng/ml PDGF + 10 ng/ml bFGF, phase PM) and then induced to 
differentiate into oligodendrocytes by removing the mitogens from the medium for 1 
day (Differentiation Medium, phase DM). Finally cells were cultured in Stem Cell 
Medium (phase SCM, Table 3.4) for 3 days.  
 
Components Final concentrations 
DMEM/F-12 (Life technologies) To volume 
Glutamine (Euroclone) 1 mM 
Glucose (Sigma) 25 mM 
FBS (Euroclone) 1% 
B27 supplement (Life technologies) 1:50 
Table 3.4: composition of SCM 
 
In both protocol, cells were fixed with 4% paraformaldehyde and processed for 
immunocytochemistry (see 3.6) or whole-cell lysates were prepared and analyzed by 
western blotting (see 3.7) at various time points (see Results and Figures). 
3.5.1 PHARMACOLOGICAL TREATMENTS 
In either protocol, we have verified if and how the exposure to various 
pharmacological agents (including GPR17 receptor ligands) can modulate OPCs 
plasticity and their differentiation to neurons. In particular, we have utilized the non-
selective GPR17 agonist UDP-glucose (10 µM) and antagonist Cangrelor (10 µM), in 
parallel to the anticonvulsant agent valproic acid (VPA, 500 µM) for the indicated time 
periods (see Results and Figures). All reagents were obtained from Sigma-Aldrich, 
except for Cangrelor that was a kind gift of The Medicines Company, Parsippany, NJ, 
USA. 
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3.6 IMMUNOCYTOCHEMISTRY, IMAGE PROCESSING AND DATA 
ANALYSIS 
Immunocitochemical analyses were performed on either adherent neurospheres or 
cells cultured according to the two neurogenic protocols. In both cases cells were fixed 
at room temperature for 20 min in 0.1 M PBS (Euroclone) containing 0.12 M sucrose. 
Cells were subsequently incubated for 20 min at room temperature with Goat Serum 
Dilution Buffer (GSDB; 450 mM sodium chloride and 20 mM sodium phosphate buffer, 
pH 7.4, 15% goat serum, and 0.3% Triton X-100), before exposure to the primary 
antibodies diluted in GSDB. Rabbit anti-GFAP (1:600, Dako), mouse anti-βIII-tub 
(1:1,000; Promega, Milan, Italy), mouse anti-NG2 (1:200; Abcam) and anti-rabbit 
GPR17 (1:100; Cayman Chemical Company, Ann Arbor, MI) primary antibodies were 
used. After an overnight incubation at 4°C, cells were rinsed three times in a high salt 
buffer solution (500 mM sodium chloride and 20 mM sodium phosphate buffer, pH 7.4) 
for 10 min, and then incubated (1 hour, room temperature) with secondary goat anti-
rabbit and goat anti-mouse antibodies conjugated to AlexaFluor®488 or 
AlexaFluor®555 (1:600 in GSDB, 1h, RT; Life Technologies). Nuclei were then 
labelled with the fluorescent dye Hoechst-33258 (1:10,000 in PBS; Life Technologies). 
Cells were rinsed three times in high salt buffer, once in PBS, and finally once in 5 mM 
sodium phosphate buffer, pH 7.4. Coverslips were mounted in Dako Fluorescence 
Mounting Medium (Dako).  
Adherent neurospheres were analyzed under a Zeiss Axiovert 8400 microscope 
(Carl Zeiss, Milan, Italy), equipped with a CCD camera module. To evaluate the 
intensity of staining, fluorescent images were captured from 10 randomly chosen optical 
fields/coverslip. Since a direct count of positive cells was technically not feasible, due 
to their high number and to the low fluorescence signal at the 10x magnification (which 
better allowed to gain a general view of the effect exerted by the pharmacological 
treatment), we decided to perform a densitometric analysis of Hoechst33258, GFAP and 
βIII-tub staining, after splitting the three fluorescence channels and converting the 
colored fluorescent signals to grayscale values. The mean gray value for each optical 
field was then evaluated by the ImageJ software. Results represent the mean±S.E.M. of 
data from 3 coverslips deriving from 2 independent experiments. 
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Instead, cells subjected to neurogenic protocols #1 and #2 were analyzed by using 
a fluorescent microscope (Zeiss). In each coverslip, the total number of cells, evaluated 
by nuclear staining Hoechst dye, and number of GPR17-, βIII-tubulin, GFAP- or NG2-
positive cells were counted under a 40x magnification in 20 randomly chosen optical 
fields. 
 
3.7 WESTERN-BLOTTING ANALYSIS 
Whole-cell lysates were prepared and analyzed by Western blotting as previously 
described (Bianco et al., 2005). Briefly, approximately 30 g aliquots from each protein 
sample were loaded on 11 sodium-dodecylsulphate polyacrylamide gels, and blotted 
onto nitrocellulose or PVDF membranes (Bio-Rad Laboratories, Milan, Italy). 
Membranes were then saturated with 10 non-fat dry milk in Tris-buffered saline 
(TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 1 hour at RT, and incubated overnight 
at 4°C with mouse anti-synaptic vesicle2 (SV2, 1:2,000) and anti-βIII-tub (1:1,000, 
Promega) or rabbit anti-synaptotagmin (Syt, 1:2,000; SV2 and Syt are a kind gift of Dr. 
Claudia Verderio, CNR, Milan) and anti-GPR17 primary antibodies (1:100 home-made 
monoclonal antibody) all in 5 non-fat dry milk in TBS. Membranes were then washed 
in TBS-T (TBS plus 0.1 Tween20®), incubated for 1 h with goat anti-rabbit or anti-
mouse secondary antibodies conjugated to horseradish peroxidase (1:4,000 or 1:2,000 in 
5% non-fat dry milk in TBS respectively; Sigma-Aldrich). Detection of proteins was 
performed by enhanced chemiluminescence (ECL, Amersham Biosciences, Milan, 
Italy) and autoradiography. Non-specific reactions were evaluated by in the presence of 
the secondary antibodies alone 
 
3.8 STATISTICAL ANALYSIS  
Data were analyzed using the GraphPad Prism5 software. Differences between 
experimental conditions were analyzed using either unpaired, two-tails Student's t test, 
or one-way ANOVA followed by the Bonferroni correction. P value <0.05 was 
considered as significant. 
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4. RESULTS 
 
4.1 PURINES REGULATE ADULT BRAIN SUBVENTRICULAR ZONE CELL 
FUNCTIONS: CONTRIBUTION OF REACTIVE ASTROCYTES 
4.1.1 THE P2Y1 AGONIST ADPßS INCREASES THE PROLIFERATION OF SVZ PRECURSORS 
AND THEIR LINEAGE PROGRESSION IN VITRO 
To examine the ability of non-selective P2Y1,12,13 agonist ADPβS to modulate 
proliferation and multipotency of SVZ cells, we performed the neurosphere assay, in the 
presence of standard concentrations of both bFGF and EGF (20 ng/ml each; see 
Materials and Methods, Paragraph 3.1). After 7 days in vitro (DIV), the number and 
size of primary neurospheres were analyzed. Exposure to 50 µM ADPβS increased the 
neurosphere forming capacity of SVZ cells, as indicated by their increased number 
(Figure 4.1A, A’, B). Yet, ADPβS stimulation determined the generation of 
neurospheres with a reduced size compared to controls (Figure 4.1A, A’, C). 
Furthermore, the total number of cells yielded after the dissociation of neurospheres at 7 
DIV decreased upon treatment with the ADP analogue (1,476,562±271,023 in control 
cultures vs. 686,094±168,364 after exposure to ADPβS; p<0.05 Student’s t test). Co-
exposure to the selective P2Y1 antagonist MRS2179 (50 µM) completely abrogated 
ADPβS-induced effects on both neurosphere forming capacity and proliferation (Figure 
4.1A’’, B, C), thus demonstrating that the ADP analogue is selectively activating the 
P2Y1 receptor (P2Y1R) subtype.  
These results are in agreement with literature data suggesting a primary role for 
P2Y1R in mediating the effects exerted by extracellular nucleotides (eNTs) on SVZ 
precursor cells (Suyama et al., 2012). Moreover they are also in line with already 
published data describing an antiproliferative effect of various eNTs, including ADPβS 
at standard GF concentrations (Mishra et al., 2006; Stafford et al., 2007).  
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Figure 4.1: ADPβS modulates neurosphere formation from the SVZ in vitro. (A-A’’) 
Representative micrographs showing 7-day-old primary neurospheres generated under 
control condition (A), in the presence of ADPβS (50µM) alone (A’) or in combination 
with MRS2179 (50µM) (A’’). Quantification of the number (B) and size (C) of primary 
neurospheres generated under the various experimental conditions (3 replicates from 2 
independent experiments; *p<0.05, **p<0.01 and ***p<0.001, One-way ANOVA 
followed by Tukey post hoc analysis). Scale bars: 100 µM. 
 
Thus, to assess the effects of P2Y1R activation in the absence of GFs and to 
examine the outcome of ADPβS exposure on the lineage progression of SVZ cells, 7-
day-old control secondary neurospheres were plated without dissociation and grown for 
7 additional days in a medium without GFs (see Materials and Methods, Paragraph 
3.1.2), in the absence or presence of ADPβS. The expression of the neuronal and 
astrocytic marker βIII-tubulin (βIII-tub) and GFAP, respectively, and the mean area of 
adhering neurospheres were evaluated by immunocytochemistry, in parallel with the 
staining of cell nuclei by the Hoechst33258 dye (Figure 4.2A, A’). Exposure to 50 µM 
ADPβS led to a moderate, but significant increase in neurosphere area (121.11±17.38% 
of control neurosphere area, set to 100.00±12.89%; 19-21 optical fields from 3 
coverslips/condition; p<0.05, Student’s t test). A much higher increase in the mean 
fluorescence value for Hoechst33258 staining was detected after exposure to the purine 
analogue (Figure 4.2B, B’, E), meaning a higher number of cell nuclei per area. 
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Interestingly, immunoreactivity for both GFAP and βIII-tub clearly increased 
upon exposure to ADPβS (Figure 4.2C-D’). While the increase in GFAP 
immunoreactivity was proportional to the increased cell number (compare Figure 4.2E 
and F), βIII-tub staining in ADPβS-treated cultures exceeded the labeling in control 
condition by two-fold (Figure 4.2G), indicating a prominent effect of ADPβS on 
neuroblast production.  
 
Figure 4.2: ADPβS stimulates neurosphere differentiation and proliferation. (A, A’) 
Immunofluorescence staining for βIII-tub (red) and GFAP (green) of adherent 
undissociated neurospheres (NS) cultured in differentiating conditions in control 
medium (A) or in the presence of ADPβS (A’). Nuclei were counterstained with the 
Hoechst33258 dye (blue). (B-D’) The green, red, and blue fluorescent channels in A 
and A’ were separated and converted to greyscale for densitometric analysis, shown in 
(E) for Hoechst33258, in (F) for GFAP and in (G) for βIII-tub. Data are shown as the 
mean percentage±S.E.M. of CTR values set to 100% (19-21 optical fields from at least 3 
coverslips/condition, *p<0.05, **p<0.01, unpaired Student's t test). Scale bars: 100 μm. 
 
Therefore, in vitro results indicate that ADPβS promotes neurosphere formation 
and stimulates the generation of neurons and astrocytes. 
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4.1.2 ASTROCYTES EXPOSED TO ADPßS INFLUENCE THE GENERATION OF 
NEUROSPHERES FROM SVZ CELLS IN VITRO 
Solid evidence demonstrates that exposure of astrocytes to nucleotides in general, 
and to ADPβS in particular, induces reactive astrogliosis (Abbracchio and Ceruti, 2006; 
Franke et al., 2012). Reactive astrocytes release several mediators (see Introduction, 
Paragraph 1.5.1) which could influence the functionality of surrounding cells, such as 
SVZ progenitors. To unveil the possible effects of ADPβS-activated astroglia on neural 
progenitors, we assessed whether astrocyte conditioned media could modify 
neurosphere formation from SVZ cells. To this aim, we exposed primary astrocytic 
cultures to conventional neurosphere medium with or without 50 µM ADPβS (see 
Materials and Methods, Paragraph 3.2.2 for experimental design). Both culture media 
were then collected after 3 DIV, and utilized to generate neurospheres, as described 
above (Figure 4.34). When SVZ progenitors were grown in medium from Control 
(Astro ctr) or ADPβS-treated astrocytes (Astro ADPβS), no differences were found in 
either the number (17.67±2.56 in Astro ctr vs. 14.00±3.36 in Astro ADPβS medium, 
p>0.05 Student’s t test) or the size of primary neurospheres at 7 DIV (Figure 4.3B). To 
exclude that the Astro ADPβS medium contained: i) residual ADPβS, or ii) adenine 
nucleotides released by activated astrocytes, which could influence SVZ cell properties, 
the P2Y1 antagonist MRS2179 was added to Astro ADPβS medium at the time of 
neurosphere generation. No significant differences were found in the neurospheres 
formed in Astro ADPβS medium or in Astro ADPβS + MRS2179 (Figure 4.3B), thus 
ruling out a role eNTs in the conditioned medium from reactive astrocytes. 
Interestingly, despite the generation of a similar number of primary neurospheres 
in Astro ctr and Astro ADPβS compared to standard (formerly indicated as ctr) 
neurosphere media (not shown), a significantly lower number of cells was yielded from 
their dissociation. In fact, the total number of cells was 1,476,563±271,023 from ctr 
neurospheres vs. 157,400±36,603 and 132,500±46,199 from neurospheres grown in 
Astro ctr and Astro ADPβS media, respectively (p<0.001 ctr vs. Astro ctr and ctr vs. 
Astro ADPβS, Student’s t test). Of further interest, these numbers were also lower than 
those obtained with exposure to ADPβS alone (686,094±168,364; p<0.05 ADPβS vs. 
Astro ctr and ADPβS vs. Astro ADPβS, Student’s t test), suggesting a specific negative 
astrocyte-mediated effect on precursor proliferation. 
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Figure 4.3: ADPβS-treated astrocytes regulate the generation of secondary 
neurospheres from SVZ precursors in vitro. (A) Schematic representation of the 
experimental design (see text for details). (B) Evaluation of the size of primary 
neurospheres (NS) generated in the conditioned medium from CTR or ADPβS-treated 
astrocytes. In selected experiments, the P2Y1R antagonist MRS2179 was added to Astro 
ADPβS medium at the time of seeding of SVZ cells. (B’) Evaluation of the size of 
secondary neurospheres generated in fresh control medium and derived from cells 
obtained by the dissociation of primary neurospheres grown under the various 
experimental conditions (5 coverslips from 2 independent experiments; ***p<0.001, 
One-way ANOVA followed by Tukey post hoc analysis). Representative micrographs 
are shown in C-C’. Scale bars: 100 μm. The cartoon was produced thanks to “Servier 
Medical Art” (www.servier.com). 
 
Primary neurospheres were then dissociated and replated in ctr neurosphere 
medium, irrespectively of their initial growing condition, to generate secondary 
neurospheres (Figure 4.3A). Surprisingly, fully formed secondary neurospheres were 
already generated at 2 DIV from cells derived from primary neurospheres grown in 
Astro ADPβS medium (Figure 4.3B’, C’). Conversely, very small cell clusters were 
visible in cultures derived from primary neurospheres grown in Astro ctr medium 
(Figure 4.3B’, compare Figure 4.3C with C’) or in ctr and ADPβS medium (Figure 
4.3B’). Numbers of neurospheres were instead similar in all the tested conditions (not 
shown).  
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These findings suggest that ADPβS specifically acts on astrocytes by promoting 
the release of mediator(s) capable to “prime” SVZ precursors inducing them to 
proliferate. However, this proliferative effect is possibly concomitantly inhibited by 
other astrocyte-derived factor(s), so that only after their removal from the culture 
medium the proliferation of SVZ cells is intensively boosted.  
 
Figure 4.4: ADPβS modulates the release of various signaling molecules from 
astrocytes in vitro. Relative expression of various signaling molecules in conditioned 
medium derived from control or ADPβS-treated astrocytes, as determined by an 
antibody array (see Methods for details). A and B show molecules whose extracellular 
concentration decreased or increased after ADPβS exposure, respectively. C shows 
unchanged molecules. Results are the mean of 2 independent analyses. (**p<0.01, 
***p<0.001, unpaired Student's t test). 
 
To identify possible mediators released in the astrocyte conditioned medium and 
responsible for the above observed effects, we took advantage of the Proteome 
Profiler
TM
 Antibody Array. This approach allows the simultaneous detection of 29 
cytokines and chemokines in the tested culture media (see Materials and Methods 
Paragraph 3.2.3). Interestingly, in control neurosphere medium (see Materials and 
Methods, Tab 3.1, for the medium composition) and in the neurosphere medium added 
with ADPβS, the concentrations of all the analyzed molecules were below the detection 
limit of the array (not shown). However, 12 out of 29 molecules were detected in both 
Astro ctr and Astro ADPβS media (Figure 4.4). Indeed, exposure to the nucleotide 
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analogue either significantly reduced or increased the astrocytic release of the majority 
of these mediators (Figure 4.4A, B). Only IP-10, Rantes and TIMP-1 concentrations 
did not change between the two experimental conditions (Figure 4.4C).  
CINC-2α/β, CINC-3, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-6, IL-13, IL-17, 
CNTF, GM-CSF, TNF-α, Fractalkine, Thymus Chemokine and IFN-γ were not detected 
in either conditioned media.  
Thus, a combination of various secreted mediators, whose release by astrocytes is 
modulated by ADPβS stimulation, might account for the observed effects of ADPβS 
conditioned medium on SVZ cell properties. 
4.1.3 ADPßS ACTIVATES BOTH NICHE AND PARENCHYMAL ASTROCYTES AND INCREASES 
THE PROLIFERATION OF SVZ PRECURSORS IN VIVO 
Next we aimed at translating our in vitro data to an in vivo setting, and at 
addressing the role of P2Y1R in the regulation of adult neurogenesis in conditions 
mimicking those observed after brain injury. Thus, ADPβS (100 µM) was chronically 
infused for one week into the cerebral ventricles of wildtype mice and cell proliferation 
was monitored by BrdU administration during the last 3 days (see Materials and 
Methods, Paragraph 3.3). Incorporation of the thymidine analogue was then evaluated 
by immunohistochemistry together with the expression of cell specific markers for SVZ 
populations and parenchymal astrocytes (i.e., GFAP for astrocytes and Type B 
precursor cells, Mash1 for Type C transit-amplifying cells, and doublecortin, DCX, for 
Type A neuroblasts).  
Notably, ADPβS infusion caused a significant up-regulation of GFAP in both 
parenchymal astrocytes (arrows in Figure 4.5A’, B’ and insets A’’, B’’), thus 
confirming our in vitro and literature data demonstrating a role for eNTs in reactive 
astrogliosis (Franke et al., 2012), and in the neurogenic areas of the dorsal horn (DH) 
and lateral wall (LW) (Figure 4.5A-A’ and B-B’; quantification in C and D, 
respectively), where GFAP also labels precursor cells. In parallel, a significant 
expansion of DH area (Figure 4.5E) and a thickening of the LW (Figure 4.5F) were 
observed, confirming a specific effect of ADPβS on GFAP+ type B cells (i.e., stem cells 
and niche astrocytes). 
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Figure 4.5: a 7-day-long infusion of ADPβS increases GFAP immunostaining in the 
SVZ and induces reactive astrogliosis in brain parenchyma. (A-B’) Representative 
images of GFAP staining (green) in the dorsal horn (DH) and lateral wall (LW) of 
control (A-B) and ADPβS-treated animals (A’-B’). Significant reactive astrogliosis 
induced by the nucleotide analogue was evident in brain parenchyma (arrows in A’, B’ 
and insets A’’, B’’). (C, D) Quantification of GFAP immunostaining in the DH (C) and 
LW (D). Values represent the mean fluorescence intensity of GFAP staining/section in 
arbitrary units. (E, F) Quantification of the DH area (F) and of LW thickness (G), as 
delimited by the dashed lines in (A, A’) and (B, B’), respectively. (*p<0.05, 
***p<0.001, Student's t test). Scale bars: 50 μm in A-B’ and 150 µm in A’’, B’’. LV: 
lateral ventricle. 
 
In line with these observations, exposure to ADPβS promoted cell proliferation in 
the SVZ. A significant increase in BrdU incorporation was in fact detected in parallel in 
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the LW (Figure 4.6A-B). Namely, we observed an expansion of Mash1
+
 type C transit-
amplifying cell population (Figure 4.6C-D), which also incorporated more BrdU 
(Figure 4.6E).  
Figure 4.6: a 7 day-long infusion of ADPβS stimulates the proliferation of SVZ cells 
and increases the number of Mash1
+
, and DCX
+
 cells. (A, A’) Representative images 
of the LW from control (A) or ADPβS-treated animals (A’) immunelabelled for BrdU 
(red). (B) Quantification of the total number of BrdU
+
 cells in the LW. (C, C’) 
Representative images of the LW from ctr (C) or ADPβS-treated animals (C’) 
immunelabelled with anti-Mash1 (green) and anti-BrdU (red). (D-F) Quantification of 
Mash1
+
 (D), of Mash1-BrdU double-positive cells (E), and of the percentage of 
proliferating cells in the Mash1
+
 population (F). (G, G’) Immunofluorescence images of 
DCX (green) and BrdU (red) staining in the LW of ctr (G) or ADPβS-treated animals 
(G’). (H-J) Quantification of the total number of DCX+ (H), of DCX-BrdU double-
positive cells (I), and of the percentage of proliferating cells in the DCX
+
 population (J) 
(*p<0.05, **p<0.01, ***p<0.01) unpaired Student's t test). Scale bars: 50 μm. In all 
images nuclei were counterstained with the Hoechst33258 dye (blue). LV: lateral 
ventricle. 
 
Moreover, the total number of DCX
+
 neuroblasts and the fraction of DCX/BrdU 
double-positive cells also significantly increased after ADPβS exposure (Figure 4.6G-
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I). However, in either cell populations the percentage of proliferating cells (i.e., the 
number of cells double-positive for both BrdU and the cell population specific 
marker/the total number of cells for each cell population*100) was not increased by the 
nucleotide analog (Figure 4.6F, J). This suggests that ADPβS does not enhance the 
proliferation of either one (or both) cell populations, but rather acts by stimulating the 
proliferation of their parent precursors or by globally overactivating all SVZ 
populations. Similar results were obtained in the DH (not shown). 
4.1.4 ADPßS PROMOTES THE GENERATION OF A PROGENY OF RAPIDLY DIVIDING CELLS 
FROM GLAST-EXPRESSING STEM CELLS. 
Next, to verify whether ADPβS can foster the transition of stem-like precursors 
towards transit-amplifying cells and neuroblasts, we took advantage of 
GLAST::CreERT2;Rosa-YFP transgenic mice. In these animals, cells expressing the L-
glutamate/L-aspartate GLAST (i.e., SVZ type B cells and parenchymal astrocytes) and 
their progeny are permanently labelled by the fluorescent protein YFP upon Tamoxifen 
administration. Animals chronically received either PBS or 100 µM ADPβS in the 
lateral ventricle for one week (see Materials and Methods, Paragraph 3.3). Two hours 
before sacrifice, animals received a single administration of the thymidine analogue 
EdU to label actively dividing cells. In line with previous data, we detected an increased 
incorporation of EdU upon exposure to the purine analog (Figure 4.7A-B). Moreover, 
the number of YFP/EdU double-positive cells increased by twofold (Figure 4.7C), 
indicating that ADPβS treatment expanded a population of GLAST+ cell-derived 
progenitors in active proliferation. Although this population was for the most composed 
of GFAP-negative progenitors (Figure 4.7D), likely including Mash1
+
 and DCX
+
 cells 
(see above), exposure to ADPβS also resulted in a 2-fold increase of actively cycling 
YFP/EdU double-positive progenitors also expressing GFAP along the ventricle 
(Figure 4.7E-F). Furthermore, a small but significant increase in the total number of 
YFP/GFAP double-positive cells was detected after treatment (Figure 4.7G). These 
data indicate that ADPβS activates GFAP+ precursors in the SVZ with a consequent 
expansion of their progeny. 
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Figure 4.7: ADPβS promotes the proliferation of rapidly dividing transit-amplifying 
cells and GFAP
+
 precursor cells. (A, A’) Immunofluorescence images of EdU 
incorporation (blue) and YFP (green) staining in the LW of control (A) and ADPβS-
treated GLAST::CreERT2;Rosa-YFP animals (A’). (B-C) Quantification of the number 
of LW cells incorporating EdU (B) and of EdU-YFP double-positive cells (C). (D) 
Quantification of YFP-EdU double-positive cells, which do not express GFAP. (E, E’) 
Triple immunostaining (i.e., YFP, green; EdU, blue; GFAP, red) in the LW of ctr (E) 
and ADPβS-treated animals (E’). Inset shows in detail GFAP/EdU double staining in 
the triple labelled cells placed at the upper right corner of E’. (F, G) Quantification of 
YFP-EdU double-positive cells also expressing GFAP (F), and of GFAP-YFP double-
positive cells (G) (*p<0.05,**p<0.01 and ***p<0.001; unpaired Student’s t test). Scale 
bars: 15 μm in A-A’ and 10 μm in E-E’. LV: lateral ventricle. 
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4.2 IMPLEMENTATION OF THE STEM CELL PROPERTIES OF NG2-
EXPRESSING NEURAL PRECURSOR CELLS BY PURINERGIC SIGNALING 
It is well known that NG2
+
 precursor cells (also known as “oligodendrocyte 
precursors cells”, OPCs) can spontaneously differentiate to mature oligodendrocytes 
both in vitro and in vivo; however, when these cells are cultured upon specific 
experimental conditions, they also reveal a stem cell potential since they can generate 
both astrocytes and neurons (for details see Paragraph 1.5.2.1). To test their ability to 
generate neurons, we isolated OPCs from mixed glial cell cultures from postnatal day 2 
rat cortex and grew them according to two already published protocols, renamed here 
neurogenic protocol #1 and neurogenic protocol #2 (Kondo and Raff, 2000a; Liu et 
al., 2007) (Figure 4.8). 
In the neurogenic protocol #1, cells were cultured according to a protocol 
published in 2000 by Kondo and Raff (Kondo and Raff, 2000b). In particular, OPCs 
were initially maintained in a proliferative medium for 5 days (phase A), then 1% of 
FBS was added to the culture medium for 3 additional days to induce cells to de-
differentiate into a more permissive precursor stage (phase B). Finally, cells were 
maintained in culture for 5 days in DMEM+10 ng/ml bFGF (phase C) to induce their 
differentiation to neurons and astrocytes (Figure 4.8A). 
Neurogenic protocol #2 was based on a protocol published by Liu and colleagues 
(Liu et al., 2007). OPCs were maintained in proliferation medium for two days (phase 
PM) and then differentiation was induced by removing mitogens (differentiation 
medium, phase DM). After 1 day in phase DM, cells were shifted to a defined stem cell 
medium (SCM, see Materials and Methods, Table 3.3 for composition) for 3 days 
(phase SCM, Figure 4.8B). 
We have then verified if and how exposure to various pharmacological agents 
(including purinergic receptor ligands targeting GPR17) can modulate OPCs 
differentiation towards neurons in the two experimental protocols. To start the 
pharmacological manipulation of cultures, we have chosen a non-selective GPR17 
antagonist (Cangrelor; Cang, 10 µM), a non-selective GPR17 agonist (UDP-glucose; 
UDP-glu, 100μM) and the histone deacethylases inhibitor valproic acid (VPA, 500 
µM).  
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In neurogenic protocol #1 cells were treated with the different pharmacological 
agents during phase C only, whereas in neurogenic protocol #2 cells were treated during 
both phase DM and SCM (Figure 4.8; for details see Materials and Methods, Paragraph 
3.5.1). 
Figure 4.8: schematic representations of the two neurogenic protocols. A) 
Experimental design of neurogenic protocol #1. Cells were treated with the anti-
convulsant agent and epigenetic modulator valproic acid (VPA, 500 µM), or with a 
non-selective GPR17 antagonist (Cangrelor; Cang, 10 µM) or with a non-selective 
GPR17 agonist (UDP-glucose; UDP-glu, 100 μM) during phase C. B) Experimental 
design of neurogenic protocol #2. Cells were treated with the anti-convulsant agent and 
epigenetic modulator valproic acid (VPA, 500 µM), or with a non-selective GPR17 
antagonist (Cangrelor; Cang, 10 µM) or with a non-selective GPR17 agonist (UDP-
glucose; UDP-glu, 100 μM) during both phase DM and SCM. 
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4.2.1 NG2+ OPCS ARE MULTIPOTENT CELLS AND EXPRESS GPR17  
First of all we tested the ability of both neurogenic protocols to unveil the 
multipotency of OPCs under control condition. We performed immunocytochemistry 
analysis to characterize the composition of the cell population at the end of each phase 
of the neurogenic protocol #1. 
 
Figure 4.9: generation of βIII-tubulin positive neuron by exposing NG2+ cells to 
neurogenic protocol #1. (A) Histograms showing the percentage of cells expressing the 
different cell markers at the end of phase A (red), B (green) or C (light blue) (n=2-7; 
*p<0.05, ***p<0.001, unpaired Student’s t test). (B-D) Representative images of the 
cell progeny at the end of each phase of the experimental protocol. Scale bars: 100 μm. 
 
At the end of Phase A the majority of the cells resulted to be NG2
+
 OPCs, while 
only few GFAP
+
 astrocytes were observed (Figure 4.9; red bars in A and 
exemplificative picture in B). A significative percentage of cells expressed GPR17 (see 
below for colocalization). At the end of Phase B, the majority of cells de-differentiated 
to type 2 astrocytes characterized by strong GFAP immunoreactivity and a branched 
morphology (Figure 4.9C). Moreover, both NG2 and GPR17 expression was 
dramatically down regulated with respect to Phase A (see Figure 4.9; green bars in A). 
At the end of the last phase (phase C), the majority of the cell population re-expressed 
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NG2 and GPR17, whereas the percentage of GFAP
+
 astrocytes was significantly 
decreased with respect to phase B. Interestingly, we also observed the appearance of a 
small but significant percentage of βIII-tub+ neurons (βIII-tub, light blue bars in Figure 
4.9A; exemplificative picture in D), thus demonstrating that protocol #1 succeeded in 
redirecting a subpopulation of NG2+ cells towards a neuronal fate. 
We also characterized the co-expression of GPR17 with the typical OPC marker 
NG2 at the end of both phases A and C. In line with the results already published by our 
group, we observed that the majority of GPR17
+
 cells also co-expressed NG2, thus 
confirming that the receptor decorates a subpopulation of pre-oligodendrocyte precursor 
cells (Figure 4.10).  
 
Figure 4.10: at the end of phases A and C the majority of GPR17
+
 cells co-expresses 
NG2. (A, B) Representative images showing the co-localization of GPR17 (green) and 
NG2 (red) at the end of phase A (A) and phase C (B). (C, D) Pie charts showing the 
percentage of NG2-GPR17 double-positive cells over the total number of GPR17
+
 cells 
at the end of phase A and C. Scale bars: 100 μm. 
 
We then characterized the progeny of OPCs grown under neurogenic protocol #2 
after one day in DM or at the end of the three days in SCM. Also this protocol was able 
to redirect NG2
+
 cells towards a neuronal fate. Indeed, we observed a trend to increase 
in the percentage of βIII-tub+ neurons at the end of SCM phase in comparison to 
cultures at the end of phase DM (Figure 4.11A; phase DM: 3.52±0.65%, phase SCM: 
7.36±1.68). On the contrary, the percentage of GPR17-expressing cells was similar at 
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the end of both phases (Figure 4.11; compare orange and violet bars in A). Finally, the 
vast majority of the GPR17
+
 cells at the end of incubation in DM resulted to be NG2-
expressing OPCs (Figure 4.11B). 
  
Figure 4.11: incubation in stem cell medium (SCM) stimulates the generation of βIII-
tubulin-positive neurons “per se”. (A) Histograms showing the percentage of GPR17- 
or βIII-tubulin (βIII-tub)-positive cells at the end of 24 hours in Differentiation Medium 
(DM, orange bars) or after 72 hours in Stem Cell Medium (SCM, violet bars) (n=2-3). 
See figure 4.8 for details. (B) Pie chart showing the percentage of GPR17
+
 cells also 
expressing NG2 over the total number of GPR17
+
 cells at the end of 24 hours in DM. 
 
In conclusion, we set up two different neurogenic protocols both suitable to unveil 
the stem cell properties of NG2
+
 OPC in vitro, and to redirect them towards a neuronal 
fate. 
4.2.2 VPA IMPLEMENTS THE NEUROGENIC POTENTIAL OF OPCS AND MODULATES THE 
EXPRESSION OF GPR17 
At the end of both neurogenic protocols, two different populations of βIII-tub+ 
cells were observed under control conditions. The first population was represented by 
few cells showing the typical morphology of immature neurons, characterized by a 
small cell body and few long branches (Figure 4.12A, upper picture). In addition, βIII-
tub was expressed by a second and more abundant population of cells displaying the 
typical stellate morphology of OPCs (Figure 4.12A, lower picture).  
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When cells were treated with VPA (500 µM) we observed a significant increase in 
the total number of βIII-tub+ cells at the end of both neurogenic protocols (Figure 
4.12B, C). The number of βIII-tub+ cells was evaluated as a whole, irrespectively of 
their neuronal- or OPC-like morphology, since no changes in the ratio between the two 
cell populations were observed (neuron-like vs OPC-like, data not shown). Moreover, 
the increase in the number of βIII-tub+ cells was accompanied by a statistically 
significant reduction in the number of GPR17-expressing cells in neurogenic protocol 
#1, and by a trend to decrease in neurogenic protocol #2 (Figure 4.12B, D). In 
neurogenic protocol #1 we also evaluated the effect of VPA treatment on the expression 
of the OPC marker NG2; no differences were observed between control or VPA-treated 
cells. 
  
Figure 4.12: VPA treatment increases βIII-tubulin expression, and decreases GPR17 
expression in parallel. (A) Exemplificative images of the two different βIII-tubulin (βIII-
tub)-positive populations observed at the end of both neurogenic protocols. (B, D) 
Histograms showing the effect of VPA treatment on the percentage of GPR17-, NG2- 
and βIII-tub-positive cells at the end of the neurogenic protocol #1 (B) or on the 
percentage of GPR17- and βIII-tub-positive cells at the end of neurogenic protocol #2 
(D). Data are the mean percentage±S.E.M of control values set to 100% (n= 2-10; 
*p<0.05, unpaired Student’s t test). (C-E) Western Blot analysis of the expression of the 
neuronal marker βIII-tub and of GPR17 in cell cultures grown under control condition 
or after VPA treatment in neurogenic protocol #1 (C) and of the neuronal marker βIII-
tub, GPR17 and two synaptic proteins in cell cultures grown under control condition or 
after VPA treatment in neurogenic protocol #2 (SV2, synaptic vesicles 2; syt, 
synaptotagmin, E). β-actin is used as internal loading control. 
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To further confirm these data, we also performed western blot analysis on control 
and VPA-treated cell lysates at the end of phase C (neurogenic protocol #1) or SCM 
phase (neurogenic protocol #2; Figure 4.12C, E). An increase in βIII-tub expression 
and a decrease in GPR17 expression were observed in either neurogenic protocols, thus 
fully confirming immunocytochemistry data. In neurogenic protocol #2, we also 
investigated the expression of two synaptic proteins (namely, synaptic vesicles 2, SV2 
and synaptotagmin, syt). VPA induced a marked increase in SV2 expression compared 
to control cells, whereas Syt expression was unaffected (Figure 4.12E).  
Taken together, our results confirm that VPA is able to stimulate the 
differentiation of OPCs towards neuroblasts that not only express typical neuronal 
markers, but also display characteristics of mature neurons, as suggested by the 
presence of synaptic vesicle proteins. 
We next analyzed the effects of the pharmacological modulation of GPR17 with 
the non-selective antagonist Cang (10 µM) or agonist UDP-glu (100 μM). As for VPA, 
in neurogenic protocol #1 cells were treated during phase C only, whereas in neurogenic 
protocol #2 cells were treated during both phases DM and SCM. 
Exposure to either Cang or UDP-glu did not modify the percentage of GPR17-
expressing cells in both neurogenic protocol #1 (Cang: 87.50±11.46% and UDP-glu: 
91.34±20.48% with respect to control set to 100.00±9.94%; 20 optical fields from 9-23 
coverslips/condition), and neurogenic protocol #2 (Cang: 94.68±8.42% and UDP-glu: 
101.70±4.74% with respect to control cells set to 100.00±4.04%; 20 optical fields from 
3 coverslips/condition). In neurogenic protocol #1 we observed a trend to increase in the 
percentage of βIII-tub+ cells after either Cang or UDP-glu treatments compared to 
control cultures (Cang: 142.10±26.68% and UDP-glu: 141.10±38.48% with respect of 
control positive cells set to 100.00±24.15%; 20 optical fields from 7-19 
coverslips/condition), whereas in neurogenic protocol #2 the percentage of βIII-tub 
expressing cells seemed to be unaffected by GPR17 ligands (percentage of βIII-tub 
positive cells: Cangr 90.12±29.78% and UDP-glu 70.83±11.33% with respect of control 
positive cells set to 100.00±29.78%; 20 optical fields from 3 coverslips/condition). 
In conclusion, VPA increases the percentage of βIII-tub+ cells with the 
simultaneous down-regulation of GPR17 receptor. On contrary, neither Cang or UDP-
glu seem to affect GPR17 expression in both neurogenic protocols, whereas they exert a 
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complex modulation on βIII-tub expression that differs also between the two neurogenic 
protocols. 
4.2.3 EXPOSURE TO CANGRELOR OR VPA INCREASES THE PERCENTAGE OF GPR17+ 
CELLS THAT ALSO EXPRESS ßIII-TUBULIN 
As previously mentioned, at the end of both neurogenic protocols we observed the 
expression of the neuronal marker βIII-tub in two morphologically distinct types of 
cells: the first one presented a typical neuroblast morphology and probably represented 
immature neurons, whereas the second type of cells bore a OPC-like morphology 
(Figure 4.12A). Interestingly, GPR17 was never expressed by the first cell population. 
Conversely, in the second population, the appearance of βIII-tub/GPR17 double-
positive cells was already observed under control conditions. This is particularly 
interesting since no expression of GPR17 by neuronal progenitors have ever been 
observed in vitro. The demonstration that a subset of GPR17
+
 cells also expresses 
neuroblast markers further suggests that this receptor may also play a role in the 
neuronal differentiation of OPCs apart from being important in driving OPCs towards 
their typical oligodendrocyte lineage. 
In this respect, we analyzed the effects of our above-mentioned treatments on the 
population of GPR17/βIII-tub double-positive cells generated under both neurogenic 
protocols.  
In the neurogenic protocol #1, we observed a tendency to increase in the 
percentage of the double-positive cells (arrows in Figure 4.13A-C and Figure 4.13D) 
over the total number of cell population with respect to control cultures after treatment 
with either Cang (10 µM) or VPA (500 µM). On the contrary, the percentage of double-
positive cells in the UDP-glu (100 µM)-treated cultures was similar to control cells.  
When we considered the percentage of double-positive cells over the total 
GPR17
+
 cell population, we observed an increase following Cang and, to a greater 
extent, VPA treatment. Once again, treatment with UDP-glu had no effect on the 
double-positive cell population (Figure 4.13E-H). 
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Figure 4.13: Cangrelor and, to a greater extent, VPA expand the percentage of 
GPR17
+
 cells also expressing βIII-tubulin. (A-C) Representative pictures of cells 
grown under control conditions or in the presence of VPA (500 µM) or Cangrelor 
(Cang, 10µM). Scale bars: 100 μm. (D) Histograms showing the percentage of 
GPR17/βIII-tub double-positive cells over the total number of cells, as evaluated by 
Hoechst33258 staining (n=4-9). E-H Pie charts showing the percentage of GPR17
+
 
cells also expressing βIII-tub over the total number of GPR17+cells at the end of phase 
C under the various experimental conditions. 
 
Upon exposure to either VPA or Cang we also observed a trend to a decreased 
percentage of NG2/GPR17 double-positive cells calculated on the total number of cells 
(control: 23.28±10.85%, VPA: 8.73±2.11 and Cang: 8.49±2.92%, 20 optical fields from 
3 coverslips/condition). Nevertheless, we did not observed any change in the number of 
GPR17/NG2 double-positive cells over the total number of GPR17
+
 cell population 
(control: 58.56±15.75%, Cang: 55.10±18.33% and VPA: 45.62±8.40, 20 optical fields 
from 3 coverslips/condition).  
We next analyzed the GPR17/βIII-tub double-positive cell population also in 
neurogenic protocol #2 at the end of phase SCM (Figure 4.14). VPA exposure 
significantly increased the percentage of GPR17/βIII-tub double-positive cells with 
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respect to control cultures either when calculated over the total number of cells, or when 
expressed over the total number of GPR17-positive cells (Figure 4.14A, D, E and 
arrows in Figure 4.14B, C). At variance from neurogenic protocol #1, no effect was 
observed after Cang treatment, whereas exposure to UDP-glu tends to decrease the 
percentage of double-positive cells compared with control (Figure 4.14A, F, G).  
 
Figure 4.84: VPA treatment in Differentiation Medium and Stem Cell Medium 
implements the percentage of βIII-tub/GPR17 double-positive cells. (A) Histograms 
showing the percentage of GPR17/βIII-tub double-positive cells over the total number 
of cells, as evaluated by Hoechst33258 staining (n=2 ***p<0.01, unpaired Student’s t 
test). (B, C) Representative pictures of cells grown under control conditions or in the 
presence of VPA (500 µM). (D-G) Pie charts showing the percentage of GPR17-positive 
cells also expressing βIII-tub over the total number of GPR17+ cells under the various 
experimental conditions. 
 
Taken together our results suggest that VPA and, to a less extend Cang, select a 
population of hybrid cells with an OPCs morphology that starts acquiring neuronal 
proprieties. We are currently working on the hypothesis that the modulation of GPR17 
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receptor on these GPR17/βIII-tub double-positive cells can further favor their 
differentiation towards neurons. 
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5. DISCUSSION 
 
Restoration of damaged central nervous system (CNS) is an unresolved challenge 
of modern medicine, and a great need for additional research in this topic is foreseen, 
due to the increasing prevalence of CNS disorders and the devastating impact that they 
have on people life.  
It has been recently demonstrated that neural stem cells (NSCs) from the two 
adult neurogenic areas (i.e., the subventricular zone, SVZ, of the lateral ventricles and 
the subgranular zone, SGZ, of the hippocampus) take part the brain response upon CNS 
injuries. A variety of insults, including ischemia and mechanical injury, stimulate NSCs 
from the SVZ to move towards damaged areas in an attempt to re-establish neuronal 
connections and to replace damaged neurons (Parent et al., 2002). Furthermore, 
endogenous NSCs are recruited during chronic neurodegenerative diseases, such as 
Alzheimer’s disease and multiple sclerosis, and migrate into areas of demyelination, 
where they differentiate into glial cells (Picard-Riera et al., 2002).  
Progenitor cells have been also detected in non-neurogenic areas. Besides subsets 
of parenchymal astrocytes endowed with potential stem/progenitor properties (Buffo et 
al., 2008), another type of glia bearing progenitor properties has been recently identified 
in various CNS regions outside typical neurogenic niches (Boda and Buffo, 2010; 
Nishiyama et al., 2009). Based on their expression of the membrane chondroitin 
sulphate proteoglycan NG2, these cells are called NG2-positive cells (NG2
+
; also 
known as polydendrocytes), and are oligodendrocyte precursor cells (OPCs) that 
generate oligodendrocytes in the developing and mature CNS, serving as the primary 
source of remyelinating cells in demyelinated lesions (Nishiyama et al., 2009). As 
detailed in the Introduction, under specific conditions these cells can also generate 
neurons and astrocytes (Kondo and Raff, 2000a; Liu et al., 2007). 
The discovery that NSCs are maintained in the adult brain is progressively 
changing the current search for effective neuroregenerative approaches to acute and 
chronic diseases. In particular, the possibility to promote and foster the endogenous 
neurogenic/gliogenic ability of the brain has emerged as a new, safe, and ethically 
acceptable opportunity for both acute and chronic brain diseases. However, to this 
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purpose, it is imperative to gain a global comprehension of the signaling pathways 
controlling the survival, differentiation, proliferation, and integration of adult precursor 
cells. In fact, an in-depth understanding of the molecular basis controlling brain 
progenitor cells in physiological and pathological conditions would highlight possible 
pharmacological/biotechnological approaches to help preventing excessive tissue 
degeneration while enhancing local reparative mechanisms.  
Nevertheless, despite increased information on lineage specific transcription 
factors, cell-cycle regulators and epigenetic factors involved in the fate and plasticity of 
NSCs (Christie and Turnley, 2013), the understanding of extracellular cues driving the 
behavior of embryonic and adult NSCs is still very limited. The role of purinergic 
signaling in regulating the synchronized proliferation, migration, differentiation and 
death of NSCs during brain and spinal cord development it is now well-known (Neary 
and Zimmermann, 2009; Ulrich et al., 2012). However, increasing evidence also 
suggests a role for extracellular nucleotides (eNTs) in controlling adult neurogenesis 
(Grimm et al., 2009, 2010; Mishra et al., 2006; Stafford et al., 2007; Suyama et al., 
2012). 
On these premises, our study was aimed at evaluating the influence of purinergic 
signaling in regulating stem cell properties of adult brain SVZ cells and of NG2
+
 
parenchymal progenitors.  
The main finding of the first part of our study is that the purinergic system 
promotes proliferation and lineage progression of SVZ precursors in vitro and in vivo, 
both directly acting on progenitors, and indirectly through the involvement of reactive 
astrocytes. In fact, eNTs act as local extrinsic factors regulating NSC functions, 
particularly following traumatic or hypoxic events, when progenitors are in contact with 
high concentrations of ATP and its metabolites (i.e., ADP, sequentially followed by 
adenosine), owing to the high activity of ATP-metabolizing ectonucleotidases in 
neurogenic brain areas (Lin et al., 2007). The high micromolar concentrations of 
extracellular ATP and its metabolites under these pathological conditions (Abbracchio 
et al., 2006) also contribute to induction and modulation of reactive astrogliosis 
(Abbracchio and Ceruti, 2006). Thus, to clarify the role of purinergic system on NSC 
behavior during brain injury, we used experimental settings that reproduce a 
pathological environment in vivo and in vitro. To this aim, we administered ADPβS, a 
stable analogue of ADP, instead of ATP, mainly for two reasons: i) ATP is highly 
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instable and undergoes fast hydrolysis (Dunwiddie et al., 1997), and ii) it can activate a 
vast range of P2Y and P2X receptors subtypes (see also below) differentially from 
ADPβS which selectively activates the P2Y1,12,13 subtypes.  
NSCs grown in vitro in the presence of growth factors (GFs), like EGF and bFGF, 
and treated with ADPβS displayed increased neurosphere forming capacity, partially in 
accordance with previous works where P2Y1R activation brings to increased 
neurosphere formation (Mishra et al., 2006; Stafford et al., 2007). Moreover, ADPβS 
promoted the formation of neurospheres with a reduced size, suggesting that the 
interaction of purinergic signals with EGF and bFGF inhibited cell proliferation, as 
already reported (Stafford et al., 2007). Notably, P2Y1R activation may cause different 
effects on NSC function that appear dependent on culturing condition (i.e., GFs 
concentration and neurosphere passages) and may also reflect changes over time in the 
intrinsic properties of cultured progenitors (Mishra et al., 2006; Stafford et al., 2007). 
Moreover, exposure to ADPβS under pro-differentiative in vitro conditions (i.e., by 
removing GFs from culturing media) led to stimulation of neuronal and, to a lesser 
extent, astrocytic commitment of NSCs. Thus, altogether, in vitro findings show that 
purinergic signaling can positively regulate neurosphere formation and neurogenesis 
under defined culturing conditions. 
The above in vitro effects were fully confirmed in vivo by the i.c.v. infusion of 
ADPβS at micromolar concentrations (100 µM), with a significant upregulation of 
GFAP expression in both brain parenchyma and SVZ, showing an ADPβS-mediated 
activation of astrocytes not only at parenchymal sites (Franke et al., 2004, 2009) but 
also in the neurogenic area (see also below). Moreover, BrdU incorporation showed that 
P2Y1R activation promoted cell proliferation, consistent with a global stimulation of 
SVZ activity. In line with these results, lineage analysis in GLAST::CreERT2;Rosa-
YFP mice exposed to ADPβS showed an increase of both the total number of 
GFAP/YFP double-positive cells and of their actively cycling fraction. Furthermore, the 
immediate progeny of GLAST
+
 precursors (i.e., Mash1
+
 and DCX
+
 cells) was also 
expanded. Altogether, these findings point to an effect of activation of P2Y1R on 
GFAP
+
 type B cells leading to an expansion of Mash1
+
 and DCX
+
 populations.  
Our data partially contrast with a recently published paper. In fact, by 
administering the natural agonist ATP for 3 days to mice, Suyama et al. observed an 
increase in the number of both rapidly dividing BrdU
+ 
cells and of Mash1
+
 type C cells 
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in the SVZ with no effects on GFAP
+
 type B cells (Suyama et al., 2012). Differences in 
the agonist chosen (ADPβS vs. ATP) and in protocols of administration (with a 7-day-
long infusion in our study) could explain the differences in the results obtained. 
Moreover, apart from its fast rate of hydrolysis in vivo with a half-life of hundreds of 
milliseconds (Dunwiddie et al., 1997), ATP can activate a wide variety of purinergic 
receptors, spanning from the seven P2X ionic channels to some P2Y subtypes (mainly 
the P2Y2 and P2Y4 receptors; Fischer and Krugel, 2007). In addition to this, ATP is 
rapidly degraded first to ADP (which stimulates the P2Y1, P2Y12, and P2Y13 receptors; 
Abbracchio et al., 2006) and finally to adenosine, which activates the four types of P1 
adenosine receptors. Thus, the different effects exerted by ATP may be related to a 
more complex pattern of receptor activation with respect to ADPβS that is known as a 
selective agonist at the P2Y1, P2Y12, and P2Y13 receptor subtypes and to be relatively 
resistant to ectonucleotidase hydrolysis (Ralevic and Burnstock, 1998). 
Literature data suggest that the P2Y1R is mediating the effects of eNTs on 
precursor cells (Suyama et al., 2012); this was confirmed by the complete reversal of 
ADPβS-mediated effects exerted by the P2Y1R receptor antagonist MRS2179 in our in 
vitro experiments. Moreover, published data and RT-PCR analysis showed that all the 
three SVZ cell populations expressed the mRNA for this receptor subtype (not shown). 
Therefore, we are confident that all the observed effects are related to the activation of 
the P2Y1R. Nevertheless, at present, we cannot completely exclude the contribution of 
the two additional ADP-sensitive P2Y receptors (i.e., the P2Y12 and P2Y13), whose 
mRNA was also detected in SVZ cells.  
Since it is well-known that activation of the P2Y1R is responsible for nucleotide-
mediated reactive astrogliosis (Franke et al., 2001) our work also assessed the role of 
astrocyte reactivity on SVZ cell functions. Reactive astrogliosis virtually occurs in all 
injuries and pathologies and therefore likely affects NSC activity and neurogenesis, 
although knowledge on this issue is limited (Buffo et al., 2010). Therefore, we exposed 
SVZ cells to conditioned media from astrocytic cultures grown under ctr conditions or 
in the presence of ADPβS, and found a negative effect of both media on the expansion 
of primary neurospheres. Previous in vitro data showed a stimulatory action of cultured 
astrocytes on the proliferation and neuronal differentiation of NSCs based on both 
contact-mediated and secreted factors (Barkho et al., 2008; Lim and Alvarez-Buylla, 
1999; Song et al., 2002). In another study, reactive astrocytes activated in vitro by a 
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mechanical insult were found to promote astrogliogenesis from NSCs via released 
factors with no changes in progenitors proliferation compared to non-activated cultures 
(Faijerson et al., 2006). Our findings unveil a previously unknown inhibitory effect of 
astrocyte-derived soluble factors on SVZ progenitor activities, in line with an inhibitory 
action of reactive astrocytes on stem cell maintenance and neuron production in vivo 
(Buffo et al., 2010; Larsson et al., 2004). Moreover, astrocytes can release ATP already 
under basal conditions, which in turn influences NSC functions in the adult 
hippocampus via the P2Y1R (Cao et al., 2013). However, this does not seem the case in 
our experimental setting, because addition of the P2Y1R antagonist MRS2179 did not 
revert the observed effects. A complex pattern of soluble mediators is probably involved 
in astrocyte-mediated inhibition of NSC functions. Specifically, cytokines/chemokines 
and adhesion factors have been proposed to control these cells, although their role is far 
from being fully understood (Christie and Turnley, 2013). In this respect, some 
interesting hints come from our analysis of cytokine/chemokine/GFs content of 
conditioned media. IP-10 (also known as CXCL10), TIMP-1, and Rantes were absent in 
normal neurosphere medium and highly expressed in ctr and ADPβS astrocyte medium 
at comparable levels, and could therefore account, at least partially, for the observed 
generalized inhibitory effect of astrocyte-conditioned media on NSCs. So far, these 
signals have been implicated in the control of differentiation or motility of immature 
neurons or astrocytes, respectively (Lee et al., 2011; Park et al., 2009). A few studies 
reported a role for these cues in NSCs specification (e.g., IP-10 in combination with 
other cytokines; Barkho et al., 2006) and increased motility upon damage (TIMP-1: 
Ben-Hur et al., 2006; Rantes: Guan et al., 2008). However, their function in SVZ cells 
remains to be thoroughly investigated. Cues with pro-migratory effects on SVZ cells 
(CINC-1 and MIP-1α; Gordon et al., 2009) were also detected in astrocyte media, with 
a slight increase after ADPβS stimulation. By altering cell-to-cell interactions required 
to sustain NSC activity, these signals, in combination with others and with GFs present 
in our experimental setting, could lead to a generalized inhibition of NSC properties. In 
addition to this, a number of astrocyte-secreted molecules, which are known to 
stimulate stem cell properties also outside the brain (such as VEGF, IL-10, and LIX; 
Calvo et al., 2011; Choong et al., 2004; Perez-Asensio et al., 2013; Yang et al., 2009), 
and to be involved in cell adhesion (such as sICAM-1, L-selectin, and MIG), were 
downregulated upon exposure of astrocytes to ADPβS in astrocytic cultures. 
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Conversely, the release of molecules with chemoattractive and migration properties was 
increased by ADPβS. Globally, these data are in line with the pro-differentiative role 
exerted by the ADP analogue. Interestingly, a significant enhancement in neurosphere 
formation was detected when secondary neurospheres were generated in standard 
medium from cells derived from primary neurospheres grown in the supernatant of 
astrocytes exposed to ADPβS. This suggests that removal of inhibitory mediators 
triggered upon exposure to the purine analogue boosted the proliferation of SVZ cells 
during secondary neurosphere culturing. Alternatively, restoration of the stimulatory 
factors/pathways attenuated by the supernatant of ADPβS-exposed astrocytes could 
trigger this proliferative compensative response in secondary neurospheres. We are 
currently working on this hypothesis, which suggests that during acute phases after 
damage eNTs-mediated reactive astrogliosis does not directly affect the proliferation of 
SVZ progenitors, but rather modifies their intrinsic properties, leading to a boost toward 
neurogenesis at more later stages when the concentrations of the various mediators 
decline. In vivo, the situation is likely to be more complicated owing to the presence of 
reactive microglia, whose functions and properties can be profoundly affected by eNTs 
(Fumagalli et al., 2011). 
In conclusion, the results of the first part of my thesis represent a significant step 
forward the full understanding of the role of eNTs in controlling SVZ cell functions 
under pathological conditions, also thanks to their ability to act on a variety of cell 
populations. Moreover, our data contribute towards the understanding of the complex 
signaling network regulating neurogenesis in pathological condition and may lead to 
build the substrate for therapeutic strategies that limit brain damage and promote tissue 
regeneration 
In the second part of our study, we focused on the modulation of the neurogenic 
properties of parenchymal NG2
+
 cells by both culturing condition and pharmacological 
treatments. NG2-expressing OPCs were originally identified as the progenitors of the 
myelin-forming cells of the brain and spinal cord (Zuo and Nishiyama, 2013); however, 
recent studies have shown that these cells have the ability to revert to stem-like cells 
(Kondo and Raff, 2000a, 2000b, 2004), and to generate interneurons (Aguirre et al., 
2004; Belachew et al., 2003; Dayer et al., 2005). This seems to be particularly true 
under pathological conditions. Indeed, to follow the fate of OPCs after CNS pathology, 
Honsa and co-workers performed permanent middle cerebral artery occlusion (MCAo) 
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on adult NG2creBAC:ZEG double transgenic mice, in which enhanced green 
fluorescent protein (EGFP) is expressed in OPCs and their progeny. The number of 
EGFP
+
 cells after ischemia was significantly increased; cells displayed heterogeneous 
morphology and expressed markers of astrocytes and neuronal precursor cells. 
Moreover, OPCs multipotency was confirmed by detailed electrophysiological analysis, 
which also proved the generation of astrocytic and neuronal precursor phenotypes from 
EGFP
+
 cells after ischemia (Honsa et al., 2012). 
The mechanisms underlying the commitment of OPCs towards either myelinating 
oligodendrocytes or a distinct neural lineage are only partially understood. In these 
respect, we focused our attention on the possible role exerted by the P2Y-like receptor 
GPR17, which has been recognized as one of the three genes specifically expressed by 
adult precursor cells when compared to embryonic ones (Maisel et al., 2007). Moreover 
our recent data also demonstrate GPR17 expression by OPCs in adult brain parenchyma 
and its key role in driving cell maturation and reaction to harmful conditions (Boda et 
al., 2011; Ceruti et al., 2011; Fumagalli et al., 2011).  
First of all, we succeeded in reproducing two different published protocols able to 
unveil the stem cell potential of OPCs and, at least partially, to redirect them towards a 
neuronal phenotype. NG2 cells from rodent brain have been initially cultured according 
to a 3-phase protocol, renamed here neurogenic protocol #1 (Kondo and Raff, 2000a). 
Our data demonstrate an initial regression of NG2 precursors to an intermediate stage 
where cells lost NG2, and showed massive expression of GFAP (phase B), which was 
followed by GFAP downregulation, re-appearance of NG2 and, most important, 
acquisition of the typical neuronal marker βIII-tubulin (βIII-tub, phase C). Interestingly, 
these phenotypic shifts were accompanied by important changes of GPR17 expression, 
which was never co-expressed by the intermediate de-differentiated GFAP
+
 cells, but 
was highly expressed by NG2
+
 cells. This is in line with our previous in vivo and in 
vitro observations suggesting that GPR17 decorates normally a subpopulation of pre-
oligodendrocyte precursor cells (Ceruti et al., 2009; Ciana et al., 2006; Lecca et al., 
2008).  
A similar pattern of expression was also observed with neurogenic protocol #2 
(Liu et al., 2007). At variance from the neurogenic protocol #1, in which OPCs 
underwent non-oligodendroglial differentiation through an intermediate GFAP
+
 
precursor, cells were cultured in a defined medium (named SCM, stem cell medium) 
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previously shown to support stem cell growth (Belachew et al., 2003). In accordance 
with our previous data, the majority of GPR17
+
 cells resulted to be NG2-expressing 
OPCs. Moreover, the increased expression of the neuronal marker βIII-tub at the end of 
the protocol demonstrates that multipotentiality in vitro is an intrinsic feature of a 
subpopulation of NG2
+
 OPCs. These results emphasize the notion that postnatal 
progenitor cells expressing the chondroitin proteoglycan NG2 can no longer be 
considered as mere progenitors restricted to an oligodendroglial fate (Dawson et al., 
2000), but are multipotent parenchymal cells. 
It is already well known that the oligodendrocyte identity of OPCs is critically 
dependent on histone deacethylases (HDAC) enzymatic activity. In particular, as the 
cells progress to mature oligodendrocytes, HDAC activity is high and the final cell fate 
is established by repressing neuronal and astrocytic genes. On contrary, when HDAC 
activity is inhibited by pharmacological agents, progenitors are unable to establish an 
oligodendrocyte-specific program of gene expression, while acquiring a pattern of gene 
expression consistent with neuronal and astrocytic lineage (Liu and Casaccia, 2010; 
Marin-Husstege et al., 2002; Shen et al., 2005). In this respect, our data show that the 
above-mentioned neurogenic shift is markedly implemented by exposure to valproic 
acid (VPA, 500 µM), an anti-epileptic drug also used as HDAC inhibitor (Monti et al., 
2009). In particular, in neurogenic protocol #2 after VPA treatment the increased 
expression of the early neuronal marker βIII-tub, is accompanied by an higher 
expression of the synaptic vesicle protein 2 (SV2), an integral membrane protein 
expressed on all synaptic vesicles (Crèvecœur et al., 2013; Portela-Gomes et al., 2000). 
This suggests that exposure to the HDAC inhibitor stimulates the differentiation of 
OPCs towards maturing neurons that are acquiring proteins tipically involved in 
neurotransmitter release.  
Interestingly, VPA exposure also decreased GPR17 expression compared to 
control culture. This is in accordance with unpublished data from our laboratory 
showing that inhibition of HDACs with VPA decreases the activity of the Gpr17 
promoter (Lecca et al., unpublished). Since VPA is normally linked to a decreased 
expression of genes important for oligodendrocyte specification (Hsieh et al., 2004; Liu 
et al., 2007; Shen et al., 2005), this further supports the hypothesis that GPR17 plays a 
relevant role in OPCs maturation towards a oligodendrocyte lineage (Boda et al., 2011; 
Ceruti et al., 2011; Fumagalli et al., 2011) 
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Very complex effects are instead observed upon modulation of GPR17 receptor 
with the non-selective antagonist Cangrelor (Cang, 10µM) or agonist UDP-glucose 
(UDP-glu, 100 µM). In fact, neither Cang or UDP-glu seem to affect GPR17 expression 
in both neurogenic protocols, whereas they exerted a complex modulation on βIII-tub 
expression that depended also on the neurogenic protocol applied. It is worth 
mentioning that for our experiments we used primary cultures, that are usually 
composed of non-synchronized cells, at different stages of differentiation, and 
characterized by a different rate of proliferation. The variability among experiments is 
therefore very high leading to difficulties in obtaining consistent and significant results. 
Moreover, both neurogenic are composed of sequential and complex culturing 
conditions that could exert different effects depending on the characteristics of the 
original cell preparation.  
At the end of both protocols, GPR17 was surprisingly co-expressed in a subset of 
βIII-tub+ cells already under control condition. These βIII-tub+ cells showed the typical 
highly-branched OPC morphology, thus probably representing “hybrid” cells still 
uncommitted to a final oligodendrocyte or neuronal fate. The appearance of this hybrid 
cell population was further incremented in both neurogenic protocols by the exposure to 
VPA and, in neurogenic protocol #2, also to Cang. Interestingly, if we consider only the 
population of GPR17-expressing cells, VPA and, to a lesser extent Cang, promoted the 
expression of the neuronal marker βIII-tub in these cells. Thus, besides being a trigger 
for oligodendroglial differentiation (Fumagalli et al., 2011), GPR17 may also be 
involved in their neurogenic specification. This was already suggested by previous 
findings (Daniele et al., 2010) that highlighted a role for GPR17 in the neuronal 
differentiation of PC12 cells, and suggested that activation of this receptor may 
qualitatively influence the effects induced by classical growth factors. However, we 
never observed GPR17 expression on βIII-tub+ cells displaying the typical neuroblast 
morphology, suggesting that GPR17 expression is dowregulated at later stages of 
neuronal differentiation. In this respect, Chen and colleagues (Chen et al., 2009) failed 
to find expression of GPR17 in neurons of adult mouse brain under physiological 
conditions. It may well be that GPR17 participates to neuronal specification during 
development, is turned down during adulthood, and is then re-activated under disease 
conditions, when endogenous reparative neurogenesis is switched on, as suggested by 
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markedly increased neuronal expression of GPR17 in the ischemic rat and mouse brain 
(Ciana et al., 2006; Lecca et al., 2008).  
We are currently working on the hypothesis that, by increasing the number of 
βIIItub/GPR17 double-positive cells, VPA and, partially, Cang are selecting a particular 
“hybrid” cell subpopulation. Thus, it is tempting to speculate that on these cells, the 
modulation of GPR17 by its ligands could favor their differentiation towards fully 
mature neurons. Importantly, GPR17 is a membrane receptor, thus amenable for 
activation/blockade by signals present in the local CNS milieu, and for exogenous 
regulation by drugs, at variance from current neurogenic protocols, which mainly 
exploit genetic manipulations and are therefore less prone to a possible clinical 
exploitation.  
It has already been demonstrated that the systemic administration of VPA in 
rodents is associated with a reduction of oligodendrocyte generation and a 
corresponding increase of astrocytes and neurons (Liu et al., 2007). Moreover, VPA has 
been tested in transient and permanent MCAo rat models and brain trauma (Kim et al., 
2007; Ren et al., 2004). Postinjury administration of this HDAC inhibitor decreased 
blood-brain barrier permeability, reduced neural damage and improved neurobehavioral 
outcome of the pathology (Kim et al., 2007; Ren et al., 2004). Among the HDACs 
inhibitors, VPA is one of the most interesting drug, as its HDAC inhibitors action is 
accompanied by a wide range of biochemical and molecular effects (e.g., regulation of 
the glutamate excitatory neurotransmission and/or gamma aminobutyric acid (GABA) 
inhibitory neurotransmission, regulation of several protein kinase signaling pathways 
and of gene expression), which all appear to cooperate to neuroprotection and cognitive 
enhancement. Of course, these very exciting perspectives must be confronted with the 
potential drawbacks linked to the use of such a multitarget drug for safety purposes 
(Monti et al., 2009).  
In vivo treatment of ischemic animals with Cangr markedly prevented damage 
evolution (Ciana et al., 2006; Lecca et al., 2008) suggesting that activation of GPR17 
during ischemia indeed contributes to injury development. However, Cangr acts also as 
a potent antagonist at the P2Y12 receptor subtype which has been shown to be highly 
expressed in the megakaryocyte/platelet lineage (Burnstock and Knight, 2004). 
Blockade of this receptor in platelets is associated with a marked antithrombotic effect 
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(Savi and Herbert, 2005), which should be taken into account when designing future in 
vivo treatments. 
Besides pharmacological manipulations, the direct lineage reprogramming is one 
of the most intriguing strategies recently emerging to replace damaged neurons, 
consisting in a process where one mature somatic cell transforms into another mature 
somatic cell without undergoing an intermediate pluripotent state or progenitor cell 
type. In this approach, the desired cell type can be directly induced from mature somatic 
cells by overexpression of lineage-specific transcription factors (Graf and Enver, 2009). 
Anderson and colleagues showed that ectopic expression of Ngn1 in dermomyotome of 
chick embryo can induce neuronal morphology, and typical neuronal gene expression in 
these cells (Perez et al., 1999). Subsequently, Gӧtz and colleagues reported neuronal 
features in mammalian astroglia overexpressing PAX6 (Heins et al., 2002); upon 
transduction of Ascl1, Ngn2 and Dlx2 in neonatal astroglia, these cells showed neuronal 
morphology, generated action potentials, and exhibited functional synaptic properties 
(Heinrich et al., 2010, 2011). In order to accomplish transfection, integrating viral 
vectors such as lentiviruses and retroviruses, or non-integrating vectors such as 
adenoviruses, can be used (Patel and Yang, 2010). However, it is worth mentioning that 
these approaches manipulating the genome could have important drawbacks, such as the 
potential to cause tumor growth, and to cause mutations. In this respect the 
pharmacological manipulation of endogenous cells is still a safe and useful strategy to 
develop a possible clinical application. 
Taken together, our results strengthen the evidence that the purinergic system 
crucially regulates neuronal progenitors, either in a classical neurogenic niche or in the 
brain parenchyma. The pharmacological modulation of the purinergic system could 
therefore represent a promising and innovative approach to exploit the intrinsic ability 
of the adult brain to regenerate in acute and chronic neurodegenerative disorders.  
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